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Abstract
Preliminary testing of a dihydroxyquinoline derivative, 3-amino-6,7-dihydroxy-l,2,3,4- 
tetrahydroquinoline (6,7-ADTQ), showed substantial serotonergic depletion in mouse 
whole brain, but with only moderate selectivity. This preliminary finding warranted 
further examination of this type of novel neurotoxin. Thus, we synthesized two 
additional derivatives, 3-am inomethyl-6,7-dihydroxy-l,2,3,4-tetrahydroquinoline 
(6,7-AMDTQ) and 3-amino>6,8-dihydroxy-l,2,3,4-tetrahydroquinoline (6 ,8-ADTQ). 
We then investigated these neurotoxins in an attempt to establish a relationship between 
the physical and/or chemical nature of these toxins and their neurodegenerative abilities. 
The importance of chirality in this class of neurotoxins was also investigated. The extent 
of neuronal destruction afforded by these toxins was measured as their ability to elicit 
long-term depletion of endogenous transmitters. Two o f the three agents elicited 5-HT 
depletions equal to or greater than that attainable using generally accepted 5-HT 
neurotoxins. From initial depletion studies, we found no advantage in employing 
enantiomers over that of the racemic agent The uptake blockade interaction o f the toxic 
agents with ME, DA, and 5-HT transport sites appears to be competitive in nature, with 
Kt values ranging from 14 to 280 pM and an apparent facilitation of uptake for NE and 
DA with 6 ,8-ADTQ. Investigation of autoxidation showed that oxidation rates of 6,7- 
analogs were rapid and increased in the presence of metal ions, while the 6 ,8 - analog 
showed an overall slower rate and no significant rate change upon addition of metal ions. 
Examination of reactive 0% species produced during autoxidation showed the m ajori^ of 
O2 consumed during oxidation led to the production o f H2O2. This H2O2 generally 
decreased with an increase in metal ion concentration, presumably as a result of *OH 
production via Fenton mechanisms. Pathways leading to the production of O 2* appeared 
to be negligible. Mitochondrial oxidative phosphorylation effects indicate primarily an 
uncoupling of oxidative phosphorylation by these agents.
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Chapter 1
I. Introduction
The brain is the most complex organ in the human body. It contains - 10^2 
neurons, each ^ ic a lly  making thousands of connections with other neurons. These 
multiple interconnections between neimxis result in the abili^  to feel and show emotions 
and are responsible for the cognizant understanding of what you are reading right now. 
The brain is the origin of all qualities whrch embody and define humanity.
The laboratory of Dr. C. LeRoy Blank has long been interested in chemically 
induced neurotoxicity in the brain. Neurotoxins, chemicals that destroy nerve cells, can 
be used for a wide variety of neuro-applications. They are particularly useful in 
producing animal models of neurochemical disorders. Additionally, these chemicals can 
be used to elucidate the function of specific regions and tracts in the brain. By mote fully 
understanding the actions of neurotoxic chemicals, we may obtain insight into the 
phenomena collectively known as neurodegeneration. This chapter briefly discusses 
neurotransmission, neuroanatomy, neurotransmitters, mental disorders resulting from 
neuron and/or neurotransmitter abnormalities, and neurotoxins.
n . Neurotransmission
A. The Neuronl'5
While not the most abundant cells in the central nervous system, neurons are the 
most important. The fundamental role o f a neuron is "communication". Le., the 
receiving, integrating, and transmission of neuronal signals. Many characteristics of a 
given nerve cell in the central nervous system (CNS), including its size, shape, cellular 
components, and connections, is directly related to its specific function in the braiiL
Neurons communicate through the use of electrical and chemical signals. 
Neurons release neurotransmitters at a site o f contact with another neuron called a 
synapse (see Figure 1-1). At this synapse, there is a functionally specific region of the 
membrane on the presynaptic neuron where one or more neurochemical transmitters are 
released. The neurotransmitter(s) difiuse(s) across the synaptic cleft (20-40 nm) and 
binds to ieceptor(s) on the postsynaptic neuroiL The binding of a neurotransmitter to a 
receptor causes an electrical signal in the postsynaptic cell which is propagated through 
that cell and subsequently causes the release, or repression of release, o f a
neurotransiiiitter(s) at the succeeding synapse. The final event in neurotransmission at a 
single synapse is the termination of neurotransmitter-induced receptor activation. This is 
predominantly accomplished through a mechanism known as reuptake, whereby released 
neurotransmitters are selectively returned to the cytoplasm of the presynaptic nerve 
terminal via selective uptake sites. Once inside the nerve terminal the neurotransmitter can 
be repackaged into vesicles for future neurotransmission or can be metabolically 
inactivated. Termination of receptor activation may also occur by neurotransmitter 
metabolism in the synaptic cleft and/or diffusion away from receptor sites.
The neuron is primarily comprised of three basic parts: dendrites, a cell body, and 
an axon. In order to accommodate many incoming synaptic connections, neurons may 
have a highly branched network of dendrites (see Figure 1-1). Dendrites are neuronal 
processes which receive synaptic input from other neurons. They have receptors and 
other components designed to convert chemical transmissions into electrical signals. 
Dendrites integrate these electrical signals with other incoming signals and pass the 
integrated result to the cell body.
The cell body of a neuron, often referred to as the soma, is responsible for the 
synthesis of essential enzymes and proteins. It contains the nucleus, endoplasmic 
reticulum, lysosomes, mitochondria and other cellular components required for normal 
cell functions. The soma plays a  large role in the integration of electrical signals coming 
from the dendrites. Furthermore, the soma may also have many incoming synapses, by 
which it directly receives chemical information.
The axon is a long, thin neuronal process which is responsible for sending 
outgoing electrical information to the synapse (see Rgure 1-1). At the base of the axon, 
called the axon hillock, the integrated electrical signals from the dendrites and the soma 
form an all-or-nothing electrical signal called the action potential. This action potential 
travels down the axon to the presynaptic nerve terminal and triggers a calcium dependent 
release of neurotransmitters.
J©
Figure 1-1. A typical neuron using dopamine (DA) as a  transmitter.^
The presynaptic nerve tenninal possesses both neurotransmitter reuptake sites and 
autoreceptors. Autoreceptors, among other things, can regulate neurotransmitter release.
A neuron contains only one axon; however, an axon may be branched, giving rise to 
multiple nerve terminals.
The neurotransmission process described above is primarily pertinent to 
neurotransmitters evoking an excitatory electrical change in the postsynaptic membrane 
potential via ion-channel linked receptors. However, neurotransmitters can also evoke 
electrical inhibition. Additionally, they can also regulate cellular function by a different 
means than an electrical event Some neurotransmitters, when released, activate second 
messenger linked receptors coupled to G proteins. Activation of this type of receptor can 
result in the indirect regulation o f neuron growth, metabolism, gene expression, and 
structural effects, along with or in addition to activation o f ion channels. Therefore, 
neurotransmission may either integrate and pass on information or modify the cellular 
interworkings of a neuron.
In the brain, there are also non-neuronal cells that support the nervous system and 
are broadly classified as glial cells or glia. Glial cells line the internal and external 
surfaces of the brain, act as a boundary between blood vessels and neurons, wrap around 
axons forming myelin, surround syn^ses, and fill the spaces between neurons.
While this is a very brief discussion of the neuron and the neurochemical 
transmission process, many comprehensive overviews ex ist^ '^  which are not only 
enlightening, but also exciting to read.
B. Neurotransmitters
Neurotransmitters are the chemical substances which, when released by neurons, 
provide communication. There are many chemicals in the brain which have been 
identified as putative neurotransmitters. However, to be considered a neurotransmitter, a 
chemical must meet some very atacting criteria. A neurochemical must be localized in the 
presynaptic terminal and must be released upon axon stimulation in quantities sufficient
enough to evoke a response at postsynaptic receptors. Appropriate precursor enzymes 
for anabolism and catabolism of the neurotransmitter must also be localized in the 
presynaptic nerve terminal or vicinity. There must exist a mechanism by which 
inactivation of the released, extracellular neurotransmitter can occur. Furthermore, when 
exogenously supplied, the neurochemical should evoke a similar response to that of the 
endogenously released compound. Chemicals which meet all of these criteria are called 
neurotransmitters. Compounds which meet some, but not all, of the above criteria are 
called putative neurotransmitters. Of the many known and putative neurotransmitters in 
the brain, our current research efforts have been focused on the catecholaminergic and 
serotonergic neurotransmitters.
1. Catecholamines
The catecholam inergic neurotransmitters consist of dopamine (DA), 
norepinephrine (NE), and epinephrine (EPI). These transmitters are shown in Figure 
1-2. They all contain a catechol ring with an ethylamine side chain. The biosyntheses of 
these neurotransmitters, which all begin with L-^rosine, are also presented in Figure 1-2. 
L-Tyrosine is an amino acid that is obtained through the d iet The first step, the 
conversion of L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA) via tyrosine 
hydroxylase (TH), represents the rate limiting step in the syntheses of these compounds. 
Through the action of L-aromatic amino acid decarboxylase (L-AAAD), L-DOPA is 
converted to dopamine (DA). In dopaminergic neurons this represents the final step in 
the synthetic pathw ay. In noradrenergic and adrenergic neurons, 
dopamine-P-hydroxylase (DgH) converts DA to norepinephrine (NE). And, in 
adrenergic neurons, phenethanolamine-N-methyltransferase (PNMT) adds a  methyl 
group to the amine of NE to produce epinephrine (EPI). These neurotransmitters are 
packaged in vesicles to await release during neurotransmissiotL The catabolic pathways 
for DA and NE are shown in Hgures 1-3 and 1-4, respectively.
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Figure 1*2. Catecholamine biosynthesis.
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2. Serotonin
S-Hydroxytryptamine (5-HT), also known as serotonin, possesses an indole 
structure and is the transmitter used in serotonergic neurotransmission. Serotonin and its 
biosynthetic pathway are shown in Bgure 1-5. L-Tryptophan (TRP), an amino acid 
obtained from the diet, represents the starting point in the synthesis of 5-HT. TRP is
converted to L>S-hydroxytryptophan (S-ETTP) by tryptophan-S-hydroxylase. This 
represents the rate limiting step in the synthesis of S-HT. L-aromatic amino acid 
decarboxylase then converts S-HTP to 5-HT. The catabolism of 5-HT is shown in 
Figure 1-6. W hile there are multiple possibilities for metabolic products, the primary 
metabolite of 5 -HT is 5-hydroxyindoleacetic acid (5-HIAA). Metabolic products of 
neurotransmitters generally possess no neuronal activity. However, in the pineal gland,
5-HT is further metabolized to melatonin (MEL) which is believed to regulate, among 
other things, circadian cycles.2,3 The biosynthetic pathway for MEL is also shown in 
Hgure 1-6 .
NH,
H
TRP
NH
H
5-HTP
L-Aromadc amino acid 
decarboxylase
NH
H
Serotonin (5-HT)
Figure 1-5. Serotonin biosynthesis.
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Figure 1-& Serotonin catabolic pathways and biosynthesis of melatonin.
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In spite of the fact that neurons containing the above described transmitters only 
constitute 3-5% of the total neurons in the brain, these neurodransmitter systems have 
been implicated, either directly or indirectly, in many neurodegenerative and psychiatric 
disorders such as Parkinson's disease, Alzheimer's disease, schizophrenia, sleep 
disorders, mania, depression, and aggression. The following section will briefly 
describe a  few select mental disorders and their currently accepted associations with 
neurotransmitter system deficits and/or abnonnalities.
m . Neurodegenerative Diseases & Other Mental 
Disorders
Neurodegenerative diseases and other mental disorders have increasingly become 
a major focus o f the neuroscience communi^. This is understandable when we consider 
that 10-20 percent of the population over the age of 65 experience some form of 
dementia^ and 1-2 percent develop Parkinson's Disease.* Furthermore, the prevalence 
of other mental disorders is extraordinarily high, with approximately 6  million Americans 
suffering firom affective disorders like depression and/or mania, 14 million from various 
phobias, and 2 million from schizophrenia.^ W hile the actual causes o f most mental 
disorders still remain a mystery, the neurotransm itter and neuronal changes that 
accompany them are beghming to be unraveled.
1. Alzheimer's Disease
Alzheimer's disease is characterized by severe mental impairment and, with time, 
loss of motor function. Alzheimer’s disease begins with memory impairment of recent 
events along with loss o f the abili^  to plan multi-step tasks.^ As the disease progresses, 
there are disturbances in attention, language skills, visiospatial skills, and motor skills.
1 2
These disturbances are accompanied by a change in personality which is characterized by 
irritability, depression, and psychosis. 10 In the final stages of the disease, which occurs 
approximately 5-10 years after appearance of the initial symptoms, there is a severe 
impairment of all mental and motor functions J
At the anatomical level, Alzheimer’s disease (AD) is initially characterized by cell 
loss in the cerebral cortex. As the disease progresses, cell loss is seen throughout many 
subcortical regions of the brain. H  The pathology of AD is marked by amyloid deposits 
and neurofibrillary tangles and plaques. While many different neuronal types are affected 
in AD, some neuronal populations are affected more than others. For example, the 
cholinergic system, which uses acetylcholine (ACh) as its neurotransmitter and has been 
implicated in learning and memory,^* shows a high degree of neuronal loss. 
Degeneration of NE containing nerve cells has also been observed,!^ which may explain 
some of the behavioral changes that accompany AD. Additionally, cell death in the 
serotonergic system occurs in this disease. The observed emotional disturbances in AD 
may be associated with the cell loss in the serotonergic system.
While many transmitter systems are affected in an Alzheimer's brain, the above 
described systems display the greatest degree of the observed degeneration. Perhaps it is 
not the loss o f any one specific neuronal population, but rather the combination of 
neuronal losses that yields the symptomology and pathology of Alzheimer’s Disease.
2. Parkinson's Disease (PD)^
Parkinson's Disease (PD) is characterized by rigidity, resting tremors, and 
bradykinesia and can be accompanied by dementia and depression.^ The pathology of 
PD is marked by degeneration of neurons, predominately in the substantia nigra, and the 
presence o f Lewy bodies, i.e., cytoplasmic spherical inclusions containing 
neurofilaments. The major neurotransmitter system affected in PD is the dopaminergic 
s y s te m .  Clinical signs of PD begin to appear only after 70*80 percent o f the
13
dopaminergic neurons in the substantia nigra are lost.^^ While it appears that the 
substantia nigra neurons are the most affected, all DA systems ultimately show massive 
cell loss. And, it is the nigrostriatal DA cell loss that is thought to result in the motor 
impairment seen in PD. There is also NE cell loss in PD, although this generally occurs 
to a much lesser extent than DA cell loss. However, the degree of NE loss seems to be
higher in patients which display dementia. Additionally, cell loss in the serotonergic 
system is observed, and this may explain the depression that often accompanies PD. 
While many more neuronal systems are affected in PD than has been mentioned above, it 
is the loss in the dopaminergic system which is most characteristic of and most severe in 
PD. The widespread use of L-DOPA, a precursor of DA, in the treatment of PD is based 
on observed DA cell loss.
3. Schizophrenia^
Schizophrenia is characterized by delusions with no basis in fact, as well as 
thought which is deranged in content and form. Common symptoms displayed by 
schizophrenics include delusions that their thoughts are controlled by others, that 
everyone knows their thoughts, and that people are spying on them and trying to hurt 
them. Thoughts and ideas are random and UlogicaL Communication and speech may be 
disjointed and repetitive. Hallucinations, generally auditory, may occur with 
schizophrenia patients. The lack of ability to feel emotion may also be displayed by 
schizophrenics.
Schizophrenia has been suggested to be associated with an overstimulation of the 
dopaminergic system.^ Additionally, hypoactive 5-HT systems have been implicated in 
schizophrenia, stemming firom studies demonstrating that the concentrations of 5-HIAA 
in the cerebrospinal fluid is lower in schizophrenics than in normal patients.^ 
Furthermore, 5-HT precursor supplements have been reported to partially alleviate 
symptoms of schizophrenia.^*^
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4. Affective Disorders^
Affective disorders, including depression and/or mania, are marked by extreme 
changes in mood. Major depression is characterized by an intense feeling of despair and 
worry, loss of concentration, and low self-worth.^ This is generally accompanied by 
physical changes such as decreased libido, insomnia, and weight loss.^ Mania, which is 
less common than depression, is characterized by euphoria, hyperactivity, impaired 
judgment, uncontrollable speech, irritabili^, and insomnia.^
There are several lines of evidence which implicate both the serotonergic^* 15,16 
and noradrenergic^, 17 systems in affective disorders and, in particular, depression. 
While there is no neuron loss associated with simple depression, reduction in S-HT, NE, 
and related metabolites has been found in such p a t i e n t s . F u r t h e r m o r e ,  tricyclic 
antidepressants, which block the uptake of 5-HT and/or NE, have been significant in 
treating depression.^ These observations form the basis for the "biogenic amine 
hypothesis" of affective disorders.
From this brief overview of a select few neurodegenerative and other mental 
disorders we can see the complexly and severi^ of such conditions. It is difficult in all 
cases to state absolutely whether the disorder is caused by a change in the transmitter 
system(s) or whether the change in the transmitter system(s) is caused by the disorder. 
However, in either case, there needs to be more investigation and evaluation of all 
systems involved before we can truly understand what is actually occurring and why.
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IV. Neurotoxins
Understanding how the brain works is a difGcuIt and perplexing task. However, 
one of the easiest ways to connect pharmacological, behavioral, and physiological 
phenomena in vertebrates with a particular neuronal pathway in the brain is to first, 
produce an effect; second, inactivate the neuron subpopulation thought to control the 
observed effect; and third, reexamine the effect and identify any resulting changes. 
Physical lesioning was the best technique for many years in the rem oval and/or 
inactivation o f suspected neuronal tracts in question. However, electrolytic and surgical 
lesions are inadequate for use with the complex and interwoven nervous tissues found in 
the CNS of vertebrates. These types of lesions in CNS tissues may provide complete 
removal o f a given tract, but the associated selectivity is typically non-existent. An 
alternative to this non-selective lesioning is afforded by the use of a chemical neurotoxin. 
This is the only method which offers substantial cellular selectivify.
A neurotoxin is a molecule that causes neuronal destruction. This destruction may 
be axonal degeneration or total cell death, but in either case denervation occurs.^ 
Neurotoxins, while being employed in many facets o f the neuroscience community for 
various purposes, are particularly useful in producing anim al m odels of 
neurodegenerative diseases. When a toxin produces behavioral and physiological 
changes similar to a neurodegenerative disease, that agent can provide critical insight into 
the underlying mechanism of the disorder and, thus, implicate potentially beneficial 
treatments. This is exemplified by the novel treatments of Parkinson's Disease derived 
from the understanding of the mechanism of action of MPTP (see below).
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1. 6-Hydroxydopamine
6 -Hydroxydopamine (6 -HDA) is probably the best-known and most heavily 
studied neurotoxin. It was essentially the first toxin of its kind to be introduced to the 
scientific communi^. Following its identification by Senoh and coworkers^^ in 1959 as 
a DA by-product, 6 -HDA was shown to cause peripheral NE depletions when 
systemicaUy administered. 19,20 Ultrastructural evidence soon followed showing that the 
peripheral NE depletions actually corresponded to nerve terminal destruction.^^
NHj
HO" 'O H
6 -Hydroxydopaimne (6 -HDA)
After 6-HDA was shown to cause peripheral neuronal degeneration, its effects on 
the brain began to be investigated. Since 6 -HDA is highly polar, it does not cross the 
blood-brain barrier^^ and, hence, must be administered directly into the brain. 6-HDA, 
administered intracerebroventriculady in mice at low doses (3 nmol) results in a reduction 
in whole brain NE levels by approximately 30% while apparently not affecting any other 
transmitter systems.^^ However, at higher doses 6 -HDA becomes less selective and 
begins to destroy DA neurons as well. This is exemplified, following a 60 nmol 
injection, by a reduction in whole mouse brain NE levels to 40% o f controls and DA 
levels to 8 6% of controls.^^ When 6-HDA is injected directly into the substantia nigra it 
produces significant dopaminergic neuronal degeneration and has been used to produce 
animal models that exhibit a very similar symptomology and pathology to that of 
Parkinson's Disease.
The mechanism by which 6-HDA elicits neurodegeneration has been extensively 
studied, and many 6 -HDA reviews exist in the literature.^^ 30 ^  order for 6-HDA to
17
elicit neurodegeneration, it must first be accumulated in the neuron. Toxin accumulation 
occurs by selective uptake at endogenous reuptake, or transport, sites. This uptake has 
been shown to be a requirement for 6 -HDA toxicity in that neurodegeneration can be 
blocked by specific uptake blocking agents.31,32 xt is generally accepted that the 
selective uptake o f 6 -HDA, as well as other neurotoxins, is the most important 
characteristic associated with its neurotoxic selectivi^. Another important characteristic 
believed to be associated with the toxici^ of 6-HDA is its ability to readily undergo 
autoxidation. Le., non-enzymatic oxidation by molecular oxygen. Many mechanisms of 
action have been proposed for 6 -HDA, but the vast m ajori^ begin with neuronal 
accumulation and toxin autoxidation.
One school o f thought on 6 -HDA toxicity involves neuronal damage via reactive 
oxygen species.33-38 6-HDA has been shown to produce superoxide and hydrogen 
peroxide as byproducts of autoxidation, and it is possible for these species to directly 
damage the neuron.39-41 Additionally, autoxidation of 6 -HDA has been shown to 
produce the extremely reactive and damaging hydroxyl radical, "OH.33,42,43 This O H  
production, however, is most likely due to the interaction of hydrogen peroxide with trace 
metal ions via Fenton chemistry.44-48 Xq support of the reactive oxygen species theory, 
free radical scavenging agents have shown at least some protection against 6 -HDA 
induced neurotoxicity.^^’^ ^
0%  ^ Hjp2,02~.0H
6 -HDA 6-HDAQ
There are a number of other possible mechanisms by which 6 -HDA may elicit 
neurodestructioiL 6-HDA upon oxidation, forms a corresponding pata-quinone species
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(6 -HDAQ). This p-qoinone has reactive electiophilic sites which can undergo 
nucleophilic attack by sulfhydryl moieties of cellular components such as enzymes and 
other proteins.27.50-56 ju this way 6-HDA can bind, and even cross-link, essential 
proteins and enzymes rendering them inactive. 6-HDA and its p-quinone have also been 
shown to disrupt mitochondrial oxidative phosphorylation.^^-^ By this mechanism, the 
cell is rapidly depleted of essential high energy phosphates. Furthermore, 6-HDA could 
effect neurodegeneration by disrupting both cellular and mitochondrial calcium 
homeostasis,^3,49,6I-64 creating hypoxic conditions in the neuron, depleting neuronal 
antioxidant reserves,34,43,50 releasing intraneuronal iron firom ferritin for participation 
in «0H production,^^ and/or inducing apoptosis.^
2. MPTP
l-Methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) is a highly selective 
dopaminergic neurotoxin.^7 MPTP originated not from the scientific community but 
from a "garage chemist" making illicit drugs. MPTP was a by-product in the attempted 
preparation of a synthetic heroin. This chemist accidentally applied too much heat during 
the synthesis, which inadvertently produced significant amounts of MPTP. This accident 
was realized only after a number of heroin addicts in northern California began rqipearing 
in emergency rooms displaying parkinsonian symptoms nearly identical to that of 
Idiopathic Paddnson's Disease.^^
Since its discovery, a great deal of research has been undertaken on MPTP.^7,69 
W hile not innately toxic, MPTP is oxidized to the toxic species, l-m ethyl-4- 
phenylpyridinium (MPP^), in the body. In other words, MPTP requires bioactivation. 
MPTP, being a lipophilic molecule, can cross the blood-brain barrier. Once inside the 
brain, MPTP is oxidized to l-methyl-4-phenyl-2,3-dihydropyridinium (MPDP^), by 
M A O - B . ^7,70,71 MPDP+ is then converted to the MPP+, presumably via  
autoxidation.^^ It is speculated that the transformation of MPTP to MPP+ occurs
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predominately in astrocytes. MPP^ then diffuses to the extracellular matrix where it is 
avidly taken up by dopaminergic neurons^O due to its high afOniQr for the dopaminergic 
transport site. Once inside the DA neuron, MPP^ appears to accumulate in mitochondria. 
This accumulation is driven by the electrochemical gradient that exists between the inner 
and outer regions of the mitochondria.^^ ,72 MPP^ then acts by inhibiting oxidative 
phosphorylation at the level of complex 1,72,73 resulting in a large decrease in ATP 
production. This depletion of ATP has been observed both in vitro^^ and in vfvo.75
MAO-B
MPTP MPDP+ MPP+
The ability of MPTP to induce Parkinsonian symptoms in primates and, to a 
lesser extent, rodents has given the scientific community an excellent model of this 
disease. Understanding the mechanism by which MPTP produces neurodegeneration has 
provided some insight into the possible events which occur in Idiopathic PD and, thus, 
has indirectly provided some candidates for ameliorative pharmacological intervention. 
For example, ficom the observation that MPTP-induced parkinsonism can be blocked by 
MAO-B inhibitors,71 clinical studies have subsequently shown that early treatment of 
human patients with an MAO-B inhibitor slows the progression of PD and delays the 
need for levodopa treatmenL76,77 Additionally, the possibility o f mitochondrial 
dysfunction in patients with PD, which has now been demonstrated,78 was only pursued 
following discovery of the MPP^ inhibition of oxidative phosphorylation.
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3. 5,7-Dihydroxytryptainine
5,7-Dihydroxytryptamine (5,7-DHT), an analog of serotonin (5-HT), is a well 
known and widely used oeurotoxin.29,30 This compound, when administered directly 
into the brain, produces neurodegeneration of serotonergic nerves and/or nerve terminals. 
At low doses, 5,7-DHT is relatively selective for 5-HT neurons and can produce up to a 
25% depletion o f 5-HT in mouse whole brain.79 At moderate to high doses, 5,7-DHT 
can produce up to 30-35% 5-HT depletions in mouse whole brain.23,79 At moderate to 
high doses, however, 5,7-DHT also elicits NE neurodegeneration.23,79,80 However, 
these NE effects can be partially blocked with appropriate uptake blocking agents. DA 
depletions have also been ieponed.80,81 The moderate selectiviQr of this 5-HT analog is 
attributed to its ability to act as a substrate at 5-HT transport sites.^^
HO, NH
HO
5,7-DHT
Although the mechanism of action of 5,7-DHT has not yet been elucidated, it is 
known that uptake is essential.^^ Furthermore, it is believed that autoxidation is a 
prerequisite for 5,7-DHT toxicity. Oxidation of 5,7-DHT, as well as oxidative formation 
of this toxin from 5-HT, have been extensively studied.82-84 Qne theory on 5,7-DHT 
tox ici^  is that neurodegeneration is elicited by the free radicals and reactive oxygen 
species produced during autoxidation. It has been shown, for example, that superoxide 
and hydrogen peroxide are produced during 5,7-DHT autoxidation.^^ Li support of the 
free radical theory, partial protection from 5,7-DHT toxicity has been demonstrated upon
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pietieatment with &ee radical scavenging agents.^^>^^ Another possible mechanism of 
action stems from the formation of reactive quinone intermediates. These intermediates 
can react with nucleophiles such as proteins and enzymes thereby rendering essential 
neuronal functionalities useless.^^*^^
It has recently been shown that 5,7-DHT is oxidized by a radical mechanism 
leading to the highly toxic 5-hydroxytryptamine-4,7-dione,^'85 among other products. 
Additionally, it has been proposed that it is this oxidation product that elicits 
degeneration.84,85 Interestingly, while the oxidative action of MAO is not required for 
5-HT degeneration, it is required for the 5,7-DHT induced NE degeneration. And, by 
inhibiting MAO activity, NE degeneration by 5,7-DHT can be reduced or eliminated.^*
5,6-Dihydroxytryptamine (5,6-DHT), a structural analog of 5,7-DHT, came into 
use as a serotonin neurotoxin about the same time as 5,7-DHT. 5,6-DHT has been 
extensively studied and used.26,30,82,88,90-92 However, due to its lower potency and 
higher lethality, it is no longer used to the same extent as 5,7-DHT and, therefore, will 
not be discussed any further.
V. Purpose of Dissertation Research
Neurotoxins are very important research tools in the field o f neurochemistry, 
particulariy in the study of neurodegenerative diseases.^^ There are a number of such 
neurotoxins which have been used in CNS investigations and, particularly, to produce 
animal models of various mental disorders. W hile there are many neurotoxins, few 
provide good neuronal selectivity. And, while there have been many new neurotoxins 
recently discovered or developed and tested,70,94-100 thg most commonly used 
catecholaminergic and indolaminergic toxins today are still 6 -HDA and 5,7-DHT. 
Considering the non-specific destructive (endotcies exhibited by existing toxins, the need
2 2
for development of neurotoxins which are highly selective and very complete in the 
destruction of a given transmitter system remains.
The research presented in the following chapters encompasses the synthesis and 
the chemical and biological characterization of a series o f dihydroxytetrahydroquinoline 
derivatives. The impetus of this project was two-fold. The first was to produce new 
agents which were very selective for and toxic to a specific transmitter system, preferably 
the serotonergic system. Previous studies had suggested that this series of compounds 
could possibly be potent serotonergic neurotoxins.^^ The second was to investigate the 
mode o f action of the developed toxins, by which we might be able to (1) use the 
knowledge gained firom these studies to develop even more selective and more potent 
neurotoxins, and (2) more completely understand the mode of action(s) of other toxins 
which have been heavily studied but not yet completely understood.
A previous report by L. Lin^3 showed that a fixed side chain catecholamine 
derivative, 3-amino-6,7-dihydroxy-1,2,3,4-tetrahydroquinoline (6,7-ADTQ), was 
capable of eliciting substantial 5-HT depletions. We, thus, decided to more thoroughly 
investigate this type of compound by designing and characterizing various ADTQ analogs 
in an attempt to find more selective and potent serotonergic agents. The specific 
compounds investigated included the enantiomers of 6,7-ADTQ and two analogs, namely 
3-aminomethyl-6,7-dihydroxy-l,2,3,4-tetrahydroquinoline (6,7-AMDTQ) and 3-amino-
6,8-dihydroxy-l,2,3,4-tetrahydroquinoline (6 ,8 -ADTQ). The enantiomers were 
investigaled to evaluate the biological relevance of toxin stereochemistry. The rational for
6,7-AMDTQ design was to increase in bulkiness of the 3-position substitution of the 
parent species in an attempt to enhance the selectivity for serotonergic neurons and 
decrease the selectivity for catecholaminergic neurons. The rational for 6,7-AMDTQ 
design was to give the parent agent a similar hydroxy configuration as displayed by the 
classic serotonergic toxin 5,7-DHT.
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The following chapters describing and discussing the investigations undertaken 
are entitled:
Chapter 2
Synthesis of 3-Aminoniethyl-6,7-dihydroxy-l,2,3,4-tetrahydroquinoline and 3-Amino-
6,8-dihydroxy-l,2,3,4-tetrahydroquinoline
Chapter 3
Basic Chromatography and Electtochemistry
Chapter 4 
Neuiotoxici^
Chapters 
Mode of Action I: Uptake Interactions
Chapter 6
Mode of Action H: Ease of Oxidation & Acid/Base Properties
C huter 7
Mode of Action HI: Autoxidation and Reactive Oxygen Species
Chapters
Mode of Action IV: Disruption of Mitochondrial Oxidative Hio^horylation
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Synthesis of 3-Ammomethyl-6,7-dihydroxy- 
1^ ,^4-tetrahydroqulnollne & 3-Amino-6,8- 
dihydroxy-l,2,3,4-tetrahydroqumoiine
Chapter 2
I. Introduction
Neurotoxins, such as 6-hydro}^dopamine (6 -HDA) and 5,7- and 5,6-dihydroxy- 
tryptamine (5,7- and 5,6-DHT), have been employed for more than 25 years to study 
behavioral, physiological, and pharmacological phenomena associated with specific 
neuronal pathways. While highly specific when compared to surgical or electrolytic 
methods, such chemical toxins still exhibit a high degree of non-target tissue destruction. 
Considering this, it is not surprising that there has been an on-going search for agents
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which exhibit higher degrees of selectivity and toxicity toward specific neuronal 
populations. Additionally, the mode of action by which 6-HDA and related neurotoxins 
elicit toxici^ has, for the most part, eluded researchers. Therefore, the relentless effort to 
elucidate the mechanism by which these type of agents elicit neurodegeneration continues.
With the above in mind, we have designed fixed side chain analogs of 6 -HDA 
with hopes to (I) provide neurotoxins which are superior to those in use and (2) more 
completely determine the destructive mode(s) of action o f such agents. With a more 
complete understanding o f how toxins elicit neurodestruction, the alleviation and/or 
postponement of onset of neurodegenerative disorders might be achieved. This rationale 
has already been realized through new treatments of Idiopathic Parkinson's Disease 
derived from the understanding of the mode of action of MPTP.^^
This chapter describes the synthesis of two putative neurotoxic agents, 
3-am inom ethyl-6,7-dihydroxy-l,2,3,4-tetrahydroquinoline (8 ) and 3-amino-6,8- 
dihydroxy- 1,2,3,4-tetrahydroquinoline (17) starting from easily available dimethoxy- 
benzaldehydes.
HO,. .NHg
NHa
HO
H
.  17
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n. Synthetic Summaries
This section provides a brief outline of the synthetic steps involved in the 
production o f 3-am inom ethyl-6 ,7-d ihydroxy-l,2 ,3 ,4-tetrahydroquinoline 
dihydrobromide (8*2HBr or 6,7-AMDTQ*2HBr) and 3-amino-6,8-dihydroxy-I,2,3.4- 
tetrahydroquinolme dihydrobromide (17«2HBr or 6,8-ADTQ*2HBr). The details o f each 
of the synthetic steps arc presented in the following experimental section, while NMR 
spectra of the intermediates and the final products, along with their associated peak 
assignments, appear in the final section, NMR Spectra and Assignments.
A. Synthesis of 3«Aminomethyl-6,7-dihydroxy-l,2,3*4- 
tetrahydroqainoline Dihydrobromide
The first step in the synthesis of 3-amino-6,7-dihydroxy-1,2,3,4-tetrahydro­
quinoline dihydrobromide was the condensation of 3,4-dimethoxybenzaldehyde, 1, with 
dimethylmalonate in the presence of piperidine and benzoic acid. This reaction is an 
example of a Knoevenagel condensation of an aldehyde and an enolizable compound, 
base catalyzed by an amine. The condensed product 2 was obtained in a  yield of 8 8 % 
and the associated proton NMR spectrum was in agreem ent with literature
reports. 1 01 ,102
-CO2CH3 
C H s^
CO2CH3
C H ,O . .^ C H O
C,H5C00apiperidi«
1 2 
Sdiem e 2-1. Synthesis of dimethyl-3,4-dimethoxybenzylidenemalonate, 2.
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Reduction of the ben^lidene derivative 2 was accomplished through catalytic 
hydrogenation using palladium on carbon as a catalyst This reaction proceeded at a 
moderate rate and resulted in a clean product 3 with a yield of 8 6 %. The proton NMR 
spectrum agreed with previous literature reports.
CO2CH3
Œ 3OH, dioxane ^  CO2CT3
CH3O
3
Scheme 2-2. Synthesis of dimethyl-3,4-dimethoxybenzylmalonate, 3.
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The regioselective ring nitration of dimethyl-3,4-dimethoxybenzylmalonate 3 was 
realized using fuming nitric acid at 0°C. Due to the aromatic ring being highly activated, 
this nitration resulted in product 4  in quantitative yield (100%).
C H ^ Y Y ^ C O ^ C H ,
3 4
Scheme 2-3. Formation o f dimethyl-4,S-(timethoxy-2-nitrobcnzylmalonate, 4.
The tetrahydroquinoline derivative 5 was produced by catalytic hydrogenation of 
4, using palladium on carbon as a  catalyst. Reduction of the nitro group to the 
corresponding amine allowed for intramolecular cyclization of the side chain via
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nucleophilic substitution. Le., attack by the amine on the electron deficient carbonyl 
carbon. This reaction proceeded rapidly and resulted in a clean product 5 with a yield of 
72%.
CH3o A ^ N Q , « ) : “ ’ M eO aiH F.H O A c
H
4 5
Scheme 2-4. Synthesis o f 3-Carboxymethyl-6,7-dimethoxy-I,2,3,4-tetrahydro-2-
oxoquinoline, 5.
The next step involved the production of the carboxantide 6  from the methylester
5. While seemingly straightforward, this step proved to be challenging. The conversion 
was attempted using many different methods, most resulting in unsuccessful reactions. 
Reagents and reaction conditions attempted included (1) ammonium hydroxide and 
ammonium chloride at atmospheric pressure, (2 ) condensed ammonia with ammonium 
chloride in a sealed, pressure-resistant vessel with heat, (3) saturated ammonia solution in 
a sealed, pressure-resistant vessel with heat, and (4) M%A1NH2 at atmospheric pressure 
conditions. All these attempts yielded the amide firom the methylester, but the major 
product formed was 3-carboxamide-6,7-dimethoxy-2-hydroxyqainoline (6 a), the 
oxidized form of 6 , and small amounts, if any, of the desired product 6 .
*  V ^ N ^ O HH H
5 6 6a
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Attempts to determine the problem(s) with these reactions led us to studies using 
pure, desired product 6 . Exposing 6  to the same reaction conditions in which it was 
formed resulted in a time dependent conversion to the oxidized product 6 a. Thus, the 
time for the reaction was optimized to allow for maximal formation of 6  while limiting the 
follow-up oxidation reaction.
M eO ftTH F c H , o " '^ ^ N ' ^ 0  
H K
5 «
Scheme 2-5. Synthesis of 3-carboxamide-6,7-dimethoxy-l,2,3,4-tetrahydro-2-
oxoquinoline, 6 .
The reagents and reaction conditions ultimately employed were ammonia and 
ammonium hydroxide with a high anunonia pressure and an elevated temperature. The 
major product under these conditions remained 6 a; however, due to solubility differences 
in methanol, the desired product was isolable. While this reaction was neither fast nor 
efficient, the product was obtained in a yield of 24%.
Conversion of the two amide functionalities of 6  to their corresponding amines 
was achieved via diborane reduction. The reaction proceeded at a moderate rate and was 
followed by hydrolysis of the borate complex with dilute hydrochloric acid. This resulted 
in a relatively pure (~95%) diamine 7 in a yield of 88%. Further purification using silica 
gel column chromatography was not useful due to the fact that the diamine degraded 
while on the column.
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C H ^ A ^ N - ^ O  2-«MHCI
H H
6  7
Scheme 2-6. Synthesis of 3-aminoniethyl-6,7-dimethoxy-l,2,3,4~tetrahy(iroqumolme,
7.
The final step in this synthesis was the cleavage of the methyl ethers to their 
corresponding hydroxy functionalities. An excess of 48% hydrobromic acid under reflux 
conditions in a pressure vessel produced the desired product With minor workup, a light 
tan solid, 8*2HBr, was obtained in high purity with a yield of 74%.
N«2  48 % HBr ^ 2
A -2HBr
H H
7 8
Scheme 2-7. Synthesis of 3-aminomethyl-6,7-dihydroxy-l,2,3,4- 
tetrahydroquinoline*2HBr, 8*2HBr.
The synthesis of 3-aminomethyl-6,7-dihydroxy-I,2,3,4-tetrahydroquinoline 
dihydrobromide ^2H B r) was completed with an overall yield of 9%. The ammonolysis 
reaction provided the poorest yield in  this synthetic pathway and was the major 
contributor to the low overall yield. The ring-formation reaction shown in Scheme 2-4, 
however, proved to be a useful and efficient general method for the production of 
tetrahydroquinoline ring structures.
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B. Synthesis of 3>Amino-6,8-dihydroxy-l,2,3,4- 
tetrahydroquinoline Dihydrobromide
The first step in the synthesis of 3-amino-6,8-dihydroxy-l,2,3,4-tetrahydro- 
quinoline dihydrobromide was the formation of the oxazolone firom the corresponding 
aldehyde. This was accomplished by condensing 3,5-dimethoxybenzaldehyde, 9, with 
hippuric acid in the presence of powdered sodium acetate and acetic anhydride. This 
reaction gave a yellow crystalline product, 10, with an 86% yield.
CHO
9
CgHgCONHCHzCOiH 
NaOAc, AC2O
rH ,n
10
Scheme 2-8. Formation of 4-(3,5-dimethoxybenzylidene)-2-phenyl-5-oxazolone,
10 .
Opening of the azlactone ring and addition of the desired methoxy group was 
achieved by basic methanolysis. The reaction afforded a white crystalline product, 11, in 
a yield o f 88%.
N r w  NHCOPh
V  « . . r n . C02CH3
CH30 10 Œ3O 11
Scheme 2-9. Synthesis of methyl-2-benzoylamino-3-(3,S-dimethoxyphenyl)-2-
propenoate, 11 .
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Reduction of the vinyl moiety was accomplished through hydrogenation, using 
palladium on carbon as a catalyst The reaction progressed at a moderate rate and gave a 
clean product in quantitative yœld (100%).
NHœPh
Hz, Pd/C NHCOPh
CH30  11 CH30  12
Scheme 2-10. Formation of methyl-2-benzoylantino-3-(3,5- 
dimethoxyphenyl)propanoate, 12 .
A ^ ic a l  attempt at nitration of the aromatic ring o f 12 employed fuming nitric 
acid with chloroform as the solvent The nitration of 12, however, proved quite 
perplexing. Using a  6-fold mole excess of faming nitric acid and a reaction temperature 
of 0°C, a yield of 16% was obtained for nitrated product 13 following silica gel column 
purification. Attempts to optimize this reaction with regards to the amount of fuming 
nitric acid (2 - to 6-fbld mole excess), nature o f the solvent (chloroform, acetic acid, and a 
mixture of these), and the reaction temperature (-78 to 25X ) were undertaken. But, each 
of these alternatives resulted in a lesser yield than the original reaction. Since all o f these 
fuming nitric acid reactions resulted in large amounts of uncharacterizable product(s), 
some milder nitration conditions were attempted. These included (1) ammonium nitrate 
and trifluoroacetic anhydride, which led to multiple side products but no discernible 
desired product, and (2 ) tetraniuomethane with pyridine, reported to nitrate tyrosine in 
good yield, but which only provided the desired product 13 in an 8% yield in the current
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case. Following this string of imsuccessfiil attempts, we employed a 2- to 4-fold excess 
of 70.4% nitric acid with acetic acid as the solvent and reaction temperatures ranging &om 
-10 to 25°C. These conditions appeared to be reasonably promising with yields ranging 
between 10 to 19%. Ultimately, by applying simplex optimization, maximal yield was 
achieved using a 4-fold excess of 70.4% nitric acid in  acetic acid at 1S°C. The reaction, 
under these conditions, was neither clean nor efficient, resulting in a yield of only 19% 
after purification.
COjCH, HOAc
CH3O CH3O
Scheme 2-11. Synthesis of methyl-2-benzoylamino-3-(3,5-dimethoxy-2-
nitrophenyl)propanoate, 13.
Catalytic hydrogenation, using palladium on carbon, resulted in reduction of the 
nitro group to its corresponding amine, which subsequently underwent intramolecular 
cyclization to afford the lactam derivative 14. This reaction gave a clean product with a 
90% yield.
MeOH, TOP, dioxane^
CH3O 13 CH3O 14“
Scheme 2-12. Formation o f 3-benzoylamino-6,8-dimethoxy-l,2,3,4-tetrahydro-2-
oxoquinoline, 14.
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The amide functionalities o f 14 were converted to their corresponding amines 
through a diborane reduction. The time required for reduction was substantial because 
the benzoyl amide functionali^, due to its characteristically low electrophilicity, 
underwent reduction at a much slower rate than did the ring amide. The product obtained 
from this reaction was not clean and, thus, was purified by silica gel column 
chromatography, resulting in a yield of 90% for 15.
NHCOPh
14
CH3O
1. BHvTHF
2.6M HC1
15
Scheme 2-13. Formation of 3-benzylamino-6,8-dimethoxy-l,2,3,4-
tetrahydroquinoline, 15.
N-debenzylation was achieved through catalytic hydrogenation, using palladium 
on carbon. The reaction was slow and resulted in some uncharacterizable by-products. 
Utilizing silica gel column chromatography, 16 was obtained in an 83% yield.
HOAc
CH3O CH3O15 16
SchenK 2-14. Synthesis of 3-amino-6,8-dimethoxy-l,2,3,4-tetrahydroquinoline, 16.
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Deprotection of the methyl ethers employed an excess of 48% hydrobromic acid 
under reflux conditions in a sealed, pressure-resistant vessel. A considerable amount of 
time was required for this reaction to reach completion, with the 8-methoxy cleavage 
requiring a five-fold longer period of time than what was needed for the 6 -methoxy 
cleavage. This reaction required 26 hours. Stopping the reaction before this time resulted 
in a mixture of the dihydroxy and 8-monomethoxy products. This reaction gave the 
desired product 17 with a satisfactory puri^ and a yield of 8 6 %.
CHjO
HO,
48%  HBr •2HBr
HO
17
Scheme 2-15. Formation of 3-amino-6,8-dihydroxy-l,2,3,4- 
tetrahydroquinoline*2HBr, 17«2HBr.
The complete synthesis of 3-amino-6,8-dihydroxy-1,2,3,4-tetrahydroquinoline 
dihydrobromide, 17*2HBr, gave an overall yield of 8%. The aromatic ring nitration was 
the major stumbling block in the pathway. Many different reaction conditions for this 
nitration were tried, but the optimal yield obtained was only 19%. However, considering 
that the complete synthesis required 8 steps, we were reasonably satisfied with an overall 
8% yield.
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m . Experimental
A. General Methods
Tetrahydiofiinui (THF) was refluxed over calcium hydride and f ^ h ly  distilled 
prior to use. Acetic anhydride was distilled from phosphorus pentoxide. Methanol was 
refluxed over Mg turnings and iodine, distilled, and stored over 4Â, 8-12 mesh molecular 
sieves. Ethyl acetate was refluxed over sodium and benzophenone and freshly distilled 
prior to use. All other chemicals and reagents were purchased and used without further 
purification.
Proton NMR spectra were acquired using a Varian XL-300 MHz spectrometer. 
While the location of peaks and their associated splitting constants are presented in this 
section, actual spectra for each intermediate and associated peak assignments are 
presented in the next and final section, entitled NMR Spectra and Assignments. Mass 
spectra were recorded using a VG-ZAB-E instrument
B. Synthesis of 3-Aminomethyl-6,7-dihydroxy-1,2,3,4- 
tetrahydroquinoline Dihydrobromide
1. Dimethyl*3,4*dimethoxybenzylidcneinaionate (2)
To a 5(X) mL round bottomed flask, fitted with a water condenser, was added
3,4-dimethoxybenzaldehyde 1 (16.6 g, 100 mmol), dimethylmalonate (12.54 mL, 110 
nunol), benzoic acid (0.3 g, 2.5 mmol), and piperidine (0.93 mL, 9.4 mmol). This 
mixture was heated at 85°C, with continuous stirring, for 1.2 h. The reaction solution
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was allowed to cool to room temperature followed by addition of cold methanol (7S mL), 
at which time crystals began to form. The reaction mixture was cooled in an ice bath for 
30 min. The crystalline product was collected by suction filtration, washed with cold 
methanol (2 x 10 mL) followed by hexane (3 x 30 mL) and allowed to air dry. The white 
crystalline product was obtained in a yield of 88%.
iH NMR (CDCI3): Ô = 7.68 (s, IH), 7.05 (d, J  = 8.2 H z , IH), 6.97 (1, IH), 6.85 (d, J 
= 8.3, IH), 3.89 (s, 3H), 3.85 (s, 6H), 3.82 (s, 3H).
2. D im ethyl-3,4-dim ethoxybenzylm alonate (3)
The ben^lidene derivative 2 (20.4 g, 87 mmol) was dissolved in a mixture of hot 
methanol (50 mL) and dioxane (1(X) mL), and degassed with nitrogen. 10% palladium 
on carbon (5 g) was added and hydrogenation was carried out at 60 psi in a Parr shaker 
apparatus for 8 h. The reaction mixture was then filtered through a bed of Celite, the 
deposited carbon washed with hot methanol (2 x 10 mL), and the filtrate solvent stripped 
to give atanoiL  This reaction afforded a yield of 86% for 3.
IH NMR (CDCI3): 6  = 6.75-6.68 (m, 3H), 3.81 (s, 3H). 3.80 (s, 3H), 3.60 (s, 6H), 
3.61 (t, J  = 7.8, IH). 3.13 (d, J = 7.8, 2H).
3. D im ethyl-4,5-dim ethoxy-2-iiitrobenzyim aIonate (4)
Fuming nitric acid (16.3 mL, 354 mmol) was added dropwise to a solution of 
dimethyl-3,4-dimethoxybenzylmalonate 3 (16.6 g, 58.9 mmol) dissolved in chloroform 
(160 mL) at 0°C under a nitrogen atmosphere. The reaction was stirred at 0°C for 4 h. 
The reaction mixture was neutralized and washed with a  saturated sodium hydroxide 
solution followed by water. The organic layer was dried with Na2S0 4 , followed by 
rotory evaporation to give a yellow solid in quantitative yield (100%).
IH NMR (CDCI3): 5 = 7.63 (s, IH), 6.78 (s, IH), 3.96-3.93 (m, IH), 3.92 (s, 6H),
3.69 (s, 6 H), 3.49 (d, J  = 7.5 Hz, 2H).
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4. 3-Carboxymethyl-6y7-dimethoxy*l,2,3y4*tetrahydro>2-oxoquinoline
(S)
The nitrophenyl derivative 4 (1.2 g, 3.67 mmol) was dissolved in a mixture of 
warm THF (IS mL) and methanol (60 mL). After cooling to room temperature, 10% 
palladium on carbon (200 mg) and glacial acetic acid (0.6 mL) were added. The 
hydrogenation vessel was pressurized to 40 psi of hydrogen in a Parr shaker apparatus. 
The reaction was stopped after 6  h at room temperature, bubbled with nitrogen gas, 
diluted with warm THF (SO mL), filtered through a bed of Cëlite, and the residue washed 
successively with hot THF (2 x 10 mL) and hot chloroform (2 x 10 mL). The combined 
filtrate was stripped of sovent to yield a sticky solid. This was dissolved in SO mL of 
chloroform, and the mixture was washed with a saturated sodium bicarbonate solution 
followed by water. The organic layer was separated, and the solvent was stripped. The 
product was dissolved in hot methanol (10 mL) and then cooled to 0°C, with a white 
precipitate forming during the cooling. The precipitate was collected by suction filtration 
and washed with cold methanol (2 x S mL). The collected product was obtained in a 72% 
yield.
iH NMR (CDCI3): 5 = 7.69 (bs, IH), 6 .68  (s, IH), 6.31 (s. IH), 3.83 (s, 6 H), 3.74 (s, 
3H), 3.60 (dd, J  = 8.4 & 6.3 Hz, IH), 3.30 (dd, J * 1S.9 & 8.4 Hz, IH), 3.0S (dd, J =
1S.9 & 6.3 Hz, IH).
MS (70 eV-DIP) m/z (relative intensif): 26S 21), 206 (100).
MS (FAB) m/z (relative intensity): 266 ^+ 1 ,1 0 0 ), 265 (98), 206 (S4).
5. 3-Carboxainide-6y7>diniethoxy>l,2,3y4*tetrahydro-2«oxoqiiinoline (6)
The methylester derivative 5 (200 mg, 0.7SS mmol), methanol (8  mL), and THF 
(8  mL) were added to a  pressure bottle and heated to effect dissolution. The solution was 
cooled to 0°C, degassed with argon, and ammonium hydroxide (4 mL) was added. The 
solution was saturated with ammonia gas, and the pressure bottle was sealed and heated
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to 6S°C for 22 h. A white piecipitate formed as the leaction proceeded. The solution was 
cooled to room temperature, and the precipitate was collected by suction filtration. 
Further purification by silica gel chromatography was unsuccessful due to instabili^ of 
the product. A yield of 24% was obtained.
IR NMR (DMSO-d<>): 8  = 9.97 (bs, IH ), 7.43 (s, IH), 7.07 (s, IH), 6.81 (s, IH), 6.49
(s, IH), 3.69 (s, 3H), 3.67 (s, 3H), 3.28 (dd, J = 9.9 & 6 .6  Hz, IH), 3.08 (dd, J =
15.9 & 9.9 Hz, IH), 2.88 (dd, J = 15.9 & 6 .6  Hz, IH).
MS (70 eV-DIP) m/z (relative intensity): 250 (M+, 32), 206 (100).
MS (12 eV-DIP) m/z (relative intensity): 250 (M+, 30), 206 (100).
MS (FAB) m/z (relative intensity): 251 (M +1,100), 250 (63), 206 (81).
6 . 3-Aniinomethyl*6,7>dimethoxy-l,2^,4-tetrahydroqiiinoline (7)
The carboxamide compound 6  (100 mg, 0.40 mmol) was placed in a pear-shaped 
side arm flask equipped with a water condenser and maintained under a  nitrogen 
atmosphere. The reaction flask was lowered to 0°C, and BH3:THF (1 M, 9.6 mL, 9.6 
mmol) was added dropwise. The solution was heated at reflux for 3.5 h with continuous 
stirring. The reaction mixture was hydrolyzed with 6  M HCl imtil the evolution of 
hydrogen subsided, stirred for a further 30 min, and cooled. The solution was basified 
with a saturated sodium hydroxide solution to pH 10-11 and extracted with chloroform (4 
X 50 mL). The organic extracts were combined, dried using Na2S0 4 , and the organic 
solvent stripped to yield a thick oiL Any purification by colunm chromatography is not 
recommended due to instability of the product The reaction gave a pure product with a 
yield of 88%.
IH NMR (CDCI3): 8  = 6.50 (s, IH), 6.09 (s, IH), 3.76 (s, 6H), 3.33 (dd, J = 10.8 &
3.3 Hz, IH ), 2.94 (dd, J = 10.8 & 8.7 Hz, IH), 2.76 (dd, J = 15.9 & 5.1 Hz, IH),
2.69 (dd, J = 7.2 & 2.4 Hz, 2H), 2.39 (dd, J = 15.9 & 8.7 Hz, IH), 2.00-1.86 (m, 
IH).
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MS (70 eV-DEP) m/z (relative intensity): 222 (M+ 100). 192 (12), 190 (70).
7. 3-A ininom ethyl-6,7-dihydroxy*l,2,3y4-tetrahydroqiiinoline * 2H B r (8  
• 2HBr)
Dimethoxy derivative 7 (80 mg, 0.37 mmol) was placed in a  pressure bottle, and 
the bottle was flushed with argon. Hydrobromic acid (48%, 1.4 mL, 2S.9 mmol) was 
added, the bottle was sealed, and the mixture was heated at reflux for 8 h. The solution 
was lyophilized, and the resultant crude solid was repeatedly washed with ether (6 x 1 
mL) and acetonitrile (6 x 1  mL) in an alternating fashion until the organic layer remained 
clear. A light tan solid was isolated in a 74% yield.
IH NMR (D2O); 8  = 6.79 (s, IH), 6.75 (s, 0.5H, part, exch.), 3.67 (bd, Japp = 11.1, 
IH), 3.19-3.03 (m, 3H), 2.94 (dd, J = 15.6 & 3.9 Hz, IH), 2.59 (dd, J = 15.6 & 10.8 
Hz, IH), 2.54-2.44 (m, IH).
MS (12 eV-DIP) m/z (relative intensity): 194 (M+, 76), 176 (26).
C. Synthesis of 3-Amino-6,8-dihydroxy-l,2,3,4- 
tetrahydroquinoline Hydrobromide
1. 4-(3y5-Dim edioxybenzylidene)-2-phenyl*S*oxazolone (10)
3,5-dimethoxybenzaldehyde 9 (17 g, 102 mmol), hippuric acid (19.25 g, 107 
nunol), anhydrous sodium acetate (8.39 g, 102 mmol) and acetic anhydride (50 mL, 530 
mmol) were added to a 250 mL round bottomed flask equipped with a  water condenser 
fitted with a drying tube. The reaction mixture was heated a t 85°C with continuous 
stirring for 2.5 h, during which time the color of the solution turned from white to a 
bright yellow. The mixture was cooled, and cold ethanol (65 mL) was added, upon 
which a yellow crystalline product appeared. The mixture was further cooled. The
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mixture was then filtered with suction, and the solid product was washed with cold 
ethanol (2 x 25 mL), with boiling water (3 x 20 mL), and, finally, with ice-cold ether (5 
mL). The yield was 8 6%.
IH NMR (CDCI3): 6  = 8.14 (bd, Japp = 6.9 Hz, 2H), 7.63-7.49 (m, 3H), 7.40 (d, J =
2.4 Hz, 2H), 7.15 (s, IH), 6.65 (t, J  = 2.4 Hz, IH ), 3.87 (s, 6H).
2. M ethyU 2-benzoylaiiiino-3-(3,S-dim ethoxyphenyl)-2>propenoate (11)
The azlactone compound 10 (26.3 g, 85 mmol), anhydrous sodium carbonate 
(26.82 g, 255 mmol), and methanol (263 mL, dry) were added to a 500 mL round 
bottomed flask equipped with a water condenser fitted with a drying tube. The contents 
were refluxed for 45 min during which time the yellow color of the reaction mixture 
disappeared. The mixture was filtered hot, and the captured solid washed with hot 
methanol (2 x 15 mL). The combined filtrate was cooled in the refrigerator for a 
minimum of 3 h. A white crystalline product formed and was collected by filtration and 
washed with 1:1 methanolnvater (2 x 10 mL). The yield was 88%.
IH NMR (CDCI3): 6  = 7.85 (bd, Japp = 7.2 Hz, 2H). 7.70 (bs, IH), 7.56-7.43 (m, 
3H), 7.36 (s, IH), 6.64 (d, J = 2.1 Hz, 2H), 6.40 (t, J  = 2.1 Hz, IH), 3.85 (s, 3H),
3.65 (s, 6H).
3. M ethyl-2>benzoylam ino-3>(3,5-diinethoxyphenyl)propanoate (12)
Propene derivative 11 (9.89 g, 29 mmol) was dissolved in hot THF (55 mL). To 
this solution was added methanol (55 mL), 10% palladium on carbon (1.50 g) and glacial 
acetic acid (0.75 mL). Hydrogenation was carried out at 60 psi for 10 h in a Parr shaker 
tq)paratus. The reaction solution was filtered through a thick layer of Celite. The filtering 
agent was washed with hot methanokchloroform (1:3, 3 x 10 mL). Solvent was 
removed, yielding an oil which turned into a white solid upon drying with an oil pump 
vacuum. This reaction was quantitative (1(X)% yield).
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IH NMR (CDCI3): 5 = 7.73 (d, J =  7.8 Hz, 2H), 7.52-7.38 (m, 3H), 6.59 (d, J = 7.2 
Hz, IH), 6.33 (t, J = 2.4 Hz, IH), 6.26 (d, J = 2.4 Hz, 2H), 5.06 (dt, J  = 7.5 & 5.4 
Hz, IH), 3.77 (s, 3H), 3.69 (s, 6H), 3.25-3.12 (m, 2H)
4. M ethyl-2-benzoylaiiiino-3>(3,S-diniethoxy*2>nitrophenyl)propanoate
(13)
Initial attempted syntheses
a) The propanoate derivative 12 (I g, 2.9 mmol) was dissolved in chloroform (10 
mL), and the mixture was purged with nitrogen. To this solution, fuming niuric acid (128 
pL, 17.5 mmol) was added dropwise. The reaction was stirred at 0‘C for 9 h. The 
workup of the mixture was the same as that described below for the most successful 
conditions. These conditions gave a yield of 16%.
b) The propanoate derivative 12 (50 mg, 0.146 mmol) was dissolved in chloroform 
(100 pL), and the mixture was purged with nitrogen. To this solution were added 
ammonium nitrate (11.9 mg, 0.146 mmol) and trifluoroacetic acid (73 ^L, 0.51 mmol). 
The reaction was stirred at room temperature for 1 h. The workup of the mixture was the 
same as that described below for the most successful conditions. These conditions gave a 
yield of 3%.
c) In a round bottomed flask equipped with a condenser fitted with a drying tube, the 
starting material (105 mg, 0.307 mmol) was dissolved in CHCI3 (3 mL). To this 
solution were added ethanol (1 mL, 100%), pyridine (50 ^iL) and tetranitromethane (0.4 
g). The mixture was heated at reflux for 4 h. At the completion of the reaction, 6  M HCl 
(20 mL) was added, and the reaction mixture was extracted with EtOAc. The organic 
layer was dried with Na2S0 4 , and the solvent was stripped to yield a  violet solid. The 
crude product was purified using preparative TLC and afforded an 8% yield.
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Final, m ost successful synthesis
The propanoate derivative 12 (3.41 g, 9.9 mmol) was dissolved in glacial acetic 
acid (136 mL), and the solution was purged with nitrogen. The nitrating agent, 70.4% 
nitric acid (2.25 mL, 39.6 mmol) mixed with glacial acetic acid (4 mL), was added 
dropwise to the solution. The reaction was stirred at 15°C for 24 h, after which the 
mixture was neutralized with a sodium hydroxide solution to a neutral pH. (Chloroform 
(SO mL) was added, and the layers were allowed to separate. The chloroform layer was 
dried with Na2S0 4 , and the solvent was removed to give a blackish product which was 
purified by column chromatography (SiOi, 75:25 CHClgiEtOAc, 40 g SiOg/g crude 
product). The yield o f the nitrated product following column purification was 18.6%.
IH NMR (CDCI3): 5 = 7.78 (bd, Japp = 6.9 Hz, 2H), 7.51-7.38 (m, 3H), 7.10 (d, J =
7.0 Hz, IH), 6.43 (d, J  = 2.4 Hz, IH), 6.39 (d, J  = 2.4 Hz, IH), 4.98 (ddd, J  = 9.3 &
7.1 & 5.1 Hz, IH), 3.83 (s, 3H), 3.77 (s, 3H), 3.76 (s, 3H), 3.23 (dd, J = 14.4 & 5.1 
Hz, IH), 3.03 (dd, J = 14.4 & 9.3 Hz, IH).
5. 3-B enzoylam ino-6,8-dim ethoxy- l,2 ,3 ,4 -tetrahydro-2> oxoquinoline
(14)
The nitro compound 13 (4.25 g, 10.9 mmol) was dissolved in a hot mixture of 
methanol (140 mL), THF (6  mL), and 1,4-dioxane (120 mL). The solution was 
degassed with nitrogen and cooled to room temperature. Palladium on carbon (10%, 682 
mg) and glacial acetic acid (3.25 mL) were added, and hydrogenation was carried out at 
65 psi for 48 h in a  Parr shaker apparatus. The solution was degassed with nitrogen and 
filtered through a bed o f Celite. The deposited charcoal was washed with hot chloroform 
(2 X 10 mL), and the cmnbined filtrate was stripped of the solvent leaving a  thick oiL The 
oil was dissolved in chloroform (50 mL), and the resulting solution was washed with a 
5% sodium bicarbonate solution, followed by water. The organic layer was separated
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and dried with Na2S0 4 , and the solvent was removed to give an o£f-white solid. The 
yield was 90%.
IH NMR (CDCI3): 5 = 7.86 (bd, Japp = 6.9 Hz, 2H), 7.71 (bs, IH), 7.54-7.41 (m, 
3H), 7.33 (d, J = 4.3 Hz, IH). 6.39 (d, J = 2.7 Hz, IH), 6.37 (d, J = 2.1 Hz, IH),
4.66 (ddd, J = 14.1 & 6.3 & 4.4 Hz, IH). 3.84 (s 3H), 3.78 (s, 3H), 3.69 (dd, J = 15.3 
& 6.3 Hz, IH), 2.83 (dd, J  = 153 & 14.1 Hz, IH).
6. 3-Benzylamino-6y8-diinethoxy*ly2y3y4*tetrahydroqiiinoline (IS)
To the quinoline product 14 (893 mg, 2.7 mmol) in a 300 mL round bottomed 
flask equipped with a water condenser and a dropping funnel was added BHgzTHF (1 M, 
44 mL, 44 mmol), dropwise, at room temperature under a  nitrogen atmosphere. The 
solution was heated at reflux for 3 h and then cooled. The reaction mixture was 
hydrolyzed with 6  M HCl tmtil no more hydrogen evolved. Water was added until all the 
salts dissolved. The mixture was stirred for an additional 30 min and then cooled. THF 
was stripped from the mixture. The reaction mixture was basified with a saturated 
sodium hydroxide solution to pH 10-11 and extracted with chloroform (4x50  mL). The 
organic extracts were combined, dried with Na2SÛ4 , filtered, and the solvent was 
removed to give a thick brown oil which was purified by column chromatography (Si0 2 , 
90:10 CHClgzMeOH). The yield of purified 15 was 90%.
IH NMR (CDCI3): 6  = 7.38-732 (m, 5H), 6.28 (d, J  = 2.4 Hz, IH), 6.17 (J = 2.4 Hz, 
IH), 3.89 (s, 2H), 3.78 (s, 3H), 3.72 (s, 3H), 3.36 (bt, Japp = 7.2 Hz, IH), 3.15-3.08 
(m, 2H), 2.95 (dd, J  = 16.5 & 3.9 Hz, IH), 2.69 (dd, J  = 16.5 & 7.5 Hz, IH).
MS (70 eV-DIP) m/z (relative intensity): 298 (M+. 100), 192 (88).
7. 3-Ainino>6»8*diinethoxy*l,2^,4*tetrahydroqiiinoline (16)
N'Benzylamine derivative 15 (532 mg, 1.79 mmol) was dissolved in glacial 
acetic acid (13.3 mL). The solution was degassed with nitrogen, and 10% palladium on
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carbon (107 mg) was added. Hydrogenation was carried out at 65 psi for 98 h in a Parr 
shaker apparatus. The solution was filtered through a bed o f Ceiite, the carbon powder 
washed with hot chloroform (2 x 10 mL), and the filtrate solvent was removed to yield an 
oil. This oil was dissolved in chloroform (100 mL), washed with a 10% sodium 
hydroxide solution, and washed with water. The organic layer was isolated and dried 
with Na2S0 4 , and the solvent was removed to give a gummy solid which was purified by 
column chromatography (SiOz, 90:10 CHCl^iMeOH). The purified product was 
obtained in an 83% yield.
IR NMR (CDCI3): 6  = 6.28 (d, J = 2.4 Hz, IH), 6.16 (d, J = 2.7 Hz, IH), 3.78 (s, 
3H), 3.71 (s, 3H), 3.39-3.32 (m, IH), 3.30 (bd, Japp = 11.7 Hz, IH), 3.06-2.95 (m, 
2H), 2.46 (dd, J = 16.2 & 6.3 Hz, IH).
MS (70 eV-DIP) m/z (relative intensity): 208 (M+, 100), 193 (34), 192 (23).
8 . 3-A m ino-6,8-dihydroxy-l,2 ,3 ,4-tetrahydroqttinoU ne«2H B r (17*2HBr)
The dimethoxy compound 16 (232 mg, 1.12 mmol) was placed in a pressure 
bottle. The bottle was flushed with argon, followed by addition of an excess of 48% 
hydrobromic acid (3.0 mL). The mixture was heated at reflux for 26 h. The solution 
was lyophilized, and the solid obtained was repeatedly washed with ether (6x1 mL) and 
acetonitrile ( 6x1  mL) in an alternating fashion until the organic wash solvents remained 
clear. A  tan solid product was obtained with a yield of 86%.
IH NMR (D2O); 8  = 6.38 (d, J  = 2.7 Hz, 0.5H, part exch.), 6.3 (d, J = 2.4 Hz, IH), 
3.98-3.88 (m, IH) [alternatively, this multiplet could be reported as 3.93 (dddd, J = 9.9, 
9.6, 5.3, & 3.5 Hz, IH)], 3.83 (ddd, J = 12.3 & 3.5 & 1.7 Hz, IH), 3.42 (dd, J  = 12.3 
& 10.2 Hz, IH), 3.23 (bdd, Japp -  16.8 & 5.4 Hz, IH), 2.94 (dd, J = 16.8 & 9.3 Hz, 
IH).
MS (70 eV-DIP) m/z (relative intensity): 180 (M+, 100), 164 (22), 82 (53), 80 (55).
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IV. NMR Spectra and Assignments
This section contains the 300 MHz proton NMR spectra and associated signal 
assignments for the compounds discussed above in sections II and EL
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Figure 2 1. Proton NMR spectum of 2 in CDCI3 .
CH
Hs
CO2CH3
CO2CH3
Table 2-1. Proton NMR signal assignments for 2 in CDCI3.
P ro to n (s) M ultip licity Chem ical sh if^  
5
(ppm )
C oupling 
constant, J
(H z)
=CH s 7.68
H-6 d 7.05 8 .2
H-2 s 6.97
H-5 d 6.85 8.3
-OMe s 3.89
-CChMe's s 3.85
-OMe s 3.82 •
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Figure 2-2. Proton NMR spectum of 3 in CDCI3 .
Table 2-2. Proton NMR signal assignments for 3 in CDCI3.
Proton(s) Multiplicity Chemical shift, 
5
(ppm)
Coupling
constant,!
(Hz)
m 6.75-6.68
-OMe s 3.81
-OMe s 3.80
-C02Me's s 3.66
-CH t 3.61 7.8
. -CH2 d 3.13 7.8
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Figure 2-3. Proton NMR spectum of 4 in CDCI3 .
CO2CH3
I  ^  CO2CH3 
H5
Table 2*3. Proton NMR signal assignments for 4 in CDCI3.
Proton(s) Multiplicity Chemicai shift, 
5
(ppm)
Coupling 
constant, J  
(Hz)
H-5 s 7.63
H-2 s 6.78
-CH* m 3.96-3.93
-OMe’s s 3.92
-COzMc's s 3.69
-CHî d 3.49 7.5
* One would a priori expect to see a triplet for -CH. Unfortunately, we were unable to 
resolve the actual pattern due in part to a coincidental overlap of these peaks with those of 
the -OMe's at 5 = 3.92.
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Figure 2-4. Proton NMR spectum of 5 in CDCI3 .
5Table 2-4. Proton NMR signal assignments for 5 in CDCI3.
Proton(s) Multiplicity Chemical shiA, 
5
(ppm)
Coupling
constant,!
(Hz)
-NH bs 7.69
H-8 s 6.68
H-5 s 6.31
-OMe's s 3.83
-CGîMe s 3.74
H-3 dd 3.60 8.4,6.3
H-4a dd 3.30 15.9,8.4
H-4b dd 3.05 15.9,6.3
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Figure 2-5. Proton NMR spectum of 6 in DMSO-d^.
6Table 2-5. Proton NMR signal assignments for 6  in DMSO-d^.
Proton(s) Multiplicity Chemical shift,
5
(ppm)
Coupling
constant,!
(Hz)
-CONH2 bs 9.97
-NH s 7.43
-CONH2 s 7.07
H-8 s 6.81
H-5 s 6.49
-OMe s 3.69
-OMe s 3.67
H-3 dd 3.28 9.9.6.6
H-4a dd 3.03 15.9,9.9
H-4b dd 2.88 15.9,6.6
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Figure 2-6. Proton NMR spectum of 7 in CDCI3 .
Hs Ht«H4bH9 %
Table 2-6. Proton NMR signal assignments for 7 in CDCI3.
Proton(s) Multiplicity Chemical shift, 
5
(ppm)
Coupling 
constant, J  
(Hz)
H-5 s 6.50
H-8 s 6.09
-OMe's s 3.76
H-2a dd 3.33 10.8,3.3
H-2b dd 2.94 10.8,8.7
H-4a dd 2.76 15.9,5.1
H-9* dd 2.69 7.2,2.4
H-4b dd 2.39 15.9,8.7
H-3 m 2 .00-1.86 -
* One would a priori expect to see a doublet for -CH2 (H-9); however, we observed a 
doublet of doublets. This is most likely a result of the H-9 protons being diastereotopic. 
Since they are diastereotopic, we would expect to see two doublet o f doublets. But, their 
chemical shifts may be so similar that a non-first order spectrum is observed.
59
2 PPM
Figure 2-7. Proton NMR spectum of 8*2HBr in D2O.
Hs Hfo H«, H9 H9
NH2
Table 2-7. Proton NMR signal assignments for 8  in D2O.
Proton(s) Multiplicity Chemical shift, 
5
(ppm)
Coupling
constant,!
(Hz)
H-5 s 6.79
H-8 s 6.75
H-2a*» ** bd 3.67
H-2b**&H-9 m 3.19-3.03
H-4a*» ** bdd 2.94 15.6,3.9
H-4b** dd 2.59 15.6,10.8
H-3 m 2.54-2.44 -
* COSY shows there to be a long range coupling between H-2a and H-4a which is 
obscured in the broad doublet seen a t5  = 3.67 and the broad doublet of doublets at S = 
2.94.
** Equatorial protons, in general, are more deshielded than axial protons and have a 
greater potential for long range coupling; therefore, it is presumed that H-2a and H-4a are 
equatorial and H-2b and H-4b are axial
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Figure 2-8. Proton NMR spectum of 10 in CDCI3 .
CH3O
10
Table 2-8. Proton NMR signal assignments for 10 in CDCI3.
Proton(s) Multiplicity Chemical shift, 
5
(ppm)
Coupling
constant,!
(Hz)
C6H5 (ortho) bd 8.14 JaDD — 6.9
GiHs (meta, oara) m 7.63-7.49
H-2&H-6 d 7.40 2.4
=CH s 7.15
H-4 t 6.65 2.4
-OMe’s s 3.87 *
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Figure 2-9. Proton NMR spectum of 11 in CDCI3 .
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Table 2 -9 . Proton NMR signal assignments for 11 in C D C I3.
Proton(s) Multiplicity Chemical shift, 
8
(ppm)
Coupling 
constant, J  
(Hz)
CgHi (ortho) bd 7.85 Jann —  7 .2
-NH bs 7.70
QHs (meta, para) m 7.56-7.43
=CH s 7.36
H-2 & H-6 d 6.64 2.1
H-4 t 6.40 2.1
-COîMe s 3.85
-OMe's s 3.65 •
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Figure 2-10. Proton NMR spectum of 12 in CDCI3 .
«2 NHCOPb
Y  Y  GO2CH3
CH30
12
Table 2-10. Proton NMR signal assignments for 12 in CDCI3.
Proton(s) Multiplicity Chemical shift,
5
(ppm)
Coupling
constant,!
(Hz)
C^ 5  (ortho) d 7.73
CgHs (meta, para) m 7.52-7.38
-NH bd 6.59 7.2
H-4 t 6.33 2.4
H-2 & H-6 d 6.26 2.4
-CH* dt 5.06 7.5,5.4
-COîMe s 3.77
-OMe’s s 3.69
m 3.25-3.12
* Upon cursory inspection, -CH appears as a doublet of doublets. But, with rigorous 
examination, it is actually observed to be an overlapping doublet of triplets.
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Figure 2-11. Proton NMR spectum of 13 in CDCI3 .
NHCOPb
CO2CH3
13
Table 2-11. Proton NMR signal assignments for 13 in CDCI3.
Proton(s) Multiplicity Chemical shiA, 
6
(ppm)
Coupling 
constant, J  
(Hz)
CgHs (ortho) bd 7.78 JauD = 6.9
CftHs (meta, para) m 7.51-7.38
-NH d 7.1 7.0
H-4 d 6.43 2.4
H-6 d 6.39 2.4
-CH ddd 4.98 9.3,7.1,5.1
-COiMe s 3.83
-OMe s 3.77
-OMe s 3.76
-CH2» dd 3.23 14.4,5.1
-CH2* ___ dd 3.03 14.4,93
* One would expect a priori to see a simple doublet for -CH2; however, we observed a 
doublet of doublets for each o f the -CH2 protons. This is most likely a result o f the -CH2 
protons being diastereotopic. Since they are diastereotopic, we would expect to see two 
doublet of doublets.
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Figure 2*12. Proton NMR spectum of 14 in CDCI3 .
NHCOPh
CH3O
14
Table 2-12. Proton NMR signal assignments for 14 in CDCI3.
Proton(s) Multiplicity Chemical shift,
5
(ppm)
Coupling 
constant, J 
(Hz)
O5H5 (ortho) bd 7 .8 6 Jano ~  6 .9
Ar-NH bs 7 .7 1
C fiH ^ (meta, para) m 7 .5 4 - 7 .4 1
PhCONH d 7 .3 3 4 .3
H - 5 d 6 .3 9 2 .7
H -7 d 6 .3 7 2.1
H -3 ddd 4 . 6 6 1 4 .1 ,6 .3 ,4 .4
-OMe s 3 . 8 4
-OMe s 3 .7 8
H-4a dd 3 .6 9 1 5 3 , 6 . 3
H - 4 b dd 2 .8 3 1 5 3 ,1 4 .1
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Figure 2-13. Proton NMR spectum of IS in CDCI3 .
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Table 2-13. Proton NMR signal assignments for 15 in COCI3.
Proton(s) Multiplicity^ Chemical shift, 
5
(ppm)
Coupling
constant,!
(Hz)
C6H5 m 7.38-7.22
H-5 d 6.28 2.4
H-7 d 6.17 2.4
Ph-CHs s 3.89
-OMe s 3.78
-OMe s 3.72
H-4a bt 3.36
H-3&H-4b m 3.15-3.08
H-2a dd 2.95 16.5,3.9
H-2b dd 2.69 16.5,7.5
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Figure 2-14. Proton NMR spectum of 16 in CDCI3 .
16
Table 2-14. Proton NMR signal assignments for 16 in CDCI3.
Proton(s) Multiplicity Chemical shiA, 
5
(ppm)
Coupling
constant,!
(Hz)
H-5 d 6.28 2.4
H-7 d 6.16 2.7
-OMe s 3.78
-OMe s 3.71
H-3 m 3.39-3.32
H-4a bd 3.30 11.7
H-2a&H-4b m 3.06-2.95
H-2b dd 2.46 162,6.3
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Figure 2-15. Proton NMR spectum of l7*2HBr in D2O.
H4. H *
Table 2-15. Proton NMR signal assignments for 17 in D2O.
Proton(s) Multiplicity Chemical shift, 
5
(ppm)
Coupling
constant,!
(Hz)
H-5 d 6.38 2.7
H-7 d 6.30 2.4
H-3*** dddd 3.93 9.9,9.6,5.3,3.5
H-2a*t ddd 3.83 12.3.3.5.1.7**
H-2b* dd 3.42 12.3,102
H-4at bdd 3.23 16.8,5.4
H-4b* dd 2.94 16.8,9.3
* Alternatively, H-2a could be simply reported as a multiplet at 3.85-3.80.
** J = 1.7 Hz is presumed to be a long range coupling o f H-2a to H-4a which is 
obscured in the broad doublet of doublets seen at 5 = 3.23. This long range coupling is 
verified by COSY.
*** Alternatively, H-3 could be simply reported as a multiplet a t 3.98-3.88.
^ Equatorial protons, in general are more deshielded than axial protons and have a greater 
potential for long range coupling; therefore, it is presumed that H-2a and H-4a are 
equatorial while H-2b and H-4b are axial
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Basic Chromatography and 
Electrochemistry
Chapter 3
I. Introduction
hi the field of neuroscience, it is frequently useful to have the ability to quantitate 
neurotransmitters and related metabolites in the CNS. Many different methods can be 
used to accomplish this, yet none possess the simplicity, ease, high sensitivity, 
versatili^, and rapidness exhibited by high performance liquid chromatography (HPLC) 
coupled with electrochemical detection (EC). This combination, commonly known as 
LCEC, was first developed in the laboratory of R.N. Adams at the University of Kansas
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in the early I970's. Since that time, LCEC has become the most widely used tool for the 
routine separation and determination of neurochemicals.
In order to be applicable to EC detection, a compotmd m ust possess 
electrochemical activity. Therefore, it is important to determine whether a given 
neurochemically related species can or does exhibit electroactivi^. If such activiQr exists, 
it is often of interest to determine the specific nature of its electrochemical characteristics. 
The initial electrochemical characterization of a species most generally employs cyclic 
voltammetry or linear sweep voltammetry. Using these techniques, basic information, 
such as the associated formal potential(s), and in-depth information, such as the nature 
and rate(s) o f follow-up reaction(s), can be determined. This chapter covers pertinent 
aspects of chromatographic separation, electrochemical detection, and the fundamentals of 
cyclic voltammetry and linear sweep voltammetry.
n . Chromatography
A. Migration of Solutes
Chromatographic separation is based upon the extent to which différent solutes 
partition between a stationary phase and a mobile phase. The partition coefficient, AT, 
describes the degree to which a solute resides in the stationary phase versus the mobile 
phase and is defined as:
Q
equation 3-1
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where Q  is the molar concentration of the solute in the stationary phase and Cm is the 
molar concentration in the mobile phase.
The time required between the injection of a sample and the elution o f a solute is 
called the retention time, tR. The time required for the elution of an unretained species is 
called the dead time, to. Retention time reflects the partitioning of a solute between the 
two phases, while the dead time reflects the dead volume of the colunm.
TIME
Figure 3-1. Chromatographic elution profile.
These two parameters are used to find the capacity factor, k', which provides a  measure 
of the migration rate, or degree o f retention, o f a given solute under a given set o f 
chromatographic conditions, and is defined as:
<0
equation 3-2
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where Vsiadonaiy k  the volume of the stationary phase and Vmobfle is the volume o f the 
mobile phase. Since the capacity factor takes into account the dead time as well as the 
retention time, it is relatively independent of alterations in column length and/or diameter. 
This parameter provides a rapid assessment of the effects of different eluting solvents 
and/or packing materials on solute retention.
Another important parameter is the selectivi^ factor, ol The selectivi^ factor is a 
measure of how well a column separates two analytes, A and B. It is defined as:
equation 3-3
where B is the more strongly retained analyte, or k'b>k'a and c o l. The selectiviQr factor 
is used to calculate the resolving power of a column for two analytes and w ill be 
discussed later in this chapter.
B. Chromatographic Efficiency
Chromatographic efficiency is a measure of the band broadening that occurs as an 
analyte passes through the column. By simple inspection of the chromatogram in Figure 
3-1, it  is apparent that the shape o f an eluting peak is reminiscent o f a Gaussian, or 
normal probability curve. The associated band broadening can be viewed as the result of 
a random-walk phenomenon and diffusion processes.
While a complete discussion of the random-walk theory is beyond the scope of 
this text, a brief description is as follows. A solute molecule undergoes thousands of
8 1
transfers, during its elution, between the stationary and mobile phases. Due to statistical 
probabili^, the time a molecule spends in either phase is variable. Therefore, the time 
spent in a given phase may be relatively brief or long. Noting that a molecule only moves 
through a column while in the mobile phase, some molecules will travel more rapidly 
because they reside in the mobile phase for a greater-than-average period of time, while 
others will travel more slowly due to their greater-than-average time spent in the 
stationary phase. The outcome of these individual random processes is a symmetrical 
distribution of solute velocities around the mean analyte velocity. Thus, the degree of 
band broadening derived from the random-walk phenomena is dependent on the 
fiequency and length of these random processes, as well as the total time during which 
they are allowed to occur, Le., the time spent in the column.
Diffusion is another major contributor to band broadening. Diffusion occurs from 
a point of higher concentration to a point of lesser concentration. Molecules at the center 
of a chromatographic band, where the concentration is highest, will diffuse toward the 
edges of the band, where the concentration is lowest. And, since diffusion is 
concentration dependent, half of the diffusion occurs in the direction of the flow and half 
occurs against the flow.
As a result of these two phenomena, band broadening increases as the solute 
moves through the column. Hence, it is apparent that the degree of band broadening is 
directly proportional to the time spent on the column.
The efBciency of a chromatographic column is quantitatively expressed as either 
the plate height, H, or the number of theoretical plates, N. The plate height is defined as:
H equation 3-4
where L is the length of the column, while the number of theoretical plates is defined as:
8 2
J equation 3-5
where Ir  is the solute retention time, a  is the standard deviation of the solute band, Wb is 
the width o f the peak at its base (Wb=4<y), and W 1/2 is the width of the peak at half 
height Since N is a dimensionless parameter, the dimensions of tR and o  or W, normally 
measured as either time or distance, need to be the same.
C. Column Resolving Power
Resolution, Rs, is the quantitative measure of the separation of two analytes. It is 
defined as the distance between the centers of two analyte peaks divided by the average of 
the two base widths:
equation 3-6
An equation for R$ incorporating the number of theoretical plates, the selectivi^, and the 
capacity factor of the more strongly retained component is:
e,uad<m 3.7
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in. Electrochemistry
A. Electrochemical Detection
W hile an in-depth discussion of electrochemical detection in LCEC is beyond the 
scope o f this chapter, there exists numerous literature and text reviews on the theory, 
function and various applications of this technique. 103-115
For a compound to be amenable to electrochemical detection, it must have the 
ability to accommodate the loss or gain of one or more electrons. In other words, a 
compound must be electrochemically active. While there exists many different types of 
electrochemical detectors, most are amperometric in design. Amperomenic detectors 
oxidize or reduce only a small fraction (1-5%) of the desired species as it flows across the 
surface of the electrode.
The current produced by the gain or loss of electrons from a chemical species at 
the electrode surface is called faradaic current:
* = ^  equation 3-8
where i is the current in amps, Q is the charge in coulombs, and r is the time in seconds. 
The amount of charge is described by Faraday’s law:
QsnFN  equation 3-9
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where n is the number of equivalents per mole, F  is Faraday's constant (96,485 C eq~^), 
and is the number of moles. The instantaneous faradaic current at an electrode surface 
is, thus, given by:
I = = n F ^ ^ ^ j = (9.65 X10^) X (equivalents converted per second) equation 3-10
The measured current at an amperometric detector is proportional to the diffusional flux, 
J r ,  of the species to the electrode surface and the electrode area, A.
A /,(x -0 ,r )  equation 3-11
In fact, the rate o f conversion of the electroactive species at the electrode surface, i.e., 
current, is controlled by both the kinetics of electron transfer and the diSusion-driven flux 
of the substrate fmm the bulk of the solution to the electrode surface. In the normal 
amperometric detector, however, a  sufficient overpotential is supplied to the working 
electrode so that the electron transfer kinetics become extremely rapid. Thus, the rate 
becomes diffusion controlled. Under these conditions, the current simply becomes a 
function of the flux at the electrode surface as shown in equations 3-11 and 3-13. The 
flux is proportional to the concentration gradient a t the electrode surface according to 
Hck's first law, which assumes one-dimensional diffusion at a  planar electrode:
= equation 3-12
85
where Dr is the diffusion coefficient of species R and dC/dx is the concentration gradient 
This equation can be combined with equation 3-11 to obtain a revised expression for the 
current at an electrode surface:
equation 3-13
Equation 3-13 completely describes the observed current for a  one-dimensional, 
diffusion controlled process. Unfortunately, the situation for an electrochemical detector 
is a little more complex. The flowing stream across the electrode surface adds convection 
to the simple diffusion controlled delivery of the electroactive species to the surface of the 
electrode. Additionally, the physical dimension of the channel depth is very small which 
further restricts the above discussion by eliminating the assumption o f semi-infinite linear 
diffusion. Taking all o f these and other factors into account, Weber and P u r d y h a v e  
presented a fairly rigorous derivation for the current observed at an amperometric LCEC 
electrode which is:
i = L467nFQW
K
equation 3-14
where Cr is the bulk concentration of electroactive species R, We is the width of the 
electrode, L is the length of the electrode, U is the average volume flow rate of the 
solution, and Wg and b are the width and depth of the flow charmel, respectively. 
Expressions for other amperometric LCEC electrodes and cell designs may be found 
elsewhere. 107,116,117
8 6
B. Voltammetry
A commonly employed method used to investigate the electrochemical 
characteristics of an electroactive species is cyclic voltammetry (CV). In cyclic 
voltammetry, current is monitored as a function of applied potential, with the potential 
being scanned in one direction followed by a scan in the opposite direction. A cyclic 
voltammogram, i.e., current-potential curve, may be viewed as the electrochemical 
equivalent of a spectrum produced in spectrophotometry. A representative cyclic 
voltammogram is shown in Figure 3-2. Basic electrochemical characteristics which may 
be determined using CV are the reduction peak potential, the oxidation peak potential, the 
reversibility of a system, the number of electrons involved in the oxidation and/or 
reduction reaction(s), and the diffusion coeŒcient(s). ^ (*7,118
+200
-1 ----
Figure 3-2. Representative cyclic voltammogram.^^
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Cyclic voltammetric peak separation, AEp, serves as one criterion for the 
determination of electrochemical reversibility. For a reversible system, i.e., a system 
with facile electron transfer characteristics.
S8A£), =— mV equation 3-15
n
where Epa is the anodic peak potential, Epc is the cathodic peak potential, and n is the 
number of electrons involved in the redox process. For example, a reversible two- 
electron system is expected to have AEp = 29 mV. Furthermore, if  the system is 
reversible and the products stable, the magnitude of the anodic peak current should equal 
to that of the cathodic peak current The formal redox potential, E°', in a reversible 
system can be readily obtained from cyclic voltammetry. Two common methods used for 
E®'are:
£o/_i_£i_ ,5E îl equation 3-16
and
£°'=£@ 0.8517i^ equation 3-17
where equation 3-17 can be used for either the anodic or cathodic peak.
As electrochemical systems approach quasi-reversibility, the potential separation 
between the anodic and cathodic peaks increases, hr a system where either the anodic or 
the cathodic current becomes negligible, that system is said to be electrochemically 
irreversible. The quasi- and ir reversible cases are much more complex than the 
reversible case, since the observed current becomes dependent on charge transfer
8 8
kinetics, in addition to thennodynamics and diffusion. Detailed descriptions of these 
more complex cases are available elsewhere. 19,120
Linear sweep voltammetry (LSV) is similar to CV. However, in LSV, the 
potential is scanned only once in one direction. Thus, LSV information can be obtained 
&om a CV by simply examining only the initial potential sweep. Reversibili^ can be 
assessed from this unidirectional sweep, since a reversible system conforms to the 
equation:
56.5 mV equation 3-18
where Ep/2 is the potential at i = ip / 2. The diffusion coefficient, D, the number of 
electrons involved, n, the bulk concentration, C*, or the area of the electrode. A, can each 
be determined from the peak current in a  reversible system as:
i,=a44«3nFACr(^)v‘" 01/2 equation 3-19
or
fy =  (2.69 X @ 25®C equation 3-20
if  all other parameters in the equation are known. The appropriate units for the 
parameters are A in cm^, D in  cm^/sec, v in V/sec, C* in mol/cm^, and i in amps. 
Equations 3-19 and 3-20 tqiply to planar electrodes under diffusion controlled conditions. 
However, spherical electrodes, such as a hanging drop mercury electrode, can be treated 
in a similar manner, yielding:
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ip = iiplané)+(0.725 x 10^ ) equation 3-21
where ib (cm) is the radius of the spherical electrode, i(plane) is the current described in 
equations 3-19 and 3-20, and the other parameters are as defined above. The treatment of 
LSV for quasi- and ir reversible systems differs fiom that of reversible systems and is 
covered in-depth elsewhere.
Knowledge of the oxidation potential of various species contained in a sample for
LCEC analysis may allow one to choose an applied potential which will maximize
)
sensitivity and selectiviQr for the desired components. At a sufficient overpotential, the 
oxidation current for a given electrochemically active species becomes governed by mass 
transport and, therefore, is relatively independent of potential. However, undesirable 
noise is generally found to be proportional to the potential Thus, the optimal potential 
for a species is that which is large enough to maximize the signal, but is small enough so 
that it does not introduce any more noise than is absolutely necessary. Furthermore, if 
one is attempting analysis of a desired compound A in the presence of a 
chromatographically overlapping, undesired compound B, potential selection may be of 
some help. For example, if compound A has a formal potential significantly less than 
compotmd B, an applied potential may be chosen where only A is oxidized. This 
approach achieves electrochemical selectivi^. This situation is illustrated in Figtue 3-3, 
which shows hydrodynamic voltammograms of the hypothetical compounds A and B.
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E(+)
Figure 3-3. Hydrodynamic voltammograms for two oxidizable compounds.
A hydrodynamic voltammogram is a plot of the current produced as a  function of the 
applied electrode potential. At potential E2 in Figure 3-3, both A and B can undergo 
oxidation. However, by selecting potential Ei, compound A can be selectively oxidized 
in the presence of B. A notable characteristic of a hydrodynamic voltammogram is the 
Ei/2, defined as the potential at which i = imax /  2. The E1/2 is equal to the E°' for a 
species o f concern if the species is ekctrochemkally reversible.
IV. Conclusions
While the preceding discussions are rather rudimentary in nature, more extensive 
details can be found, for the interested reader, in multiple references (LC^03,106,121- 
123 and ECl®^’l®^*l 11»H®‘ 120). However, it is hoped that this brief introduction to 
these e ^ n tia l topics will be helpful in the understanding of the following chapters.
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Neurotoxicity
Chapter 4
I. Introduction
Neurotoxins have been used extensively in the study of neuronal function(s). 
6-Hydroxydopamine (6-HDA) and l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), for example, have frequently been employed in investigations o f the 
noradrenergic and dopaminergic systems, respectively, due to the moderate to high 
degree of potency and concomitant selectivi^ which they exhibit towards these systems. 
However, comparably effective neurotoxins for serotonergic systems have not been 
available, particulady for the mouse. 5,7-Dihydroxytryptamine (5,7-DHT) is the most 
widely used 5-HT neurotoxin. But, doses producing even modest 5-HT depletion are.
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unfortunately, accompanied by poor selectivi^. Furthermore, 5,7-DHT has only been 
shown to, at most, produce minimal (approx. 30%) serotonin depletions in mouse whole 
brain.23,79 Therefore, it is not surprising that there is an on going search for more 
potent and selective 5-HT neurotoxins.
A previous report by L. Lin^^ had shown that a  fixed side chain catecholamine 
derivative, 3-amino-6,7-dihydroxy-1,2,3,4-tetrahydroquinoline (6,7-ADTQ), was 
capable of eliciting 5-HT depletions o f approximately 50%. We, thus, decided to more 
thoroughly investigate this compound. Additionally, we designed and characterized 
various ADTQ analogs in an attempt to find more selective and potent serotonergic 
agents. The specific compounds investigated included the enantiomers of 6,7-ADTQ and 
two analogs, namely 3-am inom ethyl-6,7-dihydroxy-l,2,3,4-tetrahydroquinoline 
(6,7-AMDT(3) and 3-amino-6,8-dihydroxy-1,2,3,4-tetrahydroquinoline (6,8-ADT(3). 
This chapter examines the lethality, potency, and selectivi^ of these neurotoxic agents. It 
also briefly covers some of the associated behavioral effects of the agents.
D O ?- y x x -  '“W
H H H O  H
6,7-ADTQ 6,7-AMDTQ 6,8-ADTQ
NHj
n. Background
Neurotransmitter depletion studies are fiequently employed to evaluate the degree 
of neuronal destruction and/or degeneration elicited by a toxic agent. While absolute 
proof of destruction or degeneration requires electron microscopic or histochemical 
verification, these techniques were not accessible for the current studies. However, 
6-HDA and many of its analogs have previously been shown, using such techniques, to
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produce neuronal degeneration.21.24,124,125 Due to the similarity in chemical 
structures between the quinoline analogs and 6-HDA and its congeners, as well as the fact 
that the quinoline analogs produce long term depletions o f neurotransmitters, we believe 
that depletion measurements reasonably reflect the degree of degeneration afforded by 
these toxins.
Early studies of a  racemic mixture of 6,7-ADTQ by L_A Lin23 briefly examined 
both the toxicity and selectivity afforded by this toxin. Two doses o f 25 |Xg of the free 
base, separated by 24 hours, were administered intracerebroventricularly (Lc.v.) to mice. 
The mice were then sacrificed 9 days after the first treatment The results of these studies 
are shown in Table 4-1.
Table 4-1. 6,7-ADTQ effects on mouse whole brain neurotransmitter levels.
Compound
Neurotransmitter L e v e ls 2 3  (% controls ±  SEM)
NE DA 5-HT N
Controls
6,7-ADTQ
100± 5 1G0±6 100 ± 4  6 
6 1 ± 7  87 ± 3  5 2 ± 6  9
Treated group received two doses o f 25 ^g 6,7-ADTQ, i c.v., separated by 24 hours.
From this initial data it appeared that there were very little DA effects and only 
moderate NE effects when compared to existing NE and DA toxins. However, the ability 
of 6,7-ADTQ to elicit a  48% depletion o f 5-HT was judged significant considering that 
the widely used 5-HT toxins, 5,7-DHT and 5,6-DHT, were capable o f producing no 
more than 30-35% depletions in mouse whole b r a i n . 2 3 , 7 9  6,7-ADTQ clearly 
exhibited a lack of selectivity. In an attempt to circumvent this problem, Lin incorporated
94
NE and DA transport blocking agents. Amfonelic acid was used to block uptake by DA 
neurons, and desipramine was used to block uptake by NE neurons.^'^^ The results of 
this modified examination of 6,7-ADTQ are shown in Table 4-2. By employing these 
uptake blockers, Lin was able to eliminate virtually all the DAeffects and over 50% of the 
NE effects, while not significantly altering the 5-HT depletion.
Table 4-2. 6,7-ADTQ effects on whole mouse brain neurotransmitter levels following 
pretreatment with desipramine and amfonelic acid.
Neurotransmitter Levels^^ (% controls ±  SEM)
Compoundfs) NE DA 5-HT N
Controls 100±3 100±3 100±3 9
Desip., Amfo., 
6,7-ADTQ 84±6* 95 ± 4 72 ±3*** 9
6,7-ADTQ 56 ±3*** 92 ± 3 70 ±1*** 17
5,7-DHT» 82 ±3*** 9 9± 1 71 ±6*** 16
Significant differences compared to control values (r test): <0.05, ***P < 0.001.
Animals were treated with 12.5 fig 6,7-ADTQ on days one and two. Pretreated animals 
received a mixture of 25 mg/kg desipramine and 50 mg/kg amfonelic acid, i.p., one hour 
prior to toxin treatment Sacti&e occurred on day 9 following treatment 
^ data fitom Lin^^; toxin amount 25 fig.
While 6,7-ADTQ alone was found to lack somewhat in selectivity, it was shown, 
at the higher dose, to be capable of producing more complete 5-HT depletions than can be 
obtained with 5,7-DHT.2^’^ ^ Using uptake blockers and a lower dose, 6,7-ADTQ 
elicited selectivity comparable to that reported for 5,7-DHT. Lin's woik, thus, showed 
that 6,7-ADTQ offered some promise as a serotonergic toxin. This prompted us to 
design and investigate some analogs of this toxin.
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m . Experimental Design and Methods
A. Chemicals and Solutions
1. Chemicals
All aqueous solutions employed 18 Mt2 distilled/deionized water which was 
prepared by passing distilled water through a Milli-Q Reagent Water System (Millipore, 
Continental Water Systems, El Paso, IX ).
6,7-AMDTQ and 6,8-ADTQ were prepared by Russell J. Lewis. The racemic 
and enantiomeric forms of 6,7-ADTQ were prepared by Charles A. Francis.^
The chemicals listed below were purchased through Sigma Chemical Company 
(Sl Louis, Mo.) in high purity and used without any further purification, 
sodium chloride 
sodium hypochlorite 
diethylamine 
citric add monohydrate 
sodium octylsulfate 
Na2EDTA»2H20
neurotransmitters, metabolites, and chromatograidiic internal standards are listed 
in Table 4-3.
2. Stock Nearotransmitter and Metabolite Solutions
A stock solution for an individual compound was prepared by dissolving an 
appropriate amount of the compound in 25 mL of degassed 10*^  M HCl. This was then 
divided into ca. fifty 1.5 mL plastic storage vials and fiozen at -80°C until needed. The
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amounts used in these pieparatioiis, along with the resultant concentrations, are shown 
below in Table 4-3 for the pertinent chemicals.
Table 4-3. Stock neurotransmitter and metabolite solution preparation.
Compound Salt Form
Amount of Salt 
Used (mg)
Concentration
(mM)
ME •HCL 7.16 1.393
EPI free base 4.71 1.028
DOPAC acid form 4.63 1.101
NM •HQ 7.06 1.285
DA •HCl 5.44 1.147
5-HIAA acid form 6.79 1.421
HVA acid form 4.94 1.085
3-NfT •HCl 5.53 1.086
5-HT creatinine sulfate 11.58 1.142
N-MET oxalate 8.22 1.173
EPIN •HCl 5.04 0.990
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3. E xternal S tandard
The external standard was prepared by mixing the appropriate volume o f the 
individual stock solutions listed below in Table 4-4 and diluting the mixture to 25 mL 
with degassed 10*^  M HCL This solution was prepared 30 min before use and kept on 
ice. Excess solution was discarded within 5 h of preparation.
Table 4-4. External standard solution preparation.
Compound
NE
Stock Solution Used QiL) 
53.8
External Std. Cone. 
(nmol/mL)
2.998
EPI 24.3 0.999
DOPAC 22.7 1.000
NM 38.9 1.999
DA 130.8 6.001
5-HIAA 52.8 3.001
HVA 69.1 2.999
3-M I 69.1 3.002
5-HT 109.5 5.002
4. H om ogenization Solution
The homogenization solution was a pH 4.75 mixture containing 0.50 M acetate 
and 0.40 M NaClO^. The solution contained the LCEC internal standards N-MET and 
EPIN for convenience and was prepared as sequentially outlined below in Table 4-5 
using the amounts o f internal standards specified in Table 4-6. This solution was made
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just prior to use and was kept on ice. Excess solution was discarded within 5 h of
preparation.
Table 4>S. Homogenization solution preparation.
Compound Amount
water 90 mL
glacial acetic acid 2.94 mL
NaClOt 4.90 g
adjust to pH 4.75 with NaOH
add X uL internal standard (see Table 4-6 below)
dilute to final volume of 100 mL
Table 44L Amounts of internal standard stock solutions used in preparation of the
homogenization solution.
Lntemal Standard Amounts of Stock Solution 
UsedCuL)
Final Cone. (nmol/mL)
N-MET 213 2.500
EPIN 253 2.505
5. botonlc Saline Solution
Isotonic saline was prepared by dissolving 0.90 g sodium chloride in 100 mL 
water and stored at 2°C until needed, and discarded after 1 wedt.
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6. Toxin Solution Preparation
A caiefully limited amount of toxin was weighed and transferred to a I mL glass 
ampule that was preflushed with argon or Oi-ficee nitrogen. An appropriate amount o f 
deaerated isotonic saline solution was added to obtain the desired concentration, and the 
ampule was flushed with argon or nitrogen again. The ampule was then capped using a 
crimp cap with a rubber septum. This method minimized the amount of required toxin 
while maintaining an oxygen free environment for the stock toxin solution. The toxin 
was stable in excess of 8 hrs.
B. Chromatography
1. Chromatographic System
The LCEC system utilized was made up of a Milton Roy minipump, a Royal 
pressure gauge, an Alltech Mark m  pulse dampener, a model 7125 Rheodyne injector 
with a 10 pL injection loop, and a 7.5 cm x 4.6 mm (Ld.) column with 3 \i C-18 
Adsorbosphere stationary phase from Alltech. The column was packed in-house with a 
Haskel (Burbank, CA) column packer at a pressure of 7200 psL The chromatographic 
system was fitted with a specially designed 1 mm diameter glassy carbon electrochemical 
detector (Bioanalytical Systems, BAS, West Lafayette, IN) contained in a thin-layer flow­
through cell. The reference electrode was a BAS model MW 2021 Ag/AgCl. A BAS 
LC-4B potentiostat was employed for potential control and current monitoring, and 
chromatograms were recorded on a Rsher series 5000 Recordall strip chart recorder. All 
chromatographic tubing was stainless steeL ^ ic a lly  0.006" Ld., except between the 
column and detector, which was a short piece of 0.005” i.d. teflon tubing. Typical 
chromatographic conditions were: I.8-2.1 mL/min flow rate, 0.5 sec time constant, 1-5 
nA full scale, and applied potential of 800 mV vs. Ag/Agd.
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2. Mobile Phase
The liquid chromatography mobile phase contained 0.10 M citric acid, 0.085% 
(v/v) diethylamine, 0.05 mM EDTA, 0.255 mM sodium octylsulfate, and 5% (v/v) 
acetonitrile. The pH was adjusted to 2.50 with NaOH. The detailed preparation is 
sequentially outlined below in Table 4-7. Fresh mobile phase was prepared at least 
monthly. This mobile phase provided for separation of the 11 desired compounds in ca. 
8 min.
Table 4-7. Mobile phase preparation.
Amount
water 1400 mL
diethylamine 1.7 mL
Na2EDTA*2H20 37.16 mg
citric acid monohydrate 42.2 g
sodium octylsulfate 118.64 mg
adiust to pH 2.50 with NaOH
water 500 mL
filter through 0.45 |X aqueous filter
filtered acetonitrile 100 mL
degas with nitrogen for IS min
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3. System  Cleaning Procedure
Occasionally, the internal surfaces of the metallic components in the LCEC flow 
stream experienced deterioration leading to excessive background current and/br spurious 
chromatographic peaks. This usually could be corrected by cleaning the chromatographic 
system. In this procedure, all items down stream from and including the column were 
first removed to avoid damage. The specified amounts of solutions listed below in Table
4-9 were then sequentially pumped through the remaining system components. 
Following the final wash, the colunm and associated downstream items were reattached 
and the system was ready for operation. This procedure normally corrected the high 
background and/or spurious peak problems.
Table 4*8. LC tubing wash procedures.
Solution Volume
water 200 mL
Dilute soap/water solution 200 mL
water 200 mL
8 M nitric add 200 mL
water 200 mL
mobile phase 200 mL
4. Colum n W ashing Procedure
With multiple injections of crude brain homogenates, a  column may deteriorate, 
resulting in a diminished number of theoretical plates and a loss of separation. Flipping 
the column. Le., changing the inlet to the outlet and vice versa, generally remedied this
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problem. However, if this did not work, washing the column sometimes rectified the 
loss in column efficiency. Prior to engaging in this procedure, all components 
downstream from the column were removed from the LC system. The individual 
solvents and associated amounts, which were subsequently used to regenerate a column, 
are listed below in sequence in Table 4-9.
Table 4-9. LC column wash procedure.
Solution 1 Volume
water 50 mL
40:60 acetonitrile:water 100 mL
acetonitrile 100 mL
chloroform 100 mL
hexane 100 mL
chloroform 100 mL
acetonitrile 100 mL
40:60 acetonitrilenvater 100 mL
water 50 mL
mobile phase 1000 mL
5. Column Packing
The Haskel (Burbank, CA) colunm packing unit consisted of a reciprocating 
plunger pump with an outlet:inlet pressure amplification of 122:1. The packing material 
was prepared as a 5-20% slurry (w/v) in HPLC grade acetone. For a ^ ic a l  4.6 mm i.d. 
column, ca. 0.18 g of 3 p. C-18 Adsorbosphere particles were employed per cm of
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column to be packed. For example, 1.35 g of Adsorbosphere packing, suspended in 
20-25 mL acetone, was used for a 7.5 cm colunm. The slurry was sonicated for 10-15 
min prior to packing to ensure dispersal of packing materiaL After placing the slurry in 
the column packer slurry reservoir, 300 mL of acetone were added to the solvent 
reservoir. The column was packed at 6000-7200 psi until most of the solvent acetone had 
been consumed. The packing process required anywhere from 7 to 25 min. The colunm 
was then removed firom the packing unit, assembled, and flushed with 40:60 
acetonitrUenvater for one hr. If not used immediately, the column ends were capped, and 
the colunm was stored at 4*’C.
6. Chromatographic Separation and Parameters
We achieved a clean separation of 11 compounds, including 9 neurotransmitters 
and metabolites and 2 internal standards, with detection limits in the high femtomole to 
low picomole range. The typical elution time for an injection was between 7-9 min. A 
representative chromatogram for a processed brain sample is shown in Figure 4-1. The 
chromatographic parameters for each of the peaks shown in Figure 4-1 is presented in 
Table 4-11.
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Figure 4-1. A typical LCEC chromatogram for a brain sample.
From left to right, the peaks observed represent: the injection spike, the solvent front, 
NE, EPI, NM, DOPAC, DA, EPIN, 5-HIAA, HVA, 3-MT, 5-HT, and N-MET. The 
full-scale of the vertical axis was 5 nA, and the time required for elution of the final peak
was 7.8 min.
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T able 4-10. Experimentally determined chromatographic parameters using above
described conditions.
Solute ^(min) k ' N
ME 0.94 1.61 12787
EPI 1.2 2.32 10605
NM 1.34 2.70 10024
DOPAC 1.61 3.46 9329
DA 2.13 4.87 9013
EPIN 2.69 6.43 8984
5-HIAA 3.01 7.30 8973
HVA 4.33 10.96 9211
3-MT 5.67 14.65 8880
5-HT 6.10 15.85 8333
N-MET 7.79 20.52 8703
7. Calculadom  o f Results
Tissue concentrations of neurotransmitters and metabolites were calculated 
directly from the ratio of the peak height of the compound o f concern in a sample to that 
of the internal standard in the same sample. This is mathematically expressed for the 
determination of the 5-HT concentration in a single sample as:
!-H T ^ nmol ^
g tissue; (S“ )
(nmol 5 —HT in extstd .)
(wL of brain sample, g)
where PH5.HT is the peak height of 5-HT, PHintsid. is the peak height o f the internal 
standard, and nmol is the total nanomole of 5-HT in the 500 liL external standard. The
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internal standard used for catecholamines was EPIN, while N-MET was used for 
indolamines. Rnal results for a group of similarly treated animals were expressed as the 
mean ±  SEM. Different test groups were compared using Student's two-tailed
t-tesL 126,127
Typical whole mouse brain control values obtained for individual neurochemicals, 
using the above described LCEC approach, were (nmol/g, mean ±  SEM): NE, 2.98 ±
0.08; EPI, 0.91 ±  0.00; NM, 0.10 ±  0.02; DOPAC, 0.78 ±  0.05; DA, 8.19 ±  0.20; 
5-HIAA, 1.65 ±  0.06; HVA, 1.16 ±  0.04; 3-MT, 1.00 ±  0.05; 5-HT, 4.50 ±  0.06.
C. Experimental Procedures
1. LDso
The LDso is defined as the dosage of an agent at which 50% of treated animals 
die. While traditionally this value was determined by treating a large number of animals 
at several fixed doses, this method is time consuming, expensive, and wasteful with 
respect to animal life. Alternative, statistically valid, techniques for the determination of 
LDso values, which require fewer animals and less time, are the approaches known 
collectively as the Dixon up/down method. ^ 28-130
The Dixon up/down approaches employ a staircase bioassay in which the dose for 
a given animal in the procedure is based on the observed response of the animal treated 
immediately before i t  In an LDsostutfy, there are only two responses: live or dead. The 
result is observed at a  predetermined time. For example, if a test animal is alive at the 
predetermined time following treatment, the next animal is treated at a  higher dose; 
however, if  the animal dies before the predetermined time is reached, the next animal is 
treated at a  lower dose. For this method to work, however, two criteria must first be met. 
The doses must be equally spaced on a log scale and this spacing must be chosen close to
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log a , where (T is the standard deviation of the threshold distribution. While it is required 
that the spacing be close to log a , error in this estimation by as much as 50% does not 
effect the results dramatically.
In order to minimize the amount of time spent on an LDso study, three animals 
were ^ ic a lly  injected at any one time period. The three included one at the desired dose 
in ng, one at log (dose) + 0.1, and one at log (dose) - 0.1. If the middle animal lived, the 
results for the middle and the high dose animals were used in the data set, while the low 
dose result was discarded. If the middle animal died, the results for the middle and low 
dose animals were used, while the high dose result was discarded. In this fashion, one 
can complete an LDso study in half the normal time. The volume of the individual, 
unilateral intraventricular injections never exceeded 5 |XL. Results from animals with 
heavy bleeding, Le., those experiencing a medial sinoidal vein puncture during injection, 
were discarded from the data set. Results from animals that engaged in self-mutilation 
were treated as if the animals had died. Animals remaining alive at the end of 1 h were 
sacrificed by cervical dislocation. All animal brains were removed from the skull and 
dissected following death to verify that the injected toxin was delivered to the ventricular 
system. If  the injection did not reach the ventricular system, the results for the 
corresponding animals were not included in the final data set
Calculation o f an LDso firom the Dixon approach depends on whether one 
employs N= 6  or N> 6  animals in the data se t Since we wanted to shorten the time and 
minimize the number of animals needed for such studies, we initially decided to see if the 
less extensive data set would yield results which reasonably corresponded to those of the 
more extensive data se t Using 6 ,8-ADTQ, t=l h, and N = ll, we subjected the initial 6 
results to the shorter approach and the entire data set to the longer approach. 128-130 iq 
both cases we obtained the same 85 p.g (fiee base) for LDgg Thus, the shorter, N=6 , 
^proach was employed for all subsequent LDso determinations.
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2. Intracerebroventricular Injection
In order to reproducibly inject mice intracerebioventiicularly (i.c.v.), a specific 
procedure was developed and followed. The animal was weighed, anesthetized in an 
ether chamber, and placed upright on a surgical table. The thumb and middle finger of 
one hand were placed on the lateral posterior portions of the skull, while the index finger 
was placed on the dorsal posterior portion of the skulL Holding the animal in this way 
immobilized the head of the mouse and, simultaneously, allowed for the immobilization 
of the animal's body with the palm of the same hand.
With the other hand, the tip of the needle of a prefilled syringe was placed ca. 3 
mm posterior firom the back of the eyes and ca. 3 mm lateral from the midline. The 
syringe was held at an angle of approximately 35'’ lateral, measured from the mid-sagital 
plane. The needle was inserted through the scalp and skull, and into the brain to the 
desired depth. The depth of injection into the brain was held at a constant 4  mm though 
the use of a piece of Teflon tubing, cut to an appropriate length and fitted over the end of 
the injection needle. The toxic agent was slowly injected over the course o f ca. 7-10 sec. 
This slow injection promoted delivery of the toxin into the ventricular region and 
minimized undesirable movement up the needle track and out of the brain.
3. Depletion
ICR:Hsd male mice (Harlan Sprague-Dawley, Madison, WI) weighing 30-37 g 
were used for all depletion studies. After weighing, the animals were anesthetized in an 
ether chamber. Bilateral injections were carried out using a model 8033010 |iL  Hamilton 
syringe (Fisher Scientific, Pittsburg, PA) with the total volume never exceeding 3.5 jlL. 
(Control animals were routinely injected with equivalent volumes of saline. Animals were 
sacrificed on day 7 following injection using exposure to 7.0 kW o f microwave 
irradiation for 150 msec, delivered by a New Japan Radio model NJE-2603-10kW
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miit, 131-134 To ensure reproducible heating of brain tissue, a water load was irradiated 
1 min prior to each animal sacrificed.
Brains were removed #md weighed, with individual brain weights generally 
ranging from 450-525 mg. Each brain was placed in a 10 mL ground glass 
homogenization mortar, and 1 mL of homogenization solution was added. For external 
standards, 500 |iL  of stock external standard was used in place o f the brain. 
Homogenization involved 20 complete up/down strokes employing the highest rpm 
setting possible using a model 143 Dyna-mix motor (Fisher Scientific, Dallas, TX), 
outfitted with a Duall 22 (Kontes Glass Co., Vineland, NJ) ground glass tissue 
grinder/homogenizer. The homogenate was transferred to a 1 mL polycarbonate 
centrifuge vial and centrifuged in a type 25 rotor using a model L8-80 Beckman 
Ultracentrifuge at 21,000 rpm (50,(XX) x g) for 60 min at 4°C. The supernatant was then 
transferred to a 1.5 mL plastic storage vial and frozen at -80°C until the time o f analysis. 
The samples were individually thawed and filtered 15 min prior to LCEC analysis 
utilizing a model 926 bench top centrifuge (Fisher Scientific, Dallas, TX) and a model 
MF5500 BAS bioanalytical Systems frtc.. West Lafayette, IN) microfiltration apparatus 
with 0.45 \i RC55 nitrocellulose membrane filters.
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IV. Results and Discussion
A. LDso
The LDso for each of the quinoline analogs was assessed using the N= 6  Dixon 
t^proach^29 and an experimental time of 1 hour. A typical investigation is shown below 
for 6 ,8-ADTQ, along with calculation of the LDso, in Figure 4-2.
LDso for 6 ,8-ADTQ
Toxin 
dose, tig log(dose)
Results of Test 
(X = dead; O = living)
120 2.08 X
95 1.98 O X
76 1.88 X 0
60 1.78 o
log (LDso) = Xf + kd = 1.88 + 0.500(0.1) = 1.93, where
x f= log (final test dose)
d = log (spacing of doses)
k = tabulated value for maximum likelihood estimate QXxon and M ood^^^
LDso = antilog(1.93) = 85 Hg
Figure 4-2. LDso determination and calculation for 6 ,8-ADTQ.
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Comparable LD50 investigations were performed for each of 6,7-ADTQ, 6,7-AMDTQ, 
and 6 ,8-ADTQ. The results of these investigations, along with previously reported 
results for 6-HDA and 5,7-DHT, are presented in Table 4-11.
Table 4-11. LD50 values in mice.
LDso Values in Mice at 1 hour
Compound LDso ±  sd . Cug) LDso ±  s.d. (nmol)
6,7-ADTQ 37 ± 3 206 ± 17
6,7-AMDTQ 48 ± 5 247 ± 26
6 ,8-ADTQ 85 ±11 472 ±61
6-HDA24 134±7 793 ± 43
5,7-DHT89 52 271
s.d. was calculated firom tabulated estimated errors as determined by Dixon. ^ 28
From these results, we see * a t the LD50 values for 6,7-ADTQ and 6,7-AMDTQ 
are similar, as one might expect from the structural similarities, biterestingly, however, 
6 ,8-ADTQ exhibits an LDso approximately twice that of its 6,7-analogs. W hile the LDso 
values for all the quinoline derivatives are lower than that for 6-HDA, the values for the
6,7-analogs were quite comparable to that reported for 5,7-DHT.
For 6-HDA and its analogs, a one hour LDso had been shown to be a reasonable 
representation of the "long term". Le., 7-14 day, LDso. Thus, one hour was initially 
chosen for the quinoline LDso studies presented here. However, it was found during the
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subsequent depletion studies, much to our surprise, that the one hour LDso was not a 
good representation of the 7 day LDso with these toxins. In fact, many of the animals 
treated at doses near the LD20, while living past 1 hour, died in the five days following 
treatment Nonetheless, a one hour LDis-20^^^ generally proved to be a reasonable first 
guess for the seven day depletion studies. And, ultimately, the amoimt o f toxin used in 
the final depletion experiments was adjusted based on observed m ortali^ rates in the 
initial depletion experiments.
B. Depletion Studies
1. (±, +, and -)-6,7-ADTQ Investigations
Stereochem istry can significantly alter the biological activ ity  of a 
compound. 135,136 We, thus, investigated the effects of chirality on the neurotoxic 
properties of 6,7-ADTQ. The initial intent was to compare the potency and selectivity of 
the agents for 5-HT degeneration under conditions approaching maximal effects for each 
individually. Thus, we attempted to adjust the dose of each to maximize its effects while 
maintaining reasonable survivability in the seven day experiment. Reasonable 
survivability, defined as that which would be practically useful for others in routine 
studies, was taken to be on the order of, o r slightly greater than, 50%. The 
corresponding dose is called the "maximum usable" dose.
For the racentic and enantiomeric forms o f 6,7-ADTQ, we began with a dose of 
111 nmol for each, which was considered a conservative estimate based on the one hour 
LDso studies. The results of this study are shown in Table 4-12.
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Table 4-12. Whole mouse brain CNS neurotransmitter depletions 
7 days after i l l  nmol of (±, +, and -)-6,7-ADTQ.
Neurotransmitter Levels (% controls ±  SEM)
Compound NE DA 5-HT N
Controls 100 ± 4 100 ±3 100  ± 1 8
(±)-6,7-ADTQ 60 ± 6 *** 75 ±5*** 68 ±4*** 6
R-(+)-6,7-ADTQ 45 ±2*** 76 ±5*** 73 ±  1*** 5
S-(-)-6,7-ADT0 44 ±2*** 82 ±17 5 1 ± I* * * 2
Significant differences compared to control values (t test): ***P < 0.001.
From these equidose results, it was apparent that the S-(-)-6,7-ADTQ was more 
potent in effecting 5-HT degeneration than either the R-(+)-6,7-ADTQ or the parent 
racemic mixture. But, the survival rate for mice injected with S-(-)-6,7-ADTQ was only 
16%. Thus, we decided to lower the dose of all three species to 83 nmol and repeat the 
experiment, as shown in Table 4-13.
Table 4-13. Whole mouse brain CNS neurotransmitter depletions 
7 days after 83 nmol of (±, +, and -)-6,7-ADTQ.
Neurotiansmitter Levels (% controls ±  SEM)
Compound NE DA 5-HT N
Controls 100 ± 3 100±3 100 ± 4 7
(±)-6,7-ADTQ 48 ±2*** 79 ±5** 69 ± 5** 7
R-(+)-6,7-ADTQ 52 ±3*** 81 ±4** 73 ±3*** 9
S-(-)-6,7-ADTO 49 ±2*** 79 ± 6 ** 65 ± 7** 3
Significant differences compared to control values (t test): **P < 0.01, ***P <  0.001.
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Under these new, but still equivalent dosage, conditions, the S-(-)-6,7-ADTQ 
continued to appear more potent with respect to its 5-HT effects. However, the 
individual 5-HT results were notably not significantly différent And, more importantly, 
the survival rate for the S-(-)-6,7-ADTQ group was only 25%.
At this juncture, the difBculty associated with extrapolating a one hour LDso value 
to a seven day LD50 value was obvious. Thus, we injected another group of animals 
with only 55 nmol of S-(-)-6,7-ADTQ and stopped to examine our knowledge of 7 day 
survivability. The results are shown below in Table 4-14.
Table 4-14. Survivabili^ of mice 7 days after (±, +, and -)-6,7-ADTQ injection.
Compound Amount used (nmol) % Alive at 7 days
(±)-6,7-ADTQ 111 43%
83 58%
R-(+)-6,7-ADTQ 111 2 1 %
83 75%
S-(-)-6,7-ADTQ 111 16%
83 25%
55 75%
Thus, based on the results in Table 4-15, we were ready to compare the 
"maximum usable" effects of each of the agents. The doses indicated for this study were 
83 nmol for both (±)- and R-(+)-6,7-ADTQ and 55 nmol for S-(-)-6,7-ADTQ. An 
examination of the mouse brain effects under these conditions yielded the results shown 
below in Figure 4-4 for the neurotransmitters and in Table 4-16 for all the measured 
endogenous neurochemicals.
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B(±)-<5.7-ADTQ 
■  R-(f)-6.7-ADTQ 
0  S-(-)^7-ADTQ
5-HT
Figure 4-3. Mouse whole brain neurotiansmitter depletions by (±,+,and-)-6,7-ADTQ.
Table 4-15. Mouse whole brain neurochemical levels 7 days after treatment with 
"maximum usable" doses of (±)-, R-(+K and S-(-)-6,7-ADTQ.
Neurotiansmitter Levels, % controls ±  SEM
Compd
(±)-6,7-
N NE DA 5-HT DOPAC HVA 5-HIAA
ADIQ
R-(+)-
11 54 ±2*** 83 ±3*** 74 ±3*** 9 2 ± 5 113 ± 5* 100±5
ADIQ
S-(-)-
14 52 ±2*** 86  ±3*** 72 ±2*** 9 0 ± 4 113 ± 5 87 ±3*
ADIQ 16 55 ±2*** 88 ±3*** 71 ±3*** 83 ±4** 112 ± 6 82 ±3***
Significant differences compared to control values (f test): *P < 0.05; **P < 0.01,
*♦*/» < 0.001. 6,7-ADTQ, 83 nmol; R-(+)-6,7-ADTQ, 83 nmol; S-(-)-6,7-ADTQ, 55 
nmol Typical mouse whole brain control transmitter values were (nmol/g tissue, mean ± 
SEM): NE, 2.98 ±  0.08; DA, 8.19 ±  0.2; 5-HT, 4.5 ±  0.06.
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Employing the "maximum usable" dose for each of these species, we observed no 
discernible and/or significant effects with respect to neurotiansmitter depletions.
Summarization of all the results obtained for the racemic and enantiomeric forms 
of 6,7-ADTQ are, thus, quite straightforward. When employed at equivalent doses, the 
S-(-)-enantiomer is both more lethal and more potent in its 5-HT degenerative effects than 
either the R-(+)- enantiomer or the racemh; mixture. Simultaneously, at equivalent doses, 
no significant differences were observed for the effects of any of these three species on 
non-5-HT systems. When the dose of each species was adjusted to a "maximum usable" 
value, there was no discernible differences in the depletion effects on any of NE, DA, or
5-HT. Thus, overall, there is no substantial advantage to utilization of either enantiomers 
over that o f the parent racemic mixture in neurotoxic investigations.
2. 6,7-ADTQ, 6,7-AMDTQ, and 6,8-ADTQ Investigations
Initial efforts on 6,7-AMDTQ and 6 ,8 -ADTQ concentrated on finding an 
appropriate dose to employ for "maximum usable" comparisons to the 6,7-ADTQ. The 
one hour LDso results strongly indicated that equivalent doses would be inappropriate for 
these two species. For 6,7-AMDTQ, we initially employed 156, 78, 52 nmol. These 
doses yielded 7 day survival rates of 4%, 18%, and 89%, respectively. Thus, we 
selected 52 nmol as the "maximum usable" dose. For 6 ,8-ADTQ, two attempts at 333 
nmol yielded 7 day survival rates of 45% and 40%; thus, this value was selected for this 
toxin.
The effects of 6,7-AMDTQ, 6 ,8-ADTQ, and 6,7-ADTQ, each at its "maximum 
usable" dose, on mouse whole brain neurotransmitter levels 7 days following Le v. 
injection are shown in Figure 4-4. The corresponding effects on all measured 
endogenous neurochemicals are presented in Table 4-16. All toxins employed for these 
studies were, notably, racemic mixtures.
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5-HT
F ig u re  4-4. W hole mouse brain depletion by 6,7-ADTQ, 6,7-AMDTQ, and
6 ,8-ADTQ.
Table 4-16. Mouse whole brain neurochemical levels 7 days after treatment with 
"maximum usable" doses of 6,7-ADTQ analogs.
Neurotransmitter Levels, % controls ± SEM
Compd
(±)-6,7-
N NE DA 5-HT DOPAC HVA 5-HIAA
ADIQ
6,7-
11 54 ±2*** 83 ±3*** 74 ±3*** 9 2 ± 5 113 ± 5* 100± 5
AMDTQ
6 ,8 -
17 68  ± 2*** 100 ± 1  81 ± 2 *** 87 ± 2* 104±5 86  ± 4 *
ADTO 16 6 8 ± 1*** 91 ± 3*  73 ±2*** 88  ± 3 * 118 ±4** 68  ± 2 ***
Significant differences compared to control values it test): *P < 0.05; <0.01,
***P < 0.001. Toxin amounts used were: 6,7-ADTQ, 83 nmol; 6,7-AMDTQ, 52 nmol; 
and 6 ,8 -ADTQ, 333 nmoL Typical mouse whole brain control transmitter values were 
(nmol/g tissue, mean ±  SEM): ME, 2.98 ±  0.08; DA, 8.19 ±  0.2; 5-HT, 4.5 ±  0.06.
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These results indicate that the examined toxins are only able to elicit ca. 30% 
5-HT degeneration under the "maximum usable” conditions. This was somewhat 
disappointing. However, there were also some encouraging aspects. For example, both
6,7-AMDTQ and 6 ,8-ADTQ exhibited lesser effects on ME and DA degeneration than did 
the parent 6,7-ADTQ. Thus, these analogs are more selective than 6,7-ADTQ.
To facilitate comparisons between the quinoline analogs currently examined and 
the established 6 -HDA and 5-HT standards, we have shown neurotransmitter depletions 
produced by each in mouse whole brain 7 days following treatment with the agent in 
Table 4-17. The dose used in each case was at or near the "maximum usable" value.
Table 4-17. Mouse whole brain neurotransmitter effects of 6,7-ADTQ analogs and
similar toxins at 7 days.
Compound dose, nmol
Neurotransmitter Levels (% controls ± SEM)»
NE DA 5-HT N
(±)-6,7-ADTQ 83 54 ±2*** 83 ±3*** 74 ±3*** 11
6,7-AMDTQ 52 68  ± 2 **» 1 0 0 ± 1 81 ± 2 *** 17
6 ,8-ADTQ 333 68  ± !♦♦♦ 91 ± 3* 73 ±2*** 16
6 -HDA» 300 35 ± 6 *** 71 ± 6 ** 88  ± 3* 6
5,7-DHTc 129 82 ±3*** 9 9 ± 1 70 ± 6 *** 16
^ Significant differences compared to control values (r test): *P < 0.05; ***P < 0.001.
data from Su Ma et a L ^  
c data fiom L in ^
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From a noradrenergic viewpoint, the quinoline analogs fall short of matching the abilities 
of 6-HDA. However, from a serotonergic viewpoint, the 6,7-ADTQ and 6 ,8-ADTQ are 
equally as potent as 5,7-DHT. And, at higher doses, 6,7-ADTQ has been shown capable 
of producing 48% 5-HT depletions (see Table 4-1), which is substantially more than 
maximal 5-HT depletions of 30% reported for 5,7-DHT.
6,7-AMDTQ and 6 ,8-ADTQ are more selective than 6,7-ADTQ in that they cause 
lesser degenerative effects on the noradrenergic and dopaminergic systems. But,
5.7-DHT is clearly more innately selective than all the quinoline adducts. Fortunately, L. 
Lin has demonstrated that, by incorporating appropriate uptake blocking agents, ME and 
DA depletions produced by 6,7-ADTQ can be substantially blocked. Thus, it is not 
umeasonable to assume that the lesser ME and DA effects elicited by 6,7-AMDTQ and
6 .8-ADTQ could also be similarly blocked, possibly to an even greater extent As such, 
we would predict that uptake blocking agents could be used with all the quinoline 
congeners to eliminate these selectivi^ problems. The reader should also be reminded 
that the results presented here are from intracerebroventricular administration of the toxic 
agents. And, selectivity is a function of many different factors, including the site at 
which the toxin is administered. Thus, selectivi^ could additionally be enhanced by 
simply injecting the agent directly into a brain region containing the desired nerve ending 
and/or cell bodies to be destroyed.
C. Behavioral Effects
At the doses indicated in the depletion study, mice treated with 6,7-ADTQ,
6,7-AMDTQ, and, to a lesser degree, 6 ,8 -ADTQ exhibited extreme hyperactivity upon 
recovery from anesthesia, which took approximately 1 min. Treated animals would 
initially be motionless, with their backs arched and their tails erect Then, suddenly, they
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would jump 6 to 10 times in rapid succession, straight up 4 to 6  inches. This was 
followed by many interesting behavioral effects such as: r^ id  running around the sides 
of the cage; lying on the side or back and rubbing the head on the sides and bottom of the 
cage; rolling along the head-tail axis; lying on the back with limbs extended straight out, 
accompanied by occasional body and head tremors; and, periodically, appearing to 
experience extended seizures lasting 20 to 40 sec each. Such phases of high activity 
would last 5 to 10 min and would be followed by a 2 to 4 min period in which the animal 
would lay prone and upright, appearing entirely limp. These alternating episodes of high 
and low activity would continue for up to 1 day.
V. Conclusions
6,7-ADTQ, its enantiomers, and its analogs were investigated to determine their 
potential utility as serotonergic neurotoxins. Examinations o f the enantiomers of
6,7-ADTQ revealed the S-(-)-enantiomer, at equivalent doses, to be more potent than the 
R-(+)-enantiomer. However, the S-(-)-enantiomer was also more lethal. When the dose 
of the S-(-)-enantiomer was reduced to compensate for this lethality, it unfortunately 
displayed no significant advantage in neurodegenerative capabilities over the 
R-(+)-enantiomer or the racemic mixture. But, both 6,7-ADTQ and 6 ,8 -ADTQ produced 
substantial depletions in mouse whole brain 5-HT levels. These depletions are at least 
comparable to those produced in mouse brain by 5,7-DHT23 J 9  at "maximum usable" 
doses. Furthermore, at higher dose levels, 6,7-ADTQ produced 5-HT depletions greater 
than any previously reported for 5,7-DHT. But, these quinoline compounds were 
inherently less selective than 5,7-DHT. However, Lin has shown that the non-specific 
destruction can be substantially blocked with appropriate uptake blocking agents, thereby 
eliminating the selectivity problems.
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Considering all of the above factors, we conclude that both 6,7-ADTQ and
6 ,8-ADTQ, if employed with appropriate NE and DA uptake blocking agents, would be 
at least equally potent in their neurodegenerative effects on the mouse brain serotonergic 
system as the standard 5,7-DHT.
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Mode of Action I : Uptake 
Interaction
Chapter 5
I. Introduction
Neurotransmitter uptake, or transport, sites are present in nerve terminal 
membranes and bear the primary tesponsibili^ for inactivation of released transmitters. 
Uptake sites, therefme, play a key functional role at many synapses, Uptake sites are
also believed to be the primary site o f action of many drugs. For example, cocaine acts, 
at least in part, by blocking the uptake of DA, thereby increasing the extracellular 
concentration of this neurotransmitter.^ Other psychostimulants, such as amphetamines, 
act in a similar manner.^ The abili^  o f tricyclic antidepressants to inhibit catecholamine
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and/or indolamine transmitter reuptake led to the "biogenic amine hypothesis" of affective 
d isorders.^  In addition to drugs exerting their effects via uptake blockade, 
pharmacologically active agents may also gain access to the cytoplasm of the neuron 
through these highly selective transport sites and, once inside, elicit other effects.
It is known that 6-HDA and related analogs must be accumulated inside the 
neuron to subsequently elicit degenerative effects. This requirement is also accepted for 
MPP+, the toxic metabolite of MFTP, 5,6- and 5,7-DHT, and most other neurotoxins. 
The mechanism by which these compounds gain access to the cytoplasm involves 
selective recognition and transport by the relevant neurotransmitter uptake sites. This 
requirement is easily demonstrated by the elimination of neiuotoxicity upon incorporation 
of appropriate uptake blocking agents prior to administration of the toxin. Selective 
transport is, thus, unquestionably a primary factor involved in the selective degeneration 
exhibited by a given agent. On the other hand. Ma and c o w o r k e r s ,2 4  investigating eight 
analogs of 6 -HDA, have shown that no direct correlation exists between the degree of 
toxin-transporter interaction and the observed degeneration which occurs in affected 
neurotransmitter systems.
n. Background
Toxin afOnities for and interactions with various neurotransmitter transport sites 
are generally determined by the extent to which the toxin interferes with the uptake of 
radiolabeled neurotransmitters. This is normally accomplished in vitro utilizing 
synaptosomes, which possess much of the functional viabili^ characteristics inherent of 
in vivo nerve endings from which they are derived. 138-140 Synaptosomes are isolated 
via tissue homogenization followed by purification using a sucrose gradient centrifugation 
technique. 13fi* 138,139,141,142
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The interaction of substrates with uptake, or transport, sites are remarkably 
similar to those of substrates and enzymes, and, therefore, can be mathematically treated 
using enzyme kinetic models. A modified version of the Michaelis-Menten equation is 
the Briggs-Haldane equation:
V [5] equation 5-1
where Vq is the initial veloci^ of uptake, Vmar is the saturated or maximal uptake 
velocity, [S] is the substrate concentration, and Km is the Michaelis-Menten constant 
Taking the reciprocal of equation 5-1 leads to the Lineweaver-Buik equation:
Thus, if IAtq is plotted against 1/[S], one obtains a straight line with a slope of Km/Vmar 
and a Y-intercept of 1/Vma,. is an important parameter which is characteristic of the 
specific substrate-transporter interaction. It is also o f interest to note that, when 
Vo=Vmax  ^2, IQn—[S],
In the presence of an inhibitor, the uptake velocity becomes dependent upon both 
the substrate and inhibitor concentrations. Modifying equation 5-2 to accommodate a 
competitive inhibitor, we obtain:
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1 1
Vf
equation 5-3
where v, is the uptake veloci^ in the presence of the inhibitor, [I] is the inhibitor 
concentration, and Ki is an equilibrium constant for the interaction of the inhibitor with 
the transporter. The corresponding equations for noncompetitive and uncompetitive 
interactions are, respectively:
V;
equation 5-4
and
1 1
Vf
equation 5-5
The nature of the interaction of a  given inhibitor and transporter combination normally is 
determined in a series of experiments, each employing a unique concentration of 
inhibitor, in which the transport velocity is measured as a function o f the substrate 
concentration. The resultant data is plotted as 1/vi vs. 1/[S] and compared to the 
theoretically expected plots for each of the com petitive, noncompetitive, and 
uncompetitive cases. The theoretical plots are derived directly from equations 5-3 to 5-5 
and appear as:
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Competitive NoncQmpctitive
[I]=3x
Uncompetitive
However, diiect determinations of the IQn, Kg, and VmaT values from a Lineweaver-Burk 
plot, such as that shown above, is inadvisable due to the inappropriate weighting o f 
individual data points. For these determinations, a  nonlinear least squares provides more 
reliable constants. In our case, we used NLLSQ, a  program written by Dr. Enwall 
(University of Oklahoma), to obtain values of Km, Kg, and Vmax* as well as error 
estimates for e a c h . 2 4  Thus, a normal sequence in the determination o f the interaction o f 
an inhibitor with a transport site involved (1) identification of the type of inhibition via a
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Lineweaver-Budc double reciprocal plot, and (2) determination of the Ki value via fitting 
to the appropriate kinetic equation using NLLSQ.
In some cases, one may, a priori, know that a particular inhibitor/transporter 
interaction is competitive. In these cases, a  shorter route to the Ki is available. Using a 
fixed concentration of substrate near the Km, one meastues the initial uptake velocity at 
varying concentrations of the inhibitor. The results are typically plotted as transport 
velocity, in % control units, vs. log[l] and yields an inverted S-shaped curve. The 
inhibitor concentration, [1], at which the transport rate is 50% of its control, or maximum, 
value is signified as the ICso.^^^ Using v(=Vo /  2 and [IJ^lCso, combination and 
reduction of equations 5-2 and 5-3 yields:
equation 5-6
or
equation 5-7
Thus, Ki is directly accessible in an ICso experiment through (1) determination of ICso,
(2) knowledge of the substrate concentration employed, and (3) prior knowledge of the 
IQn value. However, as was the case with the above Lineweaver-Buik discussion, fitting 
of all the data points with NLLSQ, rather than simple graphical extrapolation, is preferred 
to avoid improper weighting of any single data point In this case, the data is fitted to the 
reciprocal of equation 5-3.
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m . Experimental Methods
A. Chemicals and Solutions
1. Chemicals
All aqueous solutions employed 18 MG distilled/deionized water which was 
prepared by passing distilled water through a Milli-Q Reagent Water System (Millipore, 
Continental Water Systems, El Paso, TX).
Radiolabeled transmitters, %-NE, ^H-DA, and ^H-S-HT, were purchased from 
DuPont NEN Research Products and stored under a nitrogen atmosphere in the 
refrigerator. EcoLite+ was purchased through ICN Biochemical, hic.
The chemicals listed below were purchased through Sigma Chemical Company 
(Sl Louis, Mo.) in high puri^  and used without any further purification. All other 
chemicals were obtained and used as described in previous chapters, 
sucrose 
TRIS buffer 
iproniazid 
potassium chloride 
calcium chloride 
lithium chloride 
magnesium chloride 
D-glucose 
L-ascocbic add 
sodium carbonate 
sodium bicarbonate 
sodium tartrate
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tncinconinic acid, disodium salt
ethylene glycol monomethyl ether (2-methoxyethanol)
2. Homogenization Solution
The homogenization solution used for the preparation of synaptosomes contained 
0.32 M sucrose, 20 mM TRIS buffer, adjusted to pH 7.4 with HCl, and 10 fXM 
iproniazid, an irreversible monoamine oxidase inhibitor. Component additions and 
solution adjustments performed sequentially as shown in Table 5-1. The prepared 
solution was stored at 4°C for up to 1 week, then discarded.
Table 5-1. Homogenization solution preparation.
Compound Amount
sucrose 54.77 R
Tris Base 1.21 g
iproniazid 1.39 mg
add490 mL water
adjust to pH 7.40 with HCl
dilute to 500 mL
3. Na+ Tris-Krebs Buffer Solution
The Na+ Tris-Krebs buffer was employed in synaptosomal incubations. It 
contained 140 mM NaCl, 5 mM KCl, 2.5 mM CaClz, 1.2 mM M gCli, 10 mM 
D-glucose, 1 mM L-ascorbic acid, 20 mM TRIS buffer, and adjusted to pH 7.4 with 
HCL Component additions and solution adjustments were performed sequentially as
1 3 0
given in Table 5-2. This solution was prepared 18 h prior to use and stored at 4**C, then 
discarded following the experiment
Table 5-2. N at Tris-Krebs buffer preparation.
Compound Amount
Naa 8.18 g
KCl 373 mg
CaOi'THsO 368 mg
MgCl2"6H2 0 244 mg
D-glucose 1.80 g
L-ascorbic acid 176 mg
Tris Base 2 .42g __
add 980 mL water
adjust to pH 7.40 with HCl
dilute to 1.00 L
4. LI+ T ris-K rebs B uffer Solation
For samples in which background, or zero, uptake was determined, Li+ Tris- 
Krebs buffer was substituted for the Na+ Tris-Krebs buffer. It contained 140 mM LiCl, 
5 mM KCl, 2.5 mM CaCl2« 12 mM MgCl2, 10 mM D-glucose, 1 mM L-ascorbic acid, 
20 mM TRIS buffer, and adjusted to pH 7.4 with HCl. Component additions and 
solution adjustments were performed sequentially as given in Table 5-3. This solution 
was prepared 18 h prior to use and stored at 4°C, then discarded following the 
experiment
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Table 5-3. Li+ Tris-Ktebs buffer preparation.
Compound Amount
u a 5.93 g
KCl 373 mg
CaCl2*2H2 0 368 mg
Mga2*6H20 244 mg
D-glucose 1.80 g
L-ascorbic acid 176 mg
Tris Base 2,42 g
add 980 mL water
adjust to pH 7.40 with HCl
dilute to 1.00 L
5. Neurotransmitter Solation
The radiolabeled transmitters, ^H-NE, ^H-DA, and 3H-5-HT, were mixed with 
their corresponding unlaheled transmitters in a molar ratio o f between 1:10 to 1:15. A
0.10 mM HCl solution was used for dissolving unlabeled transmitter and the dilution of 
the transmitter mixture to the desired concentration. The radiolabeled transmitters 
possessed a specific activ i^ of; NE, 9.0 mCi/mL; DA, 11.7 mCi/mL; and 5-HT, 25.4 
mCi/mL. The labeled/unlabeled mixture was prepared just prior to the experiment and 
was used for a maximum of 2 h. The radiolabeled transmitters wete stored at -20°C 
under a nitrogen atmosphere and were discarded within 2  months of their initial opening.
1 3 2
6. Toxin Solution Preparation
A carefully limited amount of toxin was weighed and transferred to a  1 mL glass 
vial that was preflushed with argon or C>2-free nitrogen. An appropriate amount of 
deaerated I(H  M HCl was added to obtain the highest desired toxin concentration, and 
the vial was flushed with argon or nitrogen again. For an IC 50 study, typical toxin 
incubation concentrations were lxlQ-3, 3xl(H , lx l(H , 3x10"^, lxlO*5, and 3x10^. For 
a double reciprocal study, ^ ic a l  toxin incubation concentrations were 0.5, 1, and 1.5 
times the K, value for the toxin. The desired toxin concentrations were achieved by 
diluting the original stock solution with 10*  ^M HCl. The toxin solutions were utilized 
and discarded within 1 h.
7. Blcinconinic A dd  Reagent
Protein determinations for synaptosomal preparations employed the bicinconinic 
acid method of Smith et aL ^ ^  The reagent contained 1% bicinconinic acid (BCA), 
1.74% NaiCO), 0.19% tartrate, 0.4% NaOH, 0.95% NaHCOg. Component additions 
and solution adjustments were performed sequentially as shown in Table 5-4.
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Table 5-4. Bicinconinic acid reagent preparation.
Compound | Amount
BCA-Nai 2 3  g
NagCOg anhyd. 4.35 g
tartrate*Na2*2H2 0 0.475 g
NaOH 1.00  g
NaHCOt 2.375 g
add 225 mL water
adjust to pH 1125 with solid NaHCO^
dilute to 250 mL
B. Methods and Procedures
1. B rain Rem oval
Male Sprague-Dawley rats weighing 300-400 g were anesthetized in a diethyl 
ether vapor chamber and sacrificed by decapitation. The rat head was placed on an 
absorbent towcL Holding the head securely, with the nose pointing away firom the 
experimenter, the skin was removed from the top portion of the skull by cutting with 
scissors. Starting at the severed part of the neck, cutting proceeded forward below the 
ear and eye, and along the side of the skull to a point t^proximately S mm in fix>nt of the 
eye. This was repeated on the other side of the skull. Then, by cutting under the skin, 
the skin was freed from the skull Scissors were then inserted into the magnus 
foramanus, i.e., the opening at the base of the skull, and the skull was cut down the
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midline to a point somewhere between the eyes, being careful not to cut or gouge the 
brain with the lower half of the scissors. The skull was then cut between the eyes and the 
rostral-caudal midline using bone cutting forceps. At this point, the skull was opened by 
inserting the scissors into the midline cut and opening the scissors, thereby splitting the 
dorsal portion of the skull apart and exposing the brain. The brain was quickly removed 
and placed upright on a dissection glass kept over ice. With a scalpel, the brain was cut 
coronally downward between the cerebellum and the cerebral cortex. The cerebellum, 
medulla/pons, and all caudal tissue components were discarded. The brain was then 
bisected with a mid-sagittal cut and weighed. Typical brain weights were 1.3-1.6 g.
2. Preparation of Synaptosomes
The two dissected forebrain halves were placed in separate homogenization tubes, 
each containing ca. 10 mL of homo^nization solution at 0°C. Homogenization employed 
a model 143 Dyna-mix stirrer (Rsher Scientific, Dallas, IX ) outfitted with a model S-703 
teflon pestle and model B-3103 tissue homogenizing mortar from A.H.T. Co. 
(Philadelphia, PA). Homogenization required 10 complete up/down strokes at 350 rpm, 
which corresponded to setting #  4. The homogenates were transferred to precooled, 10 
mL plastic centrifuge tubes. Isolation and purification of synaptosomes was 
accomplished by centrifugation, always at 4°C, using a model RC-5B Sorvall Superspeed 
Centrifuge and a model SM-24 rotor, both fiom DuPont Instruments (Newtown, CT). 
The tissue homogenates were centrifuged at 3000 rpm (lOOOg) for 10 min, and the 
resultant pellets, containing cellular debris, were discarded. The supernatant was 
centrifuged again at 3000 rpm for 10 min, and the resultant pellets were again discarded. 
The supernatant was then centrifuged at 10000 rpm (12000g) for 20 min to isolate 
synaptosomes. This time the supernatant was discarded, and the resulting pellets were 
resuspended at 0°C in 1 mL of homogenization solution using a  glass rod. The manually 
resuspended mixture was transferred to a single homogenization tube, the volume was
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adjusted to ca. 3 mL, and the mixture was slowly subjected to S up-down strokes to 
ensure hom ogenei^ of the synaptosomes. The synaptosomal preparation was then 
divided between the Na+ and the Li+ buffers, making the résultant synaptosomal buffer 
solutions equal in synaptosomal concentration.
3. Uptake/Blockade
250 fiL aliquots of buffer/synaptosomal solution were added to 7.4 mL glass 
incubation vials and kept at 0"C until used. Incubation was carried out in a water shaker 
bath (Eberbach Corp., Ann Arbor, MI) and the temperature held constant at 37**C by 
employing a model 71A YSI (Yellow Springs, OH) Thennistep Temperature Controller. 
Between 8-12 vials were run at a time. Synaptosomal solutions were preincubated for 5 
min in the water bath, at which time 20  ^iL of toxin was added, if  toxin was being used. 
This was immediately followed by the addition of 20 |XL of desired ^H-transmitter which 
initiated the actual uptake experiment. This mixture was then incubated for 2 min. 
Uptake was terminated by the addition of 2 mL ice cold Li+ buffer, and transferred 
immediately to an ice bath prior to filtering. The synaptosomal solution was then filtered 
through a Metricel GN-6  0.45 |xm filter membrane using a model 1225 Millipore 
(Millipore, El Paso, TX) 12 port filtration apparatus. Each vial and membrane was 
rapidly washed two times with 2 mL Li+ buffer.
The filters were carefully placed in scintillation vials and allowed to air dry 
overnight. The filters were then dissolved via the addition o f 1 mL of 2-methoxyethanol 
(ethylene glycol monomethyl ether). Once dissolved, which took approximately 4-5 h, 4 
mL of EcoLite+ scintillation cocktail was added, and the vial was capped and shaken 40 
to 50 times to ensure complete homogeneity. The vials were then placed in plastic 
scintillation containers and stored in the dark for a minimum of 48 h to insure the absence 
of light-induced fluorescence and chemical-induced luminescence. The radioactivity 
(DPM) was determined by using a model LS 5801 Beckman liquid scintillation counter.
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4. Protein Analysis
Protein concentration was determined using the bidnchoninic acid (BCA) method 
of Smith and coworkers.1^ BCA reagent (50 mL) was mixed with 1 mL of 4% CUSO4 
solution and allowed to stand for 2  h; this mixture turned candy apple green almost 
immediately. 100 |iL  of protein standard or sample was added to 2 mL of the 
BCA/CUSO4  mixture and incubated at 39 ±  l°C in a  water bath shaker for 30 min, then 
cooled to room temperature. Absorbance of the incubated solution was recorded at a 
wavelength of 562 nm using a model 8452A Hewlett-Packard spectrophotometer. All 
samples were run in triplicate. A protein calibration curve was obtained by plotting 
absorbance vs. concentration bovine serum albumin protein standard.
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IV. Results and Discussion
A. Km Values for Transm itter Systems Tested
Km values for the three neurotransmitter transporters wete initially determined to 
ensure the validity of the individual results. Typical Km values obtained for NE, DA, and 
5-HT in these uptake studies are presented in Table 5-5. These values agree well with 
those reported in the literature. The determination of a typical Km value for 5-HT is 
exemplified graphically in Figure 5-1.
Table S-S. Km values for NE, DA, and 5-HT uptake systems in rat brain
synaptosomes.
Neurotransmitter Experimentally Detennined 
Km (nM)
Literature (nM)
NE 588 ± 20 470^^5 .  664140.146
DA 232 ± 12 209147
5-HT 9 7 ± 3 83l-*8 -130^9
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0.007
5-HTKm = 97±3nM
0.005-
00
g 0.003-
0.001
0.00 0.01 0.02 0.03 0.04
Figure 5-1. 5-HT Km determination using a Lineweaver-Burk p lo t
B. Uptake Blockade by 6,7-ADTQ and its Enantiomers
Uptake inhibition by 6,7-ADTQ and its enantiomers on the noradrenergic, 
dopaminergic, and serotonergic systems were initially investigated using a double 
reciprocal Lineweaver-Burk analysis. Employing a variety of inhibitor and substrate 
concentrations, the inhibition produced by 6,7-ADTQ and its stereoisomers was foimd to 
be competitive in nature for each of the neurotransmitters examined. A typical 
determination o f the inhibition nature is given for the (±)-6,7-ADTQ blockade of NE 
uptake in Figure 5-2 below.
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6,7-ADTQ
0.012 -
e
0.008-«Ds
50 fil
25 nM
e
I ,  0.004- 0 (iM
0.000
0.000 0.001 0.0040 .002 0.003 0.005
Figure 5-2. Ki detenninadon using a  modified Lineweaver-Buik double reciprocal
p lo t
In all such cases, the entire data set derived from multiple individual experiments was 
fitted using NLLSQ to each of the competitive, noncompetitive, and uncompetitive cases. 
The Qrpe of inhibition was then assessed as the fitted model providing the smallest error 
estimates for Km, Vmax, and Ki.
Once the nature of the inhibition was established to be competitive, an IC50 
approach similar to that shown in Figure 5-3 for the S-(-)-6,7-ADTQ allowed more rapid 
and precise determination of the Ki value via a  single experiment
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Figure 5-3. K* determination using an ICso approach for S-(-)-6,7-ADTQ blockade of
ME. Concentration ofNE used was 600 nM
The Ki values obtained for uptake blockade of NE, DA, and 5-HT by 6,7-ADTQ and its 
enantiomers using this approach are summarized in Table 5-6. All the values were in the 
range of 10 to 100 pM, which indicates substantial interactions with the uptake sites.
6,7-ADTQ and its optical isomers showed their highest uptake afGnities towards the 
noradrenergic system. And, in depletion studies, we saw that 6,7-ADTQ and its 
stereoisomers showed maximal depleting potency towards the noradrenergic system. On 
the other hand, 6,7-ADTQ and its enantiomers individually displayed comparable uptake 
interactions between the dopaminergic and serotonergic systems, while these agents 
elicited substantially more 5-HT dq*Ietion than they did DA depletion. This reinforces the 
conclusion by Su Ma et al.^4 uptake is not the sole determining factor in depletion
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potency and that selectivity of an agent cannot be quantitatively correlated to the degree of 
uptake inhibition exhibited in the affected transmitter systems.
Table S-6. Ki values for 6,7-ADTQ and optical isomers.
Compound
Uptake interaction constant, K; (uM)
NE DA 5-HT
(±)-6,7-ADTQ 29 ± 5 74 ±18 86 ± 17
R-(+)-6,7-ADTQ 3 3± 7 80 ± 13 84±42
S-(->6,7-ADTO 14±1 48 ± 10 57 ± 34
Each value employed, ^ ic a lly , 6 data points with N=S for each point and N=6 for
background for each point
The Ki results for the racemic agent and its optical isomers showed that the 
R-(+)-6,7-ADTQ exhibited similar uptake site afGnities to that of the racemic 6,7-ADTQ. 
For the S-(-)-6,7-ADTQ, however, a  general trend of lower Ki values was observed for 
each of the three transmitters when compared with either the R-(+)-6,7-ADTQ or the 
racemic 6,7-ADTQ. While these uptake interactions for S-(-)-6,7-ADTQ are only 
significantly greater for the NE and DA systems, the stronger interactions do qualitatively 
correlate with the observed stronger depletions for each of NE, DA, and 5-HT by this 
enantiomer.
142
C. Toxin Uptake Blockade by Racemic 6,7-ADTQ, 
6,7-AMDTQ, and 6,8-ADTQ
Transporter afGnities of racemic 6,7-ADTQ, 6,7-AMDTQ, and 6,8-ADTQ for the 
NE, D A  and 5-HT uptake proteins were approached using the same procedures outlined 
in the previous section. The 6,7-ADTQ/transmitter combination revealed the expected 
competitive inhibition mechanism and, therefore, the remaining analogs were assumed to 
possess the same competitive nature. The resulting Ki values for these agents, obtained 
using the ICso approach, are presented in Table 5-7, along with the corresponding values 
for the catecholaminergic toxin 6-HDA
Table 5-7. Ki values for 6,7-ADTQ, 6,7-AMDTQ, 6,8-ADTQ, and 6-HDA
Compound
Uptake interaction constant Ki (UM)
NE DA 5-HT
6,7-ADTQ 29 ± 5 74 ±18 86 ± 1 7
6,7-AMDTQ — 261 ±21 124 ± 5 5
6,8-ADTQ — — 114±47
6-HDA 51 ±1* 12 ±0* NA
Each value employed, ^ ic a lly , 6 data points with N=5 for each point and N=6 for 
background for each point *values reported by Su Ma e t aL^^
Three transmitter/toxin combinations, however, yielded entirely unexpected 
results. First the 6,7-AMDTQ effects on NE uptake were foimd to be not significantly 
different in multiple experiments using toxin concentrations varying between 1.0 ^ M and
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1.0 mM. This was unexpected since 6,7-AMDTQ had cleady exhibited long term NE 
depleting effects in the previously reported studies. However, even more unusual results 
were obtained with the 6,8-ADTQ/NE and 6,8-ADTQ/DA investigations. As shown 
below in Figures 5-4 and 5-5, respectively, increasing concentrations o f 6,8-ADTQ in the 
incubation mixture provided corresponding increases in uptake accumulation o f the 
radiolabeled transmitter.
775 ±6
#  450
279 ±10
3  250
118 ± 2100±3
controls 1000 100 10
6^-ADTQQiM)
Figure 5-4. 6,8-ADTQ effects on NE uptake; [NE]=600 nM
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125 ±10
112 ±11
102±8100±7
controls 1000 100 10
__________ 6,8-ADTQ (nM)
Figure S-S. 6 ,8-ADTQ efifects on DA uptake; [DA]=230 nM
Examination of the Ki values for an individual toxin, where obtained, allows at 
least a qualitative assessment of the import of the uptake interaction on the observed long 
term depletion of individual transmitters and, thus, the inherent selectivity of the toxiiL In 
this regard, as already mentioned, the stronger interaction of 6,7-ADTQ with the NE 
transporter is qualitatively reflected in the more potent long term depletion of NE as seen 
in Table 4-16, compared to DA and 5-HT, by this toxin. However, the long term 
depletions of DA and 5-HT by 6,7-ADTQ do not correspond to their strength of 
interaction with the uptake sites. For 6,7-AMDTQ, the strength o f interaction with the 
uptake sites qualitatively, but not quantitatively, corresponds to the observed DA and
5-HT long term depletion effects. However, the lack of any measurable interaction of
6,7-AMDTQ with the NE uptake site clearly did not correlate with the observed 
substantial long term depletion of NE by this toxiiL
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Comparisons between the observed long term depletion effects and the uptake K, 
values for various toxins and a single transmitter could also reveal possible correlations. 
However, in the current studies of the three quinolines, this is considered inappropriate 
for two reasons. First, the unusual transporter interactions observed for
6.7-AMDTQ/NE, 6 ,8-ADTQ^NE, and 6 ,8-ADTQ/DA eliminate the possible use of these 
in such a comparison. Second, the long term depletion studies were performed, for 
reasons previously stated, at "maximum usable" doses for each toxin. Thus, 
comparisons between toxins would be inappropriate due to the lack of consistency in the 
employed dosages.
The apparent stimulation of uptake seen in the cases o f 6 ,8 -ADTQ/NE,
6 .8-ADTQ/DA, and 6,7-AMDTQ/NE are difficult at this point to understand and 
interpret Stimulated uptake, with increases to 400% of controls, has been reported in 
various long term investigations, however, which may be pertinent These 
investigations, and their results, include:
(1) a 10 day treatment of rats with cocaine and/or pimozide, a D2 receptor 
antagonist by Parsons et al., 1^0 which, when examined with microdialysis, 
revealed modest enhancement of DA uptake and release mediated by the D2 
autcrecepton
(2) a single or 30 day oral administration of BY-1949, a benzodiazepine derivative 
by Nagafuji e t which, when examined by normal synaptosomal uptake 
procedures at 30 min and 2 days following treatment respectively, revealed 0 
to 20% enhancements in glutamate and G ABA transport which were 
presumed due to increases in the Vn,», observed for the low affinity isoform 
of Na+,K+-ATFase;
(3) administration of lead, triethyl lead, or tetraethyl lead to rats either in a single 
dose or continuously for 3 weeks by Komulainen et al.,1^^ followed by
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normal synaptosomal uptake examination 24 hrs after final treatment, yielded 
NE and DA uptake enhancements of 0 to 50% of controls;
(4) tats treated with lithium for 12 days or lithium for 10 days and allowed 2 days 
for withdrawal by Abluwalia and Singhal,^^^ when examined thereafter, 
yielded synaptosomal uptakes of NE and DA which were elevated to as much 
as 400 and 250% of controls, respectively; and
(5) exposure of rats to hypoxia for 12 hr by Odaijuk et a l.,1 ^  when examined 12 
hr later, yklded elevated DA synaptosomal uptake to 150% of controls.
Unfortunately, all the above reviewed cases which reported substantial 
enhancements in synaptosomal uptake, such as those seen for our three anomalous 
toxin/transmitter combinations, employed days to weeks of treatment and/or at least 12 hr 
between single treatments and examination. No literature reports could be foimd in 
which, similar to our experiments, substantial enhancement of uptake was observed by 
simply adding an agent directly to the synaptosomal incubation in vitro. Substantial 
synthesis of transporter protein, leading to an increase in Vm^ T for the uptake process, 
would require 12 to 36 hr. Such protein synthesis could explain virtually all the long 
term enhancements reported above and, indeed, was actually shown to be the case for the 
hypoxia study. 154 However, protein synthesis, and the corresponding Vma» increase, 
clearly does not apply to our experimmital paradigm.
Alternatively, a Idnetically derived possible explanation o f the observed 
enhancements in uptake would be associated with the Km values. A substantial increase 
in the affinity of the uptake site for the substrate, wimessed by a substantial decrease in 
Km, could lead to approximately two-fold increases in the measured uptake since we 
employed substrate concentrations ^proxim ately equal to the original Km. This effect 
could explain what we observed with the 6 ,8-ADTQ/DA and 6,7-AMDTQ/NE 
combinations; but, it could not explain the 6 ,8-ADTQ/NE effects. And, while some^^O 
have suggested possible short term decreases in Km due to phosphorylation of the uptake
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protein, the only reported changes in were, in fact, increases to approximately
250% o f controls, and these increases required a long term period for manifestation.
Kon-kinetically derived explanations of the observed enhancements in uptake are 
possible. However, we consider these to be so speculative at present as to be 
inappropriate for discussion. In short, no factually supported reasonable explanation 
exists for the increased transport seen with the 6 ,8 -ADTQ/DA, 6 ,8-ADTQ/NE, and
6,7-AMDTQ/NE combinations.
V. Conclusions
For the majority of combinations investigated, a substantial affinity has been 
demonstrated by the toxin for the uptake site of the transmitter system which experiences 
long term depletion effects. This supports the conclusion that the uptake site is the 
primary means by which the toxin gains access to the intracellular region of the affected 
neuron. It also supports the primary importance of toxin transport in its mode of 
destructive actiotL The necessity for uptake has even more pointedly been demonstrated 
for the long term depletion of NE and DA by 6,7-ADTQ, in that uptake blockade in these 
two cases effectively blocks the observed depletion afforded by this agent
Among the enantiomeric forms of 6,7-ADTQ, the S-(-)-enantiomer was found to 
elicit more potent interactions with the various uptake sites, corresponding to the slightly 
more potent long term depletions provided by this stereoisomer.
Considering all the quinoline analogs for which Kj values were determined, it is 
obvious that selectivity, with respect to the long term depletions afforded these agents, is 
not solely determined by the stroigth of the toxin/transmitter uptake site interaction alone. 
Indeed, using such values would lead to quantitatively, and even qualitatively, incorrect
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predictions of selectivity for long term depletions in the associated neurotransmitter 
systems.
The apparent stimulated uptake observed with the 6 ,8-ADTQ/DA and
6,7-AMDTQ/NE combinations may be explained by a short term decrease in Km. 
mediated by phosphorylation of the transporter protein. However, such an 
explanation for the 6 ,8-ADTQ/NE combination is usefully inadequate. And, the time 
scale of the current experiments is far too short to invoke meaningful alterations in the 
associated Vmar values. Thus, overall, we view the apparent enhancements in transport 
seen with these combinations to simply be inexplicable at the current time.
149
Mode of Action II: Ease of 
Oxidation & Acid/Base Properties
Chapter 6
I. Introduction
The ease of oxidation of 6-hydroxydopamine (6-HDA) and its congeners has been 
repeatedly implicated in the neurodegenerative mode of action of these toxins.^«^8,30 
Inherently low oxidation potentials thermodynamically allow these agents to be oxidized 
by molecular oxygen, which produces the superoxide radical hydrogen peroxide, and the 
highly reactive hydroxyl radical. Production of these oxygen-derived cytotoxins, 
particularly the hydroxyl radical, is almost certainly a part of the mode of action of 
6 -HDA.
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The thermodynamically driven autoxidation of 6 -HDA and related analogs at 
physiological pH also produces quinone or quinoneimine products which have potential 
pertinence to the neurodegenerative process as well. Consideration of these quinoid 
products in the mode of action of the toxin, however, fiequently ignores an important and 
thermodynamically controlled aspect. Le., the state of protonation. Simple deprotonation 
could lead to excessive acidification of the intraneuronal milieu. Facile protonation and 
deprotonation, coupled with transport of both forms across the inner mitochondrial 
membrane, could seriously hamper oxidative phosphorylation. Additionally, the state of 
protonation affects the reactivi^ of these quinoid species toward nucleophilic attack and 
other follow-up chemical reactions; or, the state of protonation affects the fundamental 
stability of the quinoids.
There are, in fact, two fundamental locations on a typical oxidized 6-HDA analog 
which could reasonably be considered for protonation/deprotonation under physiological 
conditions. The first of these, the aliphatic amine, has been shown to have pK& values, in 
the protonated state, of 9.5 to These relatively high pK& values mean the
majority of such groups would exist in the relatively unreactive protonated state at pH
7.4. Thus, these are generally considered to be of lesser importance. One the other 
hand, the second site of potential protonation/deprotonation is represented by the enolic 
hydroxyl group. This group exhibits pK , values in the range of 4 to 7, which are 
considerably lower than the pKa values of 8.5 to 11 exhibited by the phenolic protons of 
the reduced species fiom which they are derived. The lower pKa values o f these enolic 
protons makes it highly likely that their deprotonation is a substantial occurrence under 
physiological conditions.
Both oxidation and the likely protonated and deprotonated forms of the resulting 
quinoid species are depicted for 6,7-ADTQ, a typical 6-HDA related species, in Hgure 
6- 1.
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Figure 6-1. Oxidation of 6,7-ADTQ showing probable forms of the oxidized toxin.
The current chapter is concerned with the determination o f two important 
thermodynamic properties of our quinoline derivatives: (1) ease of oxidation, and (2 ) pKa 
of the enolic group of the oxidized quinoid species.
n . Experimental
A. Chemicals and Solutions
1. Chemicals
All chemicals listed below were purchased through Sigma Chemical Company 
(Sl Louis, Mo.) in high puriQr and used without any further purification. Chemicals not 
listed below are listed in previous charters.
6 -hydroxydopamine (6 -HDA) hydrobromide 
potassium hydroxide (KOH)
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potassium phosphate dibasic (anhydrous) 
potassium phosphate monobasic monohydrate
AU aqueous solutions employed 18 M£2 distflled/deionized water which was 
prepared by passing distilled water through a Milli-Q Reagent Water System (Millipore, 
Continental Water Systems, El Paso, TX).
2. Toxin Solution for pK« Studies
Stock toxin solutions were made by dissolving the desired amount of toxin in an 
appropriate amount of degassed 10*^  M HCl, to yield a stock concentration of 10 mM. 
Typically 1.5 to 2 raL of stock solution were needed The stock toxin solution was stable 
in excess of 8 hr.
3. pKa B uffer Solutions
The pH buffers were generally created by adding 0.10 M KH2PO4  to 0.10 M 
K2HPO4 until the desired pH was obtained. For lower pH values, HCl was added to
0.10 M KH2PO4, while for higher pH values, NaOH was added to 0.10 M K2HPO4. 
The 0.10 M KH2PO4  and 0.10 M K2HPO4  were prepared as separate solutions by 
dissolving 13.61 g KH2P0 4 *H2 0  and 17.42 g K2HPO4, respectively, in 1.0 L of water.
B. Methods and Procedures
1. Ease o f O xidation
The ease o f oxidation of the agents was determined using cyclic voltammetry 
(CV). The E°' value for a 0.10 mM solution o f the agent was measured in 0.10 M 
phosphate buffer a t pH 7.4 and 22°C using a hanging drop mercury working electrode 
and an SCE reference electrode. The CV was obtained using a Great Plains Laboratories
1 5 3
(Norman, OK) potentiostat and was recorded on a model 2000 Omnigraphic X-Y 
recorder (Houston Instruments, Bellaire TX). The scan rate was 92.6 mV/sec. The E°' 
was determined as the average of the anodic and cathodic peak potentials.
2. pKa Determinatioiis
For the evaluation of the dissociation constant for the enolic group of the oxidized 
toxin, we incorporated UV-VIS spectroscopy. The spectra were recorded using a model 
8452A Hewlett-Packard (Palo Alto, CA) spectrophotometer equipped with a temperature 
regulated cell held at 25°C. The formal concentration of the oxidized toxin was 100 
in all experiments. A blank was periodically recorded and automatically subtracted from 
each spectrum. The blank contained all the same components as the oxidized toxin 
sample except the toxin.
To find the pK& of the enolic proton on the oxidized quinoid form of our 
compounds, we first established appropriate conditions for each toxin under which the 
oxidized products were stable and, thus, could reproducibly be sampled. This was 
accomplished by following autoxidation of the toxin in an oxygen saturated 0.10 M 
phosphate buffer at various pH values using UV-VIS spectroscopy. In these initial 
experiments, we established both the pH at which a reasonably stable oxidation product 
could be generated and the time window or "sample period" in which it remained stable. 
The "sample period" was defined as the time period between completion o f autoxidation 
and appearance of any significant follow-up reactions. Appearance of a significant 
follow-up reaction was arbitrarily determined as 3% change in the absorbance for any 
of the UV-VIS peaks observed for the oxidized toxin. The pH at which the oxidized 
toxin was generated and the "sample period" for each toxin are shown in Table 6-1.
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Table 6-1. Generation and sample period for oxidized toxins.
Toxin Generation pH* Sample period** (min)
6,7-ADTQ 7.4 7-22
6,7-AMDTQ 8.4 3-10
6 ,8-ADTQ 5.4 14-17
6 -HDA 7.4 5-18
* pH at which autoxidation was performed.
** time period following initiation of autoxidation in which oxidized toxin was stable.
To determine the pKa, SO of the stock 10.0 mM toxin was added to ISO tiL of
0.010 M phosphate buffer at the appropriate pH, and oxidized with continuous oxygen 
saturation until the beginning of the "sample period". During the "sample period", 80 pL 
aliquots of the oxidized toxin solution were added to a quartz UV cell containing 1.920 
raL of 0.10 M phosphate buffer (deoxygenated with Ar) having various pH values. The 
spectrum for each such combination was recorded within S sec following toxin 
introduction into the cell. The pH values used for observation of the oxidized quinoid 
spectra were approximately 1.S, 2.4, 2.9, 3.4, 3.9, 4.4, 4.9, S.4, S.9, 6.4, 6.9, 7.4, 
7.9, 8.4, 9.4, and 10.
In order to ensure that the toxins remained in their reduced forms in the stock 
solutions for the duration of the experiment, stability controls were periodically 
examined. A stability control was prepared by adding 10 of a toxin stock solution to 
1990 iiL of 0.10 M phosphate buffer at pH 2.4. The pH value of 2.4 was selected since 
autoxidation of all the toxins is extremely slow at this pH; therefore, the form in which 
the toxin resided in the stock solution was subsequently directly observed in the 
corresponding UV-VIS spectrum.
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3. pKa C alculations
Dissociation constants for weak acids may be determined by monitoring the pH 
dependent UV-VIS absorbance changes of such species. Deprotonation of the enolic 
hydroxyl group of our oxidized toxins is, fortunately, accompanied by such absorbance 
changes. The theory associated with such determinations begins with a definition of the 
acid dissociation constant, Ka,
K, =  ^ equation 6-1
[Htox]
where [H+] is the proton concentration in mol/L, [tox*] is the concentration of the 
deprotonated oxidized toxin in mol/L, and [Htox] is the concentration of the protonated 
oxidized toxin in mol/L. This can then be rearranged to:
 ^ equation 6-2
By mass balance considerations, we define:
[tox'\i.^-[Htox]-^\tox~} equation 6-3
The absorbance of a sample at a particular wavelength is the sum of the absorbances of 
the protonated and deprotonated forms of the oxidized toxin. Defining AHtox to be the 
expected absorbance if the toxin was totally converted to its protonated form, and AgR- to 
be the expected absorbance if the toxin was totally converted to its deprotonated form, the 
obsoved absorbance Aj becomes:
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Substitution of equation 6-2 into the numerator of the first term and equation 6-3 into the 
denominator of both terms of equation 6-4 yields:
_  }— equation 6-5
^  i^Htox\+[tox-})K^ [Htox]Htox~] ^
Then, by substimting equation 6-2 into the denominator of equation 6-5 and rearranging, 
one obtains:
equatioD M
This final equation is fitted, using NLLSQ, to all the pH-absorbance data for a given 
oxidized toxin to yield the desired K& value.
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in. Results and Discussion
A. Ease of Oxidation
1. Formal Redox Potentials
The fonnal redox potential, E°', for each of the quinoline derivatives and the 
standard 6-HDA was determined as the average of the Epc and Epa, as described 
previously in Chapter 2. The results are presented in Table 6-2.
Table 6-2. Redox potentials for 6,7-ADTQ analogs and 6 -HDA.
Toxins Eoa(mV) EocCmV) AEn(mV) E°'(mV)
6,7-ADTQ -132 -161 29 -147
6,7-AMDTQ -166 -190 24 -178
6 ,8-ADTQ -178 -201 23 -189
6 -HDA -196 -225 29 -212
- 1(H M toxin, 23**C, working e*trode HDME, reference e'trode SCE, auxiliary e'trode 
Ft, scan rate 92.6 mV/sec, 0.10 M phosphate buffer at pH 7.4, solution degassed with 
Ar, solution under N% atmosphere throughout experiment
The theoretical spread between the peak potentials for a reversible 2 electron 
system should be 29 mV. All compounds, thus, displayed AE values which were 
reasonably close to that expected for a  reversible 2 electron redox system. The E°' for 
6 -HDA was -212 mV vs. SCE, which agrees well with reports from the literature.^^’25 
The formal redox potentials determined for the quinoline analogs were found to be more
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positive than that of 6 -HDA, but fell well within the range of such values displayed by 
various 6 -HDA analogs. For example, the E®' for 6-HDA is -212 mV vs. SCE, while 
that for a-methyl-6 -aminodopamine, a known toxic analog o f 6-HDA, is -123 mV vs. 
SCE.24 hiterestingly, while we expected 6,7-ADTQ and 6,7-AMDTQ to exhibit very 
similar E®' values, due to the structural similarities of their electroactive aromatic rings, 
their E®' values differed by 31 mV.
2. Thermodynamic Considerations
From a thermodynamic standpoint, the E®' values for the quinoline analogs and 
6-HDA can be combined with the E®’ value for molecular oxygen (O2 + 4H+ + 4e* — > 
2 H2O, E®'=0.753 V vs. NHE at 37®C, pH=7.4, and Po2=0 .2 1 ). Such combinations 
show that, thermodynamically, the ratio of the oxidized to the reduced toxin should vary 
from 1.5 X 1023 for 6-HDA to 1.2 x 1Q21 for 6,7-ADTQ. The P02  value used in these 
combinations was arbitrarily chosen to be the atmospheric pressure of oxygetL But, even 
by employing P02 values 100 times lower, the oxidized-to-reduced ratios only decrease 
by a factor of 10. Thus, at reasonable levels of oxygen, these agents are strongly driven 
thermodynamically to their oxidized forms. However, in vivo toxin-molecular oxygen 
redox reactions do not occur in a redox vacuum.
Redox reactions occurring in the brain are most likely controlled by redox couples 
existing in substantial concentrations in the neuronal milieu. Ignoring subcellular locally 
and timing aspects, this overall CNS redox regulation could quite conceivably be 
associated with the ascorbate half-reaction, due to the high average concentration of 3 mM 
of this species in the b r a i n .F u r t h e r m o r e ,  McCreery et aL^^^ have reported the 
existence o f an extraneuronal CNS ascorbate redox "buffer" with a value of 
approximately -0.200 V vs. SCE. Employing this "buffer" value, an alternative 
thermodynamic analysis predicts ratios of oxidized-to-reduced toxin which fall between 
2.5 for 6-HDA and 0.02 for 6,7-ADTQ, with ratios of 0.2 for 6,7-AMDTQ and 0.4 for
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6,8-ADTQ. Using this approach, the ratios are much smaller than those found using the 
oxygen half-reaction. However, the agents are still thermodynamically driven, at least to 
some degree, to their oxidized forms. For comparative purposes, we applied the same 
CNS redox buffer approach to endogenous catecholamines. This yielded ratios which 
were 10^ to times smaller than those found for the neurotoxic agents. Therefore, 
from a thermodynamic standpoint, it appears that the quinoline agents would be 
considerably oxidized in the brain, whereas endogenous transmitters would no t
B. Determination of the pK& Values of Oxidized Toxin
1. 6,7-ADTQ
The pH dependent spectral changes seen with oxidized 6,7-ADTQ 
(ox-6,7-ADTQ) are shown in Figure 6-2. At pH 1.5 there is a band at 286 run. As the 
pH increases, this band rapidly decreases and a new band appears and grows at 298 nm. 
At pH values above 6.4, this new band shifts to a shorter wavelength (Xmax = 294 run), 
and is accompanœd by a significant increase in absorbance. The band initially at 222 nm 
increases rapidly between pH 1.4 and 2.9 and again between pH 6 and 7.4. The band at 
518 run, barely visible at low pH, also rapid increases in absorption between pH 6 and
7.4. The rapid increase in absorbance of the 222 nm band between pH 1.4 and 2.9 may 
be a result of the deprotonation of the imine functionali^. But, since this phenomenon 
was not physiologically relevant, we did not pursue it beyond this simple observation. 
The changes observed between pH 6 and 7.4 are due to the dissociation of the enolic 
proton of interest Using the data from 518 nm, as shown in Figure 6-3, we found the 
pKa of ox-6,7-ADTQ to be 6.61 ± 0.17. Analysis of the absorbance data from 222 run 
and 294 run, while providing less precision for the pK» value, agreed with this result
160
For the pH measurements described above, the toxin was preoxidized a t pH 7.4 and 
25°C, and sampled between 7-22 minutes.
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Figure 6-2. UV-VIS spectra of ox-6,7-ADTQ at various pH values.
The pH values are written on the individual traces. The pH dependence of individual
peaks are described in the text
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Figure 6-3. pK& detennination for ox-6,7-ADTQ.
Absorbance data at 518 nm was used and the toxin concentration was 100 ^iM.
2. 6,7-AMDTQ
The observed spectral changes with pH for the oxidized form of 6,7-AMDTQ 
(OX-6.7-AMDTQ) are shown in Figure 6-4. As can be seen in this figure, significant 
absorption changes occur at 218,244, 300, 344, and 518 nm. Between pH 1.5 and 3, 
there is an absorbance increase in the bands at 518 nm and 218 nm. At these 
wavelengths, absorbance begins to decrease at pH values above 6.4. The band at 344 nm 
is non-existent below pH 5.4, but its absorbance begins to increase rapidly at pH values 
above thaL This increase is paralleled by an increase at 244 nm and a decrease at 300 nm. 
The absorption band at 344 nm, however, is the tmly band that is absent at low pH values 
and appears as pH increases. Additionally, no other wavelength yielded as large an 
absorption change without interference from other parts of the spectrum.
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Figure 6-4. UV-VIS spectra of ox-6,7-AMDTQ at various pH values.
The pH values are written on the individual traces. The pH dependence of individual
peaks are described in the text.
Therefore, the absorbance changes at 344 nm were used to determine the enolic pKg of 
ox-6,7-AMDTQ. As shown in Figure 6-5, the pK& determined for ox-6,7-AMDTQ was 
I S l  ± 0.03. The absorbance changes observed between pH 1.5 and 3 may be attributed 
to the deprotonation of the protonated imine group. But, since this change is not relevant 
at physiological pH values, this was not further investigated. For the above pH 
dependent measurements, the toxin was preoxidized at pH 8.4 and 25°C, and sampled 
between 3-10 minutes.
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Figure 6-5. pKa determination for ox-6,7-AMDTQ. 
Absorbance data at 344 nm was used and the toxin concentration was 100 pM.
3. 6 ^A D T Q
The pKa determination for the enolic component of ox-6,8-ADTQ was difiBcult in 
that there was a very small time window between completion of autoxidation and 
subsequent polymerization in which to sample the oxidized toxin. Thus, for each pH 
measurement, a new batch of toxin was oxidized at pH 5.4 and 25°C, and sampled 
between 14-17 minutes. Furthermore, spectral changes with pH were minimal. The 
absorption band which yielded the best results was 460 nm. This band displayed an 
increase between pH 3 and 6, which is shown in Figure 6-6. The dissociation of the 
enolic proton most likely corresponds to this increase and was found to have a pK* value 
of 4.32 ±0.09.
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Figure 0-6. pK& detennination for ox-6,8-ADTQ.
Absorbance data at 460 nm was used and the toxin concentration was 100 pM.
At pH values higher than pH 8.4, the absorbance at 460 nm begins to decrease. This is 
believed to correlate with deprotonation of the protonated aliphatic amine. Absorption 
changes are generally not observed for deprotonation of the primary amine in these type 
of compounds, especially one so far removed from a conjugated system. However, a 
fitted pKa value o f 9.33 ±  0.32 was found, which is quite reasonable for such a process. 
Another plausible explanation is that the decreases observed at 460 nm are a result of a 
rapid follow-up reaction(s) at high pH. In preliminary studies determining the 
appropriate sample period for ox-6,8-ADTQ, we found these follow-up reactions 
substantially increased in rate with increasing pR
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4. 6-HDA
Spectra o f the oxidized fonn of 6-HDA (ox-6-HDA or 6-HDAQ) at various pH 
values are shown in Hguie 6-7. At pH 1.5, this species displayed bands at 206, 264, 
and 382 nm. With increasing pH, the band at 206 nm increased in absorption and shifted 
to longer wavelengths with a final absorption maxima at 212 nm. The band at 264 nm 
simultaneously decreased in absorbance and also shifted to longer wavelengths (268 nm), 
resulting in isobestic points at 243 nm and 276 nm. The band at 382 nm decreased 
rapidly and a new band appeared a t 486 nm, which grew with increasing pH. 
Additionally, an isobestic point was found to exist between these two bands at 404 nm.
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Figure 6-7. UV-VIS spectra o f ox-6-HDA at various pH values.
The pH values are written on the individual traces. The pH dependence of individual
peaks are described in the text
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For the above discussed pH measurements, the toxin was preoxidized at pH 7.4 and 
2S°C, and sampled between 5-18 minutes.
In studies using 6-HDA, the absorbance at 486 nm is commonly monitored as an 
indicator of the oxidized form of this toxin.34,38,164 The pH dependent increase in 
absorbance at 486 run for ox-6-HDA is due to deprotonation o f the enolic hydroxyl 
group, whereby creating a much more electron-rich conjugated system. As shown in 
Hgure 6-8, the pKa for ox-6-HDA was determined to be 3.87 ±  0.04. This value agrees 
well with those previously reported.25,165
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Figure 6-8. pK& determination for ox-6-HDA.
Absorbance data at 486 nm was used and the toxin concentration was 100 pM.
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IV. Conclusions
It is apparent firom the redox studies that our toxins have the thermodynamic 
capabili^ to readily undergo oxidation in the CNS. We believe this oxidation to be a 
prerequisite for the observed neuronal damage and/or degeneration elicited by these 
agents. Furthermore, the unique pK& values of the enolic group of the oxidized toxins 
provide oxidation pathways, at physiological pH, which likely involve one more proton 
than the number of electrons.
The thermodynamic findings in this chapter suggest a few reasonable possibilities 
which could result in neurodegeneration. These include, but are not limited to: (1) the 
ease of toxin oxidation, which implicates a possible decreases in the intraneuronal supply 
of oxygen, a possible decrease in antioxidant defense system capabilities, and a possible 
production of reactive quinoid species; (2) the capabili^ to reduce molecular oxygen, 
producing damaging reactive oxygen species; and (3) neuronal acidosis induced by 
unbalanced proton donation and acceptance during oxidation of the toxins by oxygen, 
resulting from the inherently low pK& values of the enolic groups on the oxidized agents.
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Mode of Action III: Autoxidation
& Reactive Oxygen Species
Chapter 7
I. Introduction
The neurodegenerative effects imparted by 6-HDA and associated compounds are 
believed to be related to their ability to undergo rapid autoxidation. Le., spontaneous non- 
enzymatic oxidation by molecular oxygen. Autoxidation of such compounds results in 
the production o f quinones or quinoneimines and reduced oxygen species % 0 2 , *02% 
and O H ). These two groups of autoxidation products represent two primary schools of 
thought which directly relate autoxidatirm to neurotoxicity.
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The quinone or quinoneimine product(s) formed by autoxidation are very 
susceptible towards nucleophilic attack by sulfhydryl functionalities which exist in 
abundance in the neuronal milieu. Entities which contain sulfhydryl groups include 
essential proteins and em^mes, and molecules that contribute to antioxidant defense 
systems such as glutathione (GSH). Through binding of the electrophilic oxidized 
quinoid species to these thiols, crucial neuronal functionality may be compromised.
6-HDA and related compounds have been shown to react with sulfhydryl containing 
proteins and enzymes.27,50-55 the process of reacting with the nucleophile, the toxin 
is reduced to the hydroquinone form. Once reduced, the adduct can, again, undergo 
autoxidation. The oxidized adduct is also electrophilic and can further react with other 
nucleophiles, resulting in cross-linking of proteins and/or enzymes^^*^^ to render them 
inactive. In addition, the oxidized forms of the toxins and/or adducts may be reduced 
directly by antioxidants like ascorbate. The newly reduced species are, of course, again 
susceptible to autoxidation. Multiple such oxidations by O2 and reductions by 
antioxidants is commonly known as redox cycling. The ultimate outcome of redox 
cycling is the depletion of both intraneuronal oxygen and antioxidants. Thus, redox 
cycling is a viable mechanism for neurodegeneration in its own right
It is well known that the generation of hydrogen peroxide, H2O2 . superoxide 
radical, *02", and the hydroxyl radical, O H , can result in cellular damage and/or 
destruction.39-42,49,56,166,167 Xot surprisingly, it has been shown that H2O2 . 0 2  , 
and O H  are formed during the autoxidation of 6-HDA and related analogs.33-38,43,164 
H 2 O 2 and 0 2 ", in contrast to common beliefs, are not highly reactive agents. 
Additionally, neurons contain defense systems to combat such species, including the 
enzymes glutathione peroxidase and catalase for H2O2  and superoxide dismutase for 
•02".^^^ However, the brain contains metal ions in various chelated forms, and these 
metal ions, particularly iron, in the presence of H2O2 and O 2 lead to the production of 
hydroxyl radicals. These hydroxyl radicals, created through metal-catalyzed Fenton
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and/or Haber-Weiss pathways,^»^5,48,169,170 aig highly reactive and, thus, highly 
pertinent to the neurodegenerative process of many neurotoxins.
Our dihydroxytetrahydroquinoline compounds are structurally similar to 6-HDA 
and are hypothesized to act in a manner similar to 6-HDA. Therefore, a logical and 
important step in elucidating the mechanism(s) by which our compounds produce 
neurodegeneration was to investigate the inherent rates o f autoxidation o f these 
compounds under physiological conditions. Additionally, we wanted to determine the 
distribution of reactive oxygen species produced by the autoxidation process.
n . Background on Methods
The rate of autoxidation can be conveniently determined using either an oxygen 
electrode system or UV-visible (UV-VIS) spectroscopy. Using an oxygen electrode, 
toxin autoxidation is followed indirectly through the consumption of oxygen. Using 
UV-VIS spectroscopy, formation of the oxidized toxin can be followed directly. 
Additionally, reactions following the initial oxidation, but not necessarily involving 
oxygen consumption, may also be monitored by UV-VIS. However, spectra o f follow- 
up products may obscure those of the initial oxidation products by which the process of 
autoxidation is being monitored.
Using UV-VIS spectroscopy, the apparent rate constant for autoxidation for a first 
order reaction, e.g., can be determined by monitoring the absorbance at a wavelength 
characteristic of the oxidized fixm of a toxin using:
ln |4_-^ | = -tr+ ln |A _-^ | equation 7-1
1 7 1
where A» is the absorbance at the completion of the reaction, Ao is the absorbance at the 
beginning of the reaction, and A{ is the absorbance at any time t during the reaction. By 
rearranging equation 7-1, we obtain:
equation 7-2
By fitting the absorbance data, at a specific wavelength, to equation 7-2 using NLLSQ, 
the apparent rate constant can be determined.
When employing an oxygen electrode, the initial autoxidation rate can be 
determined from the slope of the linear portion of the oxygen trace following introduction 
of toxin to the reaction cell A representative oxygen trace is shown in Figure 7-1.
Toxin
O2
Catalase
lime
Figure 7-1. Typical autoxidation oxygen trace.
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The effects of various metal ions, chelating agents, reactive oxygen species, and enzymes 
on the autoxidation reaction can be determined in the same fashion by administering the 
desired reactant prior to toxin introduction.
The H2O2 and O 2* which result from toxin autoxidation can also be determined 
utilizing the oxygen electrode. This is accomplished by introducing an appropriate 
enzyme following completion of autoxidation. To determine the production of H2O2 
finom autoxidation, catalase was used. Catalase breaks down H2O2 as:
cat
H2O2   H2O + 1/2 O2
The resulting oxygen liberated by catalase is, thus, equal to one-half of the oxygen 
consumed during autoxidation which led to the production of H2O2
The production of superoxide can be determined in a sim ilar way, using 
superoxide dismutase (SOD). SOD promotes dismutation of superoxide, "O2", as:
SOD *
2 O2 " ---------- ► H2O2 + O2
where O2* is singlet oxygen. Quantitation of O 2 using this method, however, is not 
quantitatively reliable since 02*  also spontaneously dismutates. Therefore, SOD 
provides O 2'  values which are necessarily less than actual values. Nonetheless, this was 
considered a qualitatively useful tooL
Reaction orders and rate constants, as expressed in equation 7-3, can also be 
determined using an oxygen electrode system. The rate of autoxidation can be expressed 
as:
rate = kttoxJ'COjJ’^ CH^f equation 7-3
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By determining the rate of autoxidation while varying the toxin concentration and holding 
the oxygen concentration and pH constant, we can rewrite equation 7-3 as:
rate = ki-Ctox]* equation 7-4
Taking the log of both sides of equation 7-4 yields:
log(rate) = x log[tox]+ log(kx) equation 7-5
Then, plotting the log(autoxidation rate) vs. log[toxin] yields the reaction order with 
respect to the toxin as the slope and the combined rate constant, kp, as the y-intercept A 
similar approach is used to determine the reaction orders and combined rate constants for 
oxygen and H+.
The rate constant, as defined in equation 7-3, can be extracted from the above 
determined reaction orders and combined rate constants as follows:
rate = k^Ctox]*
kT=k[OJ'[HT
log(ki.) -  log(k)+ y logtO}]+ z log[H*] equation 7-6
rearranging equation 7-6, we arrive at the solution fork:
log(k)= lcg(kT) -  y logCO;] -  z log[H*] equation 7-7
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where log O^t) is the Y-intercept o f the log(rate) vs. iogftoxin] plot, y is the slope of the 
log(rate) vs. log[0 2 ] plot, z is the slope of the log(rate) vs. log[H+] plot, and [O2] and 
[H+] are the concentrations used in the original toxin related experiments. This approach 
can also be carried out using the determined koz and kH+ combined rate constants, and 
would result in the same k value.
m . Experimental
A. Chemicals and Solutions
1. Chemicals
Chemicals listed below were purchased through Sigma Chemical Company (S t 
Louis, Mo.) in  high purity and used without any further purification. All other chemicals 
are the same as in previous chapters.
ferrous chloride tetrahydrate (FeCl2*4H2Q) 
cupric chloride tetrahydrate (CuQ2*4H2 0 ) 
diethylenetriaminepentaacetic acid (DTPA) 
catalase, 2000  units/mg 
superoxide dismutase (SOD), 4X300 units/mg 
hydrogen peroxide, 30% (w/v)
All aqueous solutions employed 18 MO distilled/deionized water which was 
prepared by passing distilled water through a Milli-Q Reagent Water System (Millipore, 
Continental W ater Systems, El Paso, TX).
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2. A utoxidation Buffer
The pH buffers were generally created by adding 0.10 M KH2PO4  to 0.10 M 
K2HPO4  until the desired pH was obtained. For lower pH values, HCl was added to 
0.10 M KH2PO4 , while for higher pH values, NaOH was added to 0.10 M K2HPO4 . 
The 0.10 M KH2PO4  and 0.10 M K2HPO4  were prepared as separate solutions by 
dissolving 13.61 g KH2P0 4 «H2 0  and 17.42 g K2HPO4, respectively, in 1.0 L of water.
3. Toxin Solution
Stock toxin solutions were made by dissolving the desired amount o f toxin in an 
appropriate amount of degassed 10~^  M HCl to yield a stock concentration of 10 mM for 
the oxygen electrode studies and 12.5 mM for the spectroscopic studies. Typically, 1.5 
to 2 mL of toxin solution were needed. The stock toxin solution was stable in excess of 8 
hr.
4. Fe^+ Stock Solution
The Fe^+ stock solution was prepared by dissolving 80.96 mg ferrous chloride 
tetrahydrate (FeCl2*4H2 0 ) in 100 mL degassed water to yield a stock concentration of 
4.072 mM. This was made 10 min prior to utilization. The stock was diluted 1:10 with 
water to obtain a 0.4072 mM Fe^* secondary stock solution. These solutions were used 
for no more than 2 0  min following their preparation.
5. Cu^+ Stock Solution
The Cu2+ stock solution was prepared by dissolving 34.71 mg cupric chloride 
tetrahydrate (CuCl2*4H2 0 ) in 100 mL degassed water to yield a stock concentration of
0.40 mM. The stock was diluted 1:10 with water to obtain the 0.04072 mM Cu2+ 
secondary stock solution. These solutions were used for no more than 20 min following 
their preparation.
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6 . Fe^+/EDTA Complex Solution
The Fe*/EDTA solution was prepared 10 min prior to utilization and was used for 
no more than 20 min following its preparation. Component additions and solution 
adjustments were performed sequentially as shown in Table 7-1.
Table 7-1. Fe^+/EDTA solution preparation.
Compoimd Amount
Na2EDTA*2H2 0 75.79 mg
add 90 mL water and make basic with KOH to dissolve EDTA
adiust to pH 7.4
FeO^MHiO 80.96 mg
dilute to final volume of 1(X) mL
7. C atalase Solution
The catalase stock solution was prepared by dissolving 4.072 mg catalase (2000 
units/mg) in 1.0 mL water. This solution was prepared and stored at -20°C until use. 
Each sample was thawed once and frozen samples were discarded after 2 months.
8 . Superoxide Dism utase Solution
The superoxide dismutase stock solution was prepared by dissolving 1.018 mg 
SOD (4000 units/mg) in 1.0 mL water. This solution was prepared and stored as 
individual 5(X) pL aliquots at -20°C until use for up to 2 months. Each aliquot was 
thawed once, used, and the remainder discarded.
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9. Diethylenetriaminepentacetic Add (DTPA) Solution
The DTPA stock solution was prepared by dissolving 16 mg DTPA in 1.0 mL 
water to yield a  final stock concentration of 41 mM. This solution was prepared 30 min 
prior to utilization, used for no more than 8 h, and then discarded.
10. Hydrogen Peroxide Solution
Stock solution was prepared by diluting 1 mL o f 30% H2O2 to 500 mL with 
water. This solution was prepared 10 min prior to utilization and used for no longer than 
30 min following its preparatioiL
B. Autoxidation, Oxygen Electrode
1. Oxygen Electrode
A model 58 YSI dissolved oxygen meter outfitted with a model 5739 YSI 
dissolved oxygen probe (Yellow Springs Instrument Co., Yellow Springs, OH) was 
used to monitor changes in dissolved oxygen concentrations. The probe was equipped 
with a fiesh membrane (0.001" standard YSI oxygen electrode membrane) and calibrated 
at least daily using an atmospheric calibration procedure. The reaction cell used for all 
experiments was a temperature regulated, water jacketed cell that fit tightly over the end of 
the O2 probe. The volume of the cell, once in place, was 2.036 mL. All oxygen 
electrode reactions were conducted at 37°C
2. Kinetic Measurements, Toxin Concentration Effects
To investigate the effect of toxin concentration on the initial rate of autoxidation, 
various volumes (25,50,75, and 1(X) pM) of 10 mM stock toxin solution were injected 
into the 2.036 mL oxygen electrode incubation cell filled with air saturated incubation
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buffer. For these investigations, the initial oxygen concentration was held constant at 7.5 
to 8.0 mg/L, the pH was fixed at 7.40, and no metal ions or complexing agents were 
added.
3. Kinetic Measurements, Oxygen Concentration Effects
The effect of oj^gen concentration on the initial autoxidation rate was investigated 
by varying the initial oxygen concentration while keeping the pH and initial toxin 
concentration constant The initial oxygen levels employed were approximately 5 ,8,10, 
and 15 mg/L. These oxygen levels were obtained by bubbling the incubation buffer with 
either oxygen or nitrogen gas for varying periods of time. For these studies, the initial 
toxin concentration was held constant at 196 ^M, the pH was 7.40, and no metal ions or 
complexing agents were added.
4. Kinetic Measurements, pH Effects
The effects of pH on initial rate of oxidation was investigated by holding the initial 
oxygen and toxin concentration constant and varying the pH. pH values of 5.40,6.40, 
7.40, and 8.40 for the incubation buffer were used. These pH values were created by 
mixing 0.10 M KH2PO4 and 0.10 M K2HPO4  incubation buffers to the desired pH. The 
initial toxin concentration was 196 pM, the initial oxygen concentration was 1 3  to 8.0 
mg/L, and no added metal ions or complexing agents were added.
5. Toxin Autoxidation in Absence and Presence of Metal ions, 
Complexing Agents, & Enzymes
Investigating the effects of various metal ions, complexing agents, and enzymes 
on the initial rate o f toxin autoxidation, the toxin concentration was kept constant at 196 
|xM (40 pL stock), the buffer was air saturated to obtain constant oxygen levels a t ca. 250 
pM  oxygen (7.5-8.0 mg oxygen/L), and the pH was fixed at 7.40. Catalase and
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superoxide dismutase injections were performed, separately, upon completion of toxin 
oxidation, i.e., after oxygen consumption had reached a plateau, to investigate the 
production o f H2O2 and O 2 , receptively. For each given condition, the same 
experiment was generally run four times; three of these four were followed by a 50 pL 
injection of stock catalase solution yielding a 200 units/mL incubation concentration, and 
one was followed by a 50 pL injection of stock SOD solution yielding an incubation 
concentration of 100 units/mL. The incubation cell was rinsed and drained three times 
with fiesh buffer between each experiment to avoid contamination.
In all experiments investigating the rates o f oxidation, the toxin was the last 
component to be added. For an individual toxin autoxidation experiment, the toxin was 
first examined without any metal ion or complexing agent present. To investigate the 
effects of metal ions on autoxidation, the following experiments were used. A SO pL 
aliquot of the 4.072 mM stock Fe^+ solution was injected into the incubation cell, 
resulting in an incubation concentration of 100 pM Fe^+, followed by the addition of 
toxin. Using the 0.4072 mM stock Fe^+ solution, which yielded an incubation 
concentration of 10 pM Fe^+, the previous experiment was repeated. The same 
experiment was conducted using (1) 50 pL of 4.072 mM stock Fe^+ZEDTA solution, 
yielding a 100 pM  incubation concentration, (2) 0.4072 mM Cu^+ stock solution, giving 
a 10.0 pM incubation concentration, and (3) 0.041 mM Cu2+ stock solution, yielding a 
1.00 pM incubation concentration.
In an effort to observe autoxidation in the absence of any trace metal ions, we 
incorporated DTPA into the incubation cell mixture. A 50 pL aliquot o f40.72 mM stock 
DTPA was added to the reaction cell, yielding a 1.0 mM incubation concentration, and 
allowed a one minute incubation prior to toxin introduction.
hr order to investigate the effects of reactive oxygen species and enzyme 
interactions with toxin autoxidation, 31 pL of 17.65 mM stock hydrogen peroxide 
solution was added to the incubation cell prior to the toxin, giving a 268.7 pM H2O2
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incubation concentration. The same experiment was conducted, separately, using SO 
of stock catalase, yielding a 200 units/mL incubation concentration, and 50 [iL o f stock 
SOD, yielding a 100 units/mL incubation concentration.
C. Autoxidation, Spectrophotometry
The UV-VIS spectra were recorded using a model 8452A Hewlett-Packard (Palo 
Alto, CA) spectrophotometer equipped with a temperature regulated cell held at 37**C 
unless otherwise noted. The formal concentration of the toxin was 196 in all 
experiments. The buffer used was an oxygen saturated 0.10 M phosphate buffer at pH 
7.4 unless otherwise noted. A blank was periodically recorded and automatically 
subtracted firom each spectrum. The blank contained all solution components except the 
toxin.
A 2460 aliquot of buffer was added to a quartz cell and placed in the 
temperature regulated cell holder for 15 min to equilibrate. After temperature 
equilibration, the solution was bubbled with oxygen for 2 min. A 40 aliquot o f 12 J  
mM stock toxin solution was administered to the cell, the cell was shaken vigorously for 
2  sec, the cell was placed back in the holder, and spectra were recorded as rapidly as 
possible. The reaction solution was reoxygenated for 30 sec at 3 to 5 min after the 
beginning o f the experiment in order to ensure maintenance of pseudo first order 
conditions.
Following the initial toxin autoxidation study, we investigated the effects of SOD, 
catalase, and H2O2  on autoxidation rates. First, we collected a  spectrum of the solution 
with the enzyme alone to examine the possible existence of conflicting absorption bands. 
We found no conflicting bands with SOD or catalase. Following this, we obtained 
spectra in the same manner as above from a solution consisting o f 2410 pL buffer, 50
1 8 1
stock SOD, catalase, or H2O2, and 40 pL stock toxin. E%al concentrations were; SOD 
100 units/mL, catalase 200 units/mL, and 268.7 H2O2 Buffer equilibration and 
oxygenation was as described immediately above.
bi order to ensure that the toxins remained in their reduced forms in the stock 
solutions for the duration of the experiment, stability controls were periodically 
examined. A stabili^ control was prepared by adding 10 pL of a toxin stock solution to 
2490 of 0.10 M phosphate buffer at pH 2.4. The pH value of 2.4 was selected since 
autoxidation of all the toxins is extremely slow at this pH, and, therefore, the form in 
which the toxin resided in the stock solution was subsequently directly observed in the 
corresponding UV-VIS spectrum.
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IV. Results:
Autoxidation and Reactive Oxygen Species
In the following studies, toxin autoxidation occurred so rapidly at 37°C that 
UV-VIS spectroscopy was not as useful in the determination of initial rates as was the 
oxygen electrode system. While monitoring autoxidation with an oxygen electrode is an 
indirect method, we were able to observe this reaction shortly after initiation, which we 
were unable to accomplish using UV-VIS. However, where possible, the oxygen 
electrode determined rates and rate changes were verified, to the best of our abilities, with 
the limited UV-VIS data.
A. 6,7-ADTQ
H
6,7-ADTQ, when put in an air saturated phosphate buffer at pH 7.4, rapidly 
formed a pinkish-purple colored solutiom The UV-VIS spectrum of reduced 6,7-ADTQ 
initially shows a band at XmaT = 305 nm. At pH 7.4, 6,7-ADTQ autoxidation occurred 
too rapidly at both 37°C and 2S°C to obtain a full sequence of spectra throughout the 
process. Thus, the autoxidation shown in Figure 7-2 was performed at the lower pH of
5.4. However, the spectra obtained at pH 5.4, notably, display the same band increases 
and decreases as do those at pH 7.4, just at a slower rate. During 6,7-ADTQ 
autoxidation at pH 7.4 there was an initial increase in absorption in the band at 305 nm.
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This band shifted to shorter wavelengths and grew throughout autoxidation with a final 
band maxima at 294 nm. This increase corresponded to the appearance of new bands at 
222 nm and 518 nm, which also grew throughout the autoxidation reaction. The 
spectrum of 6,7-ADTQ quinoneimine shows prominent bands at Xmax -  222, 294, and 
518 nm. After the completion of autoxidation, these bands began to decrease in intensity, 
although slowly in comparison to their previous growth during autoxidation, and the 
overall baseline began to slowly increase. This general baseline increase in absorption 
throughout the spectrum corresponded to the appearance of a deep purple color and, with 
time, the formation o f dark precipitates in the solution, presumably indicating 
polymerization. The same spectral changes occurred at both higher and lower pH values. 
But, the rate was much faster at higher pH values and much slower at lower pH values. 
Interestingly, autoxidation was even observed at pH 2.4, with an increase in absorption at 
518 nm and 294 nm, although the rate was approximately 60 times slower than that at pH
7.4. Again, this autoxidation was followed by decreases in band maxima and a general 
baseline increase.
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Figure 7 '3 . UV-VIS spectra o f 6,7-ADTQ autoxidation at pH 5.4 and 25®C.
Since the UV spectroscopy employed was not adequate to monitor the initial 
stages of the autoxidation process at 37*^, we primarily relied upon the oxygen electrode 
system. Using the oxygen electrode, we initially determined the autoxidation reaction 
orders with respect to toxin, 0%, and H+. To determine toxin reaction order, the initial 
oxygen concentration was held constant at 248 pM  and the pH at 7.4. The toxin 
concentrations used were 98,147,196, and 245 |iM. Autoxidation appeared to be first 
order with respect to toxin, as graphically shown in Figure 7-3. To determine the oxygen 
reaction order, the pH was fixed at 7.4, the initial toxin concentration was fixed at 196 
^M, and the 02  concentration was varied between 165 and 370 ^M. The reaction order 
for oxygen was found to be approximately 3/4, as seen in Figure 7-4. The H+ reaction 
order was determined with the initial O2 concentration fixed at 248 pM, the toxin
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concentration fixed at 196 and using pH values of 5.4, 6.4, 7.4, and 8.4. The 
reaction order was found to be approximately -1/2, as seen in Figure 7-5. The overall 
rate constant extracted from the data in Figures 7-3 to 7-5 was k = 0.0010 ±  0.0005 
Nf-l/4sec-l, and the rate expression was:
rate = k[toxI02r"[H^]
These results are sununarized in Table 7-2.
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Figure 7^ 3. Toxin concentration effects on 6,7-ADTQ autoxidation.
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Figure 7-4. Oxygen concentration effects on 6,7-ADTQ autoxidation.
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Figure 7-5. The effects of pH on 6,7-ADTQ autoxidation rate.
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Table 7-2. 6,7-ADTQ autoxidation reaction orders with respect to individual
components.
X
y
z
k
6,7-ADTQ Reaction Orders
rale = k[toxr[0,y[Hn'
0.95 ±0.06 
0.86 ±0.08 
-0.47 ±0.02  
0.0010 ±  0.0005 M-0-34sec-l
Autoxidation rates o f 6,7-ADTQ in the presence of various stimulating and/or 
inhibiting agents are shown in Table 7-3. Furthermore, the percent oxygen consumed 
during autoxidation leading to the production of H2O2 and *02" is presented in Table 7-4. 
The average initial oxygen concentration prior to autoxidation was 8 mg/L or 250 ^ M, the 
pH was 7.4, the temperature was 37*C, and the toxin concentration was 196 |iM .
Autoxidation of ca. 200 ^iM 6,7-ADTQ in the absence of any added substances 
was completed in less than 40 seconds and showed an initial oj^gen consumption rate of 
484 pmol 02/L«mirL The kapp determined from preliminary UV-VIS spectroscopy for 
autoxidation of 200 ^iM 6,7-ADTQ was ±  0.7 min*  ^(100 ±  6%, X=294 nm).
Upon addition of catalase following the completion of autoxidation, 41% of the oxygen 
consumed was returned to the solution. Therefore, a minimum of 82% of the oxygen 
consumed went to form H2O2. However, due to the possible participation o f H2O2 in 
toxin oxidation, the ability o f H2O2 to participate in Fenton and Haber-Weiss 
reactions,^*^^*^*^^^ and the modest irmate instabili^ of H2O2 in aqueous solutions, it 
is likely that more H2O2 was ultimately produced. Thus, the m ajori^ of the oxygen 
consumed during ADTQ autoxidatimi was converted to H2O2
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Table 7-3. 6,7-ADTQ autoxidation, initial rate of oxygen consumption.
Added Component(s)
Initial ( h  Consumption
N rate±SEM
(pm olO z/Ltnin)
rate±SEM  
% controls
none 4 484± 1 100 ± 0 .2
Fe2+ 1 .0xl0-*M 4 628 ± 2 130 ±0.3***
Fe2+ 1.0 X 10-5 M 4 551 ±0.6 114 ±0.1***
Cu2+ 1.0 X 10-5 M 4 1133 ±12 234 ±2***
Cu2+ l.OxlO-^M 4 534 ±0.3 110 ±0.1***
Fe2+/EDTA 1.0 x Iff* M 4 592 ± 2 122 ±0.3***
DTPA 1.0 X 10-3 M 4 408 ±18 84 ±3**
H202 2.5 X Iff* M 3 445± 8 92 ±1**
catalase 200units/mL 2 325 ± 7 67 ±1
SOD lOOunits/mL 2 577 ± 1 119 ±0.2***
Significant difierences compared to control values (t test): **P < 0.01, ***P < 0.001.
There are numerous reports showing that transition metal ions stimulate 
autoxidation of catechol-type compounds. 171-173 Hence, it was of interest to determine 
the effects that transition metal ions exert, if  any, on the autoxidation of 6,7-ADTQ. We 
first tested Fe+2 at two concentrations with a toxin concentration of 200 pM. The Fe+2 
was prepared for each experiment 10 min prior to use. There was no noticeable oxygen 
consumption due to Fe+^ alone. A reaction solution containing 10“^  M Fe+2 stimulated
6,7-ADTQ autoxidation significantly to 130% of controls. At 10*^  M Fe+^, autoxidation 
was stimulated, yet not to the degree seen at 10-* M Fe+Z Interestingly, upon addition of
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catalase following this reaction, the oxygen liberated decreased with increasing 
concentrations ofFe+^. The percent oxygen consumed during autoxidation attributable to 
the H2O2 formation was 59% for 10*5 pe+2 and 53% for 10*^  M Fe+2
Table 7-4. 6,7-ADTQ autoxidation, H2O2 and O 2' produced.
Added
Componentfs)
Percent O2 Consumed 
which was Liberated Upon 
Addition of:
Percent O2 
Consumed by 
Pathway Leading to:
Catalase SOD H2O2 •O2-
N % 02±SEM N %Q2 % 02±SE M % 02
none 3 40.8 ± 0.7 I 1 8 2± 1 2
F e + 2  1.0 X 1(HM 3 2 6± 1 1 2 53 ± 2 3
Fe+2 1.0 X 10-5 M 3 3 0± 3 1 1 5 9 ± 6 2
Cu+2 1.0 X 10-5 M 3 35.6 ±0.8 1 0 7 1 ± 2 0
Cu+2 1.0xl0-<SM 3 3 8 ± 2 1 2 77 ± 3 3
Fe+2/EDTAl.OxlO^M 3 2.0 ± 0 .4 1 0 3.9 ± 0.8 0
DTPA 1.0 X 10-3 M 3 4 0 ± 4 1 0 8 0 ± 7 0
We also conducted similar studies with Cu+2. At 10*5 M Cu+^, 6,7-ADTQ 
autoxidation was dramatically stimulated to 1133 pmol 0 2 /Lnnin, or 234% of controls. 
The m ajori^ of 6,7-ADTQ autoxidation under these conditions was complete in less than 
10 seconds. At 10^ M Cu+^, however, the rate was only slightly stimulated to 110% of 
controls. Upon addition of catalase, the oxygen liberated decreased with increasing 
concentrations o f Cu+^, but not to the extent seen with Fe+^. The percent of oxygen
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consumed during autoxidation which remained as H2O2 was 71% and 77% for 10~  ^M 
and 10^ M Cu+2, respectively.
While Fe+2 alone increases the autoxidation rate o f catecholamines and 6-HDA 
related toxins, Fe+2 complexed with EDTA has been reported to stimulate autoxidation to 
an even greater.36,38,165,173 Thus, we investigated 6,7-ADTQ autoxidation in the 
presence of 1(H M Fe+2/EDTA. Fe+2/EDTA was prepared 10 min prior to use, and no 
noticeable oxygen consumption was observed with Fe+2/EDTA alone. Fe+2/EDTA 
stim ulated the 6,7-ADTQ autoxidation rate to 122% of controls, which was 
approximately equal to that seen at 10~^  M Fe+2. Therefore, Fe+2/EDTA did not appear 
to have any different effect on autoxidation than did Fe+2 alone. However, upon addition 
of catalase following autoxidation, surprisingly little oxygen was liberated. The oxygen 
returned to the solution was only 2% of the oxygen consumed. And, there was no 
detectable •O2'.
It has been suggested that 6-HDA related compounds cannot reduce molecular 
oxygen directly, but require a co-reductant such as a transition metal ion.^^2 
Additionally, it has been shown that, by effectively chelating all available metal ions, the 
rate o f autoxidation of 6-HDA analogs is dramatically inhibited,38,173 god their 
neurotoxic capabilities are retarded.174 Thus, we investigated this hypothesis by 
incorporating diethylenetriaminepentacetic acid (DTPA). At 10*3 M, DTPA did, indeed, 
inhibit the autoxidation rate of 200 pM 6,7-ADTQ, but only slightly. The resultant rate 
was 84% of controls. Fuithennore, the percent m^gen consumed leading the production 
of H2O2  was 80%, which was approximately equal to that of 6,7-ADTQ alone.
Since H2O2  was the major product of 6,7-ADTQ autoxidation, we investigated 
the effects of H2O2  on 6,7-ADTQ autoxidation rate. With 250 pM H2O2 in the reaction 
solution, the rate o f autoxidation was inhibited to 92% o f controls. Following this 
apparent inhibition of autoxidation by H2O2, we decided to effectively remove all H2O2 
produced during autoxidation and see what effect that had. This was accomplished by the
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addition o f catalase to the reaction solution prior to autoxidation, with a Anal 
concentration of 200 unit/mL. The resulting rate was 67% of controls. If all o f the 
oxygen consumed goes to produce H2O2, then the observed rate measured by the oxygen 
electrode in the presence of catalase should be 50% o f controls. However, we found that 
82% of the oxygen consumed with 6,7-ADTQ went to produce H2O2 Therefore, if 
catalase had no stimulatory or inhibitory effects, the observed rate in the presence of 
catalase should have been approximately 59% of controls. But we found the rate to be 
67% of controls and thus, it appears that catalase has a slight stimulatory effect on
6,7-ADTQ autoxidatiotL This stimulatory effect was further substantiated by UV-VIS 
spectroscopy = 14 ±  1 min*l, 120 ±  8% of the control kapp, X=294 nm). Whether 
this stimulation is due to catalase itself, or the removal of H2O2, is not known. But the 
results from this study suggest that it is from the removal of H2O2.
Spin restrictions dictate that, whether by direct reduction of molecular oxygen or 
by use of a co-reductant, electrons are transferred to oxygen one at a time.^^*^^^ 
Therefore, autoxidation must generate O 2'. However, this may not be "free" O 2" and/or 
may be extremely short lived due to the kinetics of electron transfer with 6,7-ADTQ. The 
mechanism of autoxidation of 6-HDA and some related analogs depend on the presence 
of *02', and by removing «O2" from the reaction medium, autoxidation is inhibited. On 
the other hand, autoxidation of other 6-HDA analogs, in particular 6-AD A, proceeds by 
pathways unaffected by the removal of 0 2 * . thereby suggesting very rapid electron 
transfer kinetics. Therefore, we conducted 6,7-ADTQ autoxidation in the presence of 
100 units/mL SOD. Not only was 6,7-ADTQ not inhibited by SOD, but the rate was 
actually stimulated to 119% of controls. This stimulatory effect was also observed by 
UV-VIS spectroscopy ( k ^  = 13.9 ±  0.7 min i, 119 ±  5% of the control kapp, X=294 
nm).
192
B. (>,7-AMDTQ
HO,
KO'
H
fo a pH 7.4 phosphate buffer, 6,7-AMDTQ rapidly forms a pink-purple colored 
solution. A UV-VIS spectrum of reduced 6,7-AMDTQ initially displays bands at Xma* = 
218 nm, 284 nm, and 350 nm. The UV-VIS spectral changes that accompany 
autoxidation o f 100 pM 6,7-AMDTQ at pH 7.4 and 25°C are shown in Figure 7-6. 
Spectral changes occurring at 37°C are the same as that seen at 25°C, however, they occur 
much faster. During autoxidation, the band at 284 nm rapidly grew and shifted to longer 
wavelengths with a final absorbance maxima at 300 nm. Corresponding to this increase, 
there was a decrease in the absorption band at 218 nm, a growth and shift to a shorter 
wavelength (344 nm) of the band at 350 nm, and the appearance of a new band at 518 
nm. At the completion of autoxidation, the bands at 518 nm and 300 run began to 
decrease, the 344 nm band continued to increase, and a  new band appeared at 244 nm. 
hnterestingly, there was an absence of an overall baseline increase with time, suggesting 
the absence o f polymerization. The rate of autoxidation was pH dependent, as was 
expected. Surprisingly, even at pH 2.4 autoxidation occurs; however, there was 
tpproximately a  10 minute lag period prior to the initiation of autoxidation.
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Figure 7-6. UV-VIS spectra of 6,7-AMDTQ autoxidation at pH 7.4 and 25®C.
Autoxidation reaction orders were determined using the oxygen electrode for each 
of toxin, O2, and H+. The conditions under which the reaction order for 6,7-AMDTQ
6,7-AMDTQ was found were: 246 iiM oxygen, pH 7.4, and toxin concentrations o f 98, 
147, 196, and 246 iiM. This is shown in Figure 7-7. It was found that autoxidation is 
approximately first order with respect to 6,7-AMDTQ. With the toxin concentration and 
the pH fixed at 196 pM  and 7.4, respectively, the concentration o f O2 was varied 
between 132 and 488 iiM to determine the reaction order for oxygen. Surprisingly, the 
reaction order was found to be approximately 1/2, as shown in Figure 7-8. By holding 
the initial oxygen and toxin concentrations constant and using pH values of 5.4,6.4,7.4, 
and 8.4, the reaction order for H+ was determined to be -1/4. This is shown in Figure
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7-9. From the above data, the autoxidation rate constant for 6,7-AMDTQ was found to 
b e k = 0.0485 ±  0.0009 M-l^sec-% and the rate expression was:
rate = kC toxIO zf^EH T^
These results ate summarized in Table 7-5.
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Figure 7-7. Toxin concentration effects on 6,7-AMDTQ autoxidation.
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Figure 7-9. The effects of pH on 6,7-AMDTQ autoxidation.
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Table 7-S. 6,7-AMDTQ autoxidation reaction orders with respect to individual
components.
Reaction Orders
raie = k[tox]‘[0 ,F [H ^r
X 0.96 ±  0.03
y 0.54 ±0.06
z -0.24 ±0.02
k 0.0485 ±  0.0009 M -O^sec'l
6,7-AMDTQ autoxidation rates in the absence and presence of various metal ions, 
chelating agents, and enzymes are shown in Table 7-6. Additionally, the percent oxygen 
consumed during 6,7-AMDTQ autoxidation leading to the production o f H2O2 and 
superoxide is presented in Table 7-7. Throughout these studies, the concentration of
6,7-AMDTQ was 196 ^M, the initial concentration of O2 was approximately 250 pM, 
and the pH was 7.4.
Autoxidation of 6,7-AMDTQ in the absence of any added substances was 
completed in less than 25 seconds and showed an oxygen consumption rate o f 583 pmol 
02/L'm in. The kgpp determined from UV-VIS spectroscopy for 200 pM 6,7-AMDTQ 
was 4.8 ±  0.1 (100 ±  2%, X=518 run). Upon addition of catalase to the oxygen electrode 
reaction cell following completion of the reaction, 47% of the oxygen consumed was 
returned to the solutiotL Therefore, a minimum of 94% of the oxygen consumed during 
autoxidation went to produce H2O2 There was little oxygen liberated (1%) upon SOD 
addition. Therefore, the majority of oxygen consumed was accounted for by the 
production of H2O2.
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Table 7>6. 6,7-AMDTQ autoxidation, initial rate of oxygen consumption.
Added Component(s)
Mtial O2 Consumption
N raie±SEM
Gimol02/L«min)
rate±SEM  
% controls
none 6 583 ± 3 100 ± 0 .6
Fe2+ L O xlO ^M 4 711± 7 122 ±1»**
Fe2+ 1.0 X 10-5 M 4 634 ± 17 109 ± 3 *
Cu2+ 1.0 X 10-5 M 4 1130 ± 2 194 ±0.3***
Cu2+ 1.0xl0-«M 4 622 ± 9 107 ±2**
Fe?+/EDTA l.O xlO ^M 4 765 ± 7 131 ±1***
DTPA 1.0 X 10*3 M 4 508 ± 6 87 ± 1***
H202 2.5xlO-*M 2 522 ± 1 90 ±0.2***
catalase 200units/mL 2 492 ± 2 84 ± 0 .3
SOD lOOunits/mL 2 614 ± 1 105 ±0.2***
Significant differences compared to control values (f test): *P < 0.05; **P < 0.01, 
***P < 0.001.
W e then investigated the effects of Fe^+ on 6,7-AMDTQ autoxidation.
6,7-AMDTQ autoxidation in the presence of 10^ M Fe2+ exhibited an oxygen 
consumption rate which was stimulated to 122% of the control values. While stimulation 
was also observed at 10*^  M Fe^+, it was relatively minimal, being only 109% of 
controls. It was found that 80% and 81% of the oxygen consumed led to the production 
of H2O2 when in the presence of 10-* M and 10*5 M Fe2+, respectively. And, upon 
addition o f SOD following autoxidation, 7% of the oxygen consumed for the Fe2+ case 
was returned to the solution, which correlates to a minimum of 14% of the oxygen 
consumed being converted to «0 2 *.
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Table 7-7. 6,7-AMDTQ autoxidation, H2O2  and O 2  produced.
Added
Component(s)
Percent O2 Consumed 
which was Liberated Upon 
Addition of:
Percent O2 
Consumed by 
Pathway Leading to:
Catalase SOD H2O2 •O2-
N % Q2±SEM N % 02 % 02±SE M % 02
none 3 47 ± 0 .4 1 1 9 4 ± 1 2
Fe2+ 1 .0 x l(H M 3 40±2 1 7 8 0 ± 3 14
Fe2+ 1.0 X 10-5 M 3 40±2 1 0 8 1 ± 4 0
Cu2+ 1.0 X 10-5 M 3 43± 1 1 1 86 ± 2 3
Cu2+ 1.0 X 10-6 M 3 50± 3 1 4 100± 5 8
Fe2+/EDTA1.0xl(H M 3 7.5 ± 0.5 1 2 15 ± 1 4
DTPA 1.0 X 10-3 M 3 4 4± 1 1 1 88 ± 2 2
At 1 0 ^ M Cu^+, 6,7-AMDTQ autoxidation was stimulated to 197% of controls. 
The 10^ M Cu2+ had very little effect on the rate, and only increased it to 107% of 
controls. Unlike FeZ+, Cu^+ did not substantially efkct the resultant H2O2. The percent 
of oxygen consumed leading to the production of H2O2 was 86% and 100% for 10-5 
and 10^ M Cu^+, respectively. And the O2 liberated upon addition o f SOD in the Cu2+ 
«tperiments was minimal, yet detectable.
As mentioned earlier, Fe^+/EDTA has been reported to increase the rate of 
autoxidation of some neurotoxins above that of Fe2+ alone. At 10*  ^M Fe^+ZEDTA,
6,7-AMDTQ autoxidation was stimulated to 131% of controls, only slightly above the
199
121% of controls observed with Fe^+ alone. However, the percent oxygen recovered 
following the addition of catalase in the Fe^+ZEDTA case was only 7%, which signifies 
14% of the oxygen consumed led to the production of and/or remained as H2O2. And 
small, yet detectable amounts of *02* were found upon SOD addition to the Fe^+ZEDTA 
combination.
Autoxidation in the absence of any available metal ions was conducted using the 
strong chelating agent, DTPA. At 10*^  M, DTPA inhibited 6,7-AMDTQ autoxidation to 
only 87% of controls. Addition of catalase following this reaction that the percent of 
oxygen leading to the production of H2O2 was a substantial 88% of the oxygen 
consumed.
H2O2  was the major byproduct in the autoxidation of 6,7-AMDTQ alone. Thus, 
we were interested in determining if H2O2  participated in, or had any effect on, 
autoxidation. At 250 pM  H2O2 , the rate was inhibited to 90% o f controls. This 
concentration o f H2O2 , by itself, had no effect on oxygen concentrations monitored. 
With H2Q2 displaying an inhibitory effect, we decided to add catalase, thereby effectively 
removing all H2O2 produced during 6,7-AMDTQ autoxidation. A t 200 units/tnL 
catalase, the rate was found to be 84% of controls. If catalase exerted no effect on 
autoxidation, the rate should have been 53% of controls. Therefore, catalase either 
directly or indirectly, through the removal of H2O2, stimulated the rate o f 6,7-AMDTQ 
autoxidation. This stimulation was verified with UV-VIS spectroscopy, showing a 
stimulation to 121% of controls = 5.8 ±0.2  min-l, %=518 nm).
We also wanted to determine if 02*  played an active role in the mechanism of
6,7-AMDTQ autoxidation. For this, the reaction cell contained 100 units/mL of SOD. 
The resulting rate was found to be slightly stimulated to 105% of controls. Again, this 
stimulation was observed with UV-VIS spectroscopy = 5.8 ±0.2 min-l, 121 ±  4% 
of controls, 1=518 nm).
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C. 6,8-ADTQ
W
6,8-ADTQ readily undergoes autoxidation at pH 7.4. A UV-VIS spectrum of 200 
pM 6,8-ADTQ in the reduced form at pH 7.4 initially shows absorbance maxima at 276 
nm and 300 nm (sh). The spectral changes that accompany 6,8-ADTQ autoxidation are 
shown in Figure 7-10. Upon autoxidation, the band at 276 nm grew and shifted to 
longer wavelengths (280 nm). Correspondingly, there was an appearance and growth of 
bands at 460 run (sh) and 232 run, and a  baseline increase between the bands at 280 run 
and 460 nm. At the completion of autoxidation, the band at 280 nm began to decrease 
and shift to longer wavelengths and the overall baseline began to increase. This general 
increase in absorbance throughout the spectrum corresponded to the appearance of dark 
precipitates in the solution, presumably indicating polymerization. Similar spectral 
changes occurred at higher and lower pH values, with the resultant rate being 
proportional to pH. As we would expect, there was no observed oxidation at pH values 
below 3.4.
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Figure 7-10, UV-VIS spectra of 6,8-ADTQ autoxidation at pH 7.4 and 37®C.
Autoxidation reaction orders were determined using the oxygen electrode for each 
of 6,8-ADTQ, O2, H+. Using 6,8-ADTQ concentrations of 98, 147, 196, and 246 pM, 
an initial 0% concentration of 248 pM, and a pH of 7.4, the autoxidation reaction order 
for 6,8-ADTQ was found to be approximately 1.0, as shown in Figure 7-11. Holding 
the initial toxin concentration at 196 pM and the pH at 7.4, and varying the concentration 
of O2 between 160 and 563 pM, the oxygen reaction order was determined to be 
approximately 3/4, as shown in Figure 7-12. Keeping the initial O2 and 6,8-ADTQ 
concentrations constant and using pH values of 5.4,6.4,7.4, and 8.4, the reaction order 
with respect to H+ was approximately -1/2, as shown in Hgure 7-13. Attracted from the
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data in Hguies 7-11 to 7-13, the rate constant for 6,8-ADTQ autoxidation at 37°C was 
found to be k  s 0.0048 ±  0.0003 M l^sec^, and the rate expression was:
rate = k tto x IO jf
These results are summarized in Table 7-8.
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Figure 7-11. Toxin concentration effects on 6,8-ADTQ autoxidation.
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Figure 7-12. Oxygen concentration effects on 6,8-ADTQ autoxidation.
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Figure 7-13. The effects o f pH on 6 ,8 -ADTQ autoxidation.
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Table 7-8. 6,8-ADTQ autoxidation reaction orders with respect to individual
components.
Reaction Orders
rate =  k[tox]‘[O jr[H *r
X 1.20+0.03
y 0.74 ±0.03
z -0.56 ±0.05
k 0.0048 ±0.0003 M-OJSsec-l
6,8-ADTQ autoxidation rates in the absence and presence of various stimulating 
and/or inhibiting agents are presented in Table 7-9. The percentage of oxygen consumed 
during 6,8-ADTQ autoxidation leading to the production of H2O2 and superoxide is 
presented in Table 7-10. In these studies, the concentration of 6,8-ADTQ was 196 liM, 
the initial concentration of O2 was approximately 2S0 pM, and the pH was 7.4. 
Stimulating and/or inhibiting agents added to the reaction mixture in this study showed no 
oxygen effects when presented by themselves.
Autoxidation of 6,8-ADTQ in the absence of any added substances was complete 
in less than 1.2 min and showed an initial rate consumption rate of 344 pm ol 02/L«min 
(UV-VIS spectroscopy determined = 3.6 ±  0.2 min l, X=276 nm). Surprisingly, 
the oxygen liberated upon addition of catalase following autoxidation was considerably 
less than expected, being 30% of oxygen consumed. The percent oxygen consumed 
leading to the production of H2O2, therefore, was 60%. The oxygen liberated by the 
addition of SOD was 2% of the oxygen consumed during autoxidation.
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Table 7 9. 6 ,8 -ADTQ autoxidation, initial rate of oxygen consumption.
Added Component(s)
Initial O; Consumption
N rate±SEM
OimolG2 /L«min)
rate±SEM  
% controls
none 7 344±6 100 +  2
Fe2+ L O xlO ^M 4 437 ± 7 127 ±2***
Fe2+ 1.0 X 10*5 M 4 392 ± 6 114 ±2***
Cu2+ 1.0 X 10-5 M 5 591 ±  10 173 ±  3***
Cu2+ 1.0xl0-«M 4 348 ± 6 101 ± 2
Fe^+/EDTA 1.0 x 10^ M 4 622 ± 6 181 ±2***
DTPA 1.0 X 10-3 M 4 366 ± 3 106 ±1*
H202 2.5xlO -*M 3 438 ± 1 127 ±0.3***
catalase 200units/mL 2 264±1 77 ± 0 .2
SOD lOOunits/mL 2 363 ± 1 106 ±  0.1*
Significant differences compared to control values (r lest): *P < 0.05; < 0.001.
In our investigation of transition metal ion effects on 6,8-ADTQ autoxidation, we 
began with Fe^+. A 10^ M Fe^+ solution stimulated the observed rate to 127% of 
controls. A  10*^  M Fe^+ solution also showed a stimulation in rate to 114% of controls. 
There was a  dramatic decrease in the oxygen liberated upon the addition of catalase which 
was related to the Fe^+ concentratioiL The percent oxygen consumed which returned to 
the solution was 4.4% for 10-* M Fe2+ and 18% for 10*5 M Fe^+. And while there was 
no *C>2* detected at 10-5 M Fe^+ following SOD addition, 4% of the oxygen consumed 
during autoxidation was returned to the solution at lO^M  Fe^ ***.
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Table 7-10. 6 ,8 -ADTQ autoxidation, H2O2  and O 2* produced.
Added
Componentfs)
Percent O2 Consumed 
which was Liberated Upon 
Addition of:
Percent O2 
Consumed by 
Pathway Leading to:
Catalase SOD H2O2 _ •02-
N % 02±SEM N % 02 % 02±SE M % 02
none 5 30±1 1 2 6 0 ± 3 3
FeZ+ 1.0 X 10-4 M 3 4.4 ±0.5 1 4 9 ± 1 8
Fe2+ 1.0 X 10-5 M 4 18±2 NA 3 7 ± 4 NA
Cu2+ 1.0 X 10-5 M 4 22 ±0.6 1 0 4 6 ± 1 0
Cu2+ 1.0 X 10-a M 3 24±1 1 6 4 6 ± 2 12
Fe2+/EDTA1.0xl0-*M 3 1.3 ±0.2 1 1 2.6 ±  0.4 3
DTPA 1.0 X 10-3 M 3 33 ±0.3 1 1 66 ± 0 .6 2
We then looked at Cu2+ effects on autoxidation. We observed stimulatory effects 
at 10~^  M Cu2+ to 172% of controls. But, at 10^ M Cu^+ there was no stimulation 
present. The percent oxygen consumed during autoxidation leading to H2O2 was 
decreased to 46% at 10*^  M Cu2+. Interestingly, 1(M M Cu2+ had no effect on rate, but 
the amount of oxygen liberated by the addition of catalase was the same as that seen with 
10-5mCu2+.
Pie2+ complexed with EDTA, as previously mentioned, stimulates autoxidation of 
6-HDA type compounds to a  higher degree than does Fe2+ alone. The rate of 6,8-ADTQ 
autoxidation was stimulated substantially over that of Fe2+ alone. And, the oxygen 
returned to the solution following the addition of catalase was decreased compared to that
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found with Fe^+ alone. The oxygen liberated by catalase was 1.3% of the oxygen 
consumed. That is to say, the percent oxygen consumed during autoxidation which led to 
and/or remained as H2O2  was 2.6%. Furthermore, an equal amount of oxygen was 
returned upon the addition of SOD, thus, indicating the presence of •O2'.
By incorporating DTPA, we were able to investigate the rate of 6,8-ADTQ 
autoxidation in the absence of, essentially, all metal ions. At 10-3 \ f , DTPA showed no 
inhibitory effects on the rate, but surprisingly displayed the opposite. DTPA slightly 
stimulated 6,8-ADTQ autoxidation to a value of 106% of controls. Additionally, the 
H2O2 produced accounted for 66% of the oxygen consumed.
It is apparent that H2O2 is not the sole reduced oxygen by-product resulting from
6,8-ADTQ autoxidation; however, it is the major species resulting when in the absence of 
metal ions. Therefore, we were interested in determining if H2O2 was intimately 
involved in the autoxidation reaction or if it was just a  simple by-product, hr the presence 
of 250 H2Q2, the rate of 6,8-ADTQ autoxidation was stimulated to 127% of controls.
This stimulation was substantiated from UV-VIS investigations (k^p=4.2 ±0.1 m in'l, 
118% of controls, Xs276 tun). Thus, it appears that H2O2 plays a role in the overall 
autoxidation process o f 6,8-ADTQ. We further investigated this by conducting 
autoxidation in the presence of 200 units/mL catalase. The corresponding rate was 76% 
of controls. Since 30% of the oxygen consumed was returned to the solution following 
the addition of catalase with 6,8-ADTQ alone, one would expect the rate in the presence 
of catalase, assuming no effects, to be approximately 70% of controls. Furthermore, 
since H2O2 stimulates 6,8-ADTQ autoxidation, by eliminating all produced H2O2  during 
autoxidation we would expect the rate to be even less. However, this was not the case. 
Therefore, it tqppears that catalase itself stimulates the autoxidation of 6,8-ADTQ. The 
stimulation by catalase was further verified by UV-VIS spectroscopy, showing the kapp 
to be 121% of controls 0 ^  = 4.3 ±  0.2 min-l, 276 nm).
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Supetoxide has been suggested to play a role in the mechanism of autoxidation for 
toxins similar to 6,8-ADTQ. By conducting 6,8-ADTQ autoxidation in the presence of 
SOD, all "&ee" *02 produced during autoxidation should effectively be removed. Using 
100 units/mL SOD, we found the rate actually increased to 106% of controls. The 
increase was also observed using UV-VIS spectroscopy, with a stimulation to 115% of 
controls Q^pp = 4 .1 ±  0.1 m in'l, 276 nm).
D. 6-HDA
Autoxidation of 6-HDA and its production of reactive oxygen species have been 
extensively studied and will be elaborated upon in the discussion section, hi our studies 
we have incorporated 6-HDA for (1) comparative purposes, (2) to verify and clarify 
literature results, and (3) to possibly add new information and insight to the already 
existing vast base o f knowledge on 6-HDA chemistry.
6-HDA readily undergoes autoxidation at pH 7.4 in an air saturated phosphate 
buffer, forming a pink-red colored solution. A UV-VIS spectrum of reduced 6-HDA 
initially displays band maxima at 214 nm and 284 nm. Spectral changes that accompany 
200 iiM 6-HDA autoxidation at a pH of 7.4 and 37°C are shown in Figure 7-14. Upon 
initiation of autoxidation, the band at 284 nm grew and shifted to shorter wavelengths 
(268 nm), in the process yielding isobestic points at 292 nm and 312 nm. 
Correspondingly, the band at 214 nm grew and shifted to longer wavelengths (218 nm) 
and a new band appeared at 486 nm. The new band at 486 nm accounts for the pink-red 
color acquired by the solution as 6-HDA autoxidizes. All hands continued to grow until
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completion of autoxidation, at which point absorbances stabilized. At extended times 
following autoxidation, the absorbance bands began to decrease and the baseline 
increased. These observed changes were both pH and temperature dependent
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fig u re  7-14. UV-VIS spectra of 6-HDA autoxidation at pH 7.4 and 37°C.
Autoxidation reaction orders with respect to 6-HDA, 0%, and H+ were determined 
utilizing an oxygen electrode. While at 25X  6-HDA shows first order reaction kinetics 
with respect to the toxin (d m  not shown), at 37°C the reaction order changed. By 
determining the rate of oxygen consumption during autoxidation of 147,196,243, and 
294 iiM 6-HDA, using a fixed pH of 7.4, and an initial O2 concentration of 247 iiM, the 
reaction order for 6-HDA at 37°C was determined to be approximately 3/2, as shown in
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Figure 7-15. At a pH of 7.4 and an initial 6-HDA concentration of 196 pM, the initial 
concentration of O2 was varied between 114 and 553 pM to obtain the plot presented in 
Hgure 7-16. Using this plot, the O2 reaction order was determined to be approximately 
1/3. Employing pH values o f 5.4, 6.4, 7.4, and 8.4, the proton reaction order was 
found to be -1/3 and is graphically displayed in Hgure 7-17. Using the information in 
Hgutes 7-15 to 7-17, the overall reaction rate constant was calculated to be k s  0.031 ±
0.003 M'l^^sec'^, and the rate expression was:
rate = k[toxy^[O J°^^[H T ^
These results are surmnarized in Table 7-11.
-5.4
-5.5 [toxin]
x =  1.49 ±0.07
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Figure 7-15. Toxin concentration effects on 6 -HDA autoxidation.
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Figure 7-16. Oxygen concentration effects on 6-HDA autoxidation.
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Figure 7-17. The effects of pH on 6 -HDA autoxidation.
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Table 7-11. 6-ElDA autoxidation reaction orders with respect to individual
components.
Reaction Orders
raie = k [to x r[0 ,r[H * r
X 1.49 ±  0.07
y 0.34 ±0.03
z -O J4± 0.05
k 0.031 ±  0.003 M-0-49sec*l
The rate of 6-HDA autoxidation alone and in the presence of various catalysts 
and/or inhibitors of this reaction are presented in Table 7-12. Furthermore, the percent 
oxygen consumed during autoxidation leading to the production of H2O2  and *0 2 * is 
given in Table 7-13. In the following studies the initial concentration of O2 was 
approximately 250 nM, the 6-HDA concentration was 196 pM, and the pH was 7.4.
Autoxidation of 6-HDA in the absence of any catalysts or inhibitors was 
completed in less than two minutes and displayed an initial rate of 123 pmol C)2/L«miiL 
From UV-VIS spectroscopic studies, the rate showed a k^p  = 1.35 ±  0.02 min*  ^(X = 
486 nm). Following the completion of autoxidation, when employing the oxygen 
electrode, the addition of catalase returned 40% of the oxygen consumed back to the 
solution. Therefore, the majority of the oxygen consumed (minimum of 80%) during 
6-HDA autoxidation was accounted for by the production of H2O2 These results 
correlate well with those of the literatuie.^^*^'^^
2 1 3
Table 7-12. 6 -HDA autoxidation, initial rate of oxygen consumption.
Added Component(s)
Initial O2 Consun^tion
N rate±SEM
(Umol02/L*min)
rate±SEM  
% controls
none 5 123 ± 3 100±2
Fe2+ 1 .0xl0-*M 3 324 ± 3 264dk3***
Fe2+ 1.0 X 10-5 M 3 187 ± 1 153 ±  1***
Cu2+ 1.0 X 10-5 M 4 1012 ± 10 825 ±8***
Cu2+ 1.0xl0-«M 4 169 ± 2 137 ±2***
Fe?+/EDTA l.O xlO ^M 4 1176 ± 12 958 ± 10***
DTPA 1.0 X 10-3 M 4 123 ± 2 100±2
H202 2.5xlO -*M 2 114±1 93 ±1*
catalase 200units/mL 2 i l ± 2 9 ± 1
SOD lOOunits/mL 2 10.0 ±  0.2 8.2 ±0.1***
Significant differences compared to control values (t test): *P < 0.05; ***P < 0.001.
It has been reported that the rate o f 6-HDA autoxidation is stimulated in the 
presence of transition metal ions.36.165,171-173 We also found this to be so. At 10^ 
M Fe^+ autoxidation was increased to 264% of controls, while at 10*  ^M Fe2+ the rate 
was increased to 153% of controls. The HgOz produced from or, at least, available at the 
completion of the autoxidation decreased in an Fe?+ concentration dependent manner. 
The percent oxygen consumed that was liberated upon the addition of catalase was 12% 
and 25% for ICH M and lOr^  M Fe^*, respectively. Therefore, in the presence of Fe2+ 
there is a significant decrease in the production or availability of H2Q2 following 6-HDA 
autoxidatioiL This has also previously been observed.^^^
214
Table 7-13. 6 -HDA autoxidation, H2O2  and O 2* produced.
Percent O2 Consumed 
which was Liberated Upon 
Addition of:
Percent O2 
Consumed by 
Pathway Leading to:
Catalase SOD H2O2 0 2 -
Added
ComponentCs)
N % 02±SE M N % 02 % 02±SE M % 02
none 3 4 0 ± 2 1 4 8 0 ± 4 8
Fe2+ LOx K H M 3 12.3 ±  0.4 1 6 25± 1 12
Fe2+ 1.0 X 10-5 M 3 2 5 ± 1 NA 5 0 ± 2 NA
Cu2+ 1.0 X 10-5 M 3 4 0± 1 1 5 8 1 ± 2 9
Cu2+ 1.0 X 10-6 M 3 3 6 ± 2 1 4 7 1 ± 4 8
Ffe2+/EDTA1.0xl(HM 3 5.9 ±  0.5 1 5 12±1 9
DTPA 1.0 X 10-3 M 3 4 9 ± 2 1 4 9 7 ± 3 8
In the presence of 10*  ^ M Cu^+, 6-HDA autoxidation rate was amazingly 
increased to 825% of controls. At 1(M M Cu^+, however, the rate was stimulated to only 
137% of controls. And, the percent oxygen consumed which led to the production of 
H2O2 was not significantly different from that found for controls. Therefore, while Cu2+ 
stimulates 6-HDA autoxidation dramatically, it does not appear to alter the resultant 
reduced oxygen species.
Fie^+ZEDTA has been reported to enhance the rate of 6-HDA autoxidation over that 
found with Ffe2+ alone.^^*38,173 We found that at 1(H M Fe^+ZEDTA, autoxidation 
was dramatically stimulated to a rate of 1176 pmol 02/L*min, which was 958% of
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controls. Furthermore, the percent oxygen returned to the solution following catalase 
addition was substantially lowered (6%) in comparison to that observed with Fe^+ 
(12%).
It has been proposed by various research groups that 6-HDA autoxidation is metal 
ion mediated.3^'17^ Furthermore, in the presence o f an effective chelating agent, the rate 
of 6-HDA autoxidation has been reported to substantially decrease.38,173 However, this 
inhibition o f autoxidation by a chelator alone has m et w ith som e 
disagreement.36,165,172 Therefore, we were interested in investigating the effects of 
strong metal chelation on autoxidation. At 10*3 M DTPA, 6-HDA autoxidation displayed 
no difference in rate from that of controls. Interestingly, upon addition of catalase 
following this reaction, the percent oxygen consumed leading to H2O2  was nearly 
quantitative in nature, being 97% of controls. Therefore, while effective metal chelation 
did not appear to affect autoxidation rates, it did either enhance the production of H2O2 or 
inhibit the follow-up reactions of H2O2  with various metal ions, i.e., Fenton and Haber- 
Weiss chemistry.
The major byproduct of 6 -HDA autoxidation is H2O2. H2O2 , itself, has the 
ability to oxidize 6 -HDA. 1^2 Therefore, we wanted to investigate the active 
participation, if any, of H2O2  on 6 -HDA autoxidation. At 250 |xM H2O2 , autoxidation 
was slightly inhibited to 93% of controls. In order to further investigate this H2O2 effect, 
catalase was employed. At 200 units/mL catalase, the initial rate o f autoxidation was 
significantly inhibited to 9% of controls. This effect was interesting, yet inhibition has 
been reported by other researchers.36.65,165 Using UV-VIS spectroscopy, we again 
found an inhibition by catalase. However, we observed an initial lag period which was 
followed by a more r^ id  rate of autoxidation. The inhibition apparently measured with 
the oxygen electrode system actually corresponded to the initial lag period. Following 
this lag period, UV studies showed an inhibition of 6 -HDA autoxidation by catalase to 
47% of controls ( k ^  = 0.641 ±  0.009 min*l, X = 486 nm).
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There is a  large amount o f research showing that SOD greatly inhibits 6-HDA 
autoxidation.34,35,65,164 Conversely, it has also been demonstrated that SOD has very 
little effect on 6-HDA autoxidation except in the presence o f strong metal chelating 
agents.36,38,175 Therefore, we incorporated SOD in the initial autoxidation reaction 
mixture and found a dramatic inhibition of rate. The rate was found to be 8% o f controls. 
From UV studies we again foimd this dramatic inhibition seen with the oxygen electrode 
to be the lag period rate. However, following the lag period, 6-HDA inhibition was still 
observed at 29% of controls Otapp = 0.39 ±  0.02 min‘l, X = 486 nm).
V. Discussion
A. Rates of Autoxidation
1. Toxin Autoxidation Rates
The abili^  of molecular oxygen to oxidize 6,7-ADTQ, 6,7-AMDTQ, 6,8-ADTQ, 
and 6-HDA was followed by both oxygen consumption and UV-VIS absorbance 
changes. Hgure 7-18 summarizes the rates o f autoxidation of the various agents obtained 
using an oxygen electrode. We see that autoxidation rates under the tested conditions 
decrease in the order of 6,7-AMDTQ > 6,7-ADTQ > 6,8-ADTQ >  6-HDA. A summary 
of the determined reaction orders and the rate constants is presented in Table 7-14.
From the UV-VIS spectroscopic results, it appears that, while none of the 
oxidized forms o f the compounds are completely stable, oxidized 6,7-ADTQ and
6,8-ADTQ rapidly undergoe some form of follow-up polymerization. Oxidized
6,7-AMDTQ and 6-HDA display slow spectral changes with time; however, these 
changes, which occur up to IS hours, do not appear to be associated with polymerization 
due to the fact that there is an absence of an overall baseline absorption increase.
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6,7-ADTQ 6,7-AMDTQ 6,8-ADTQ 6-HDA
Figure 7-18. Rates of autoxidation of the quinoline agents and 6-HDA.
Table 714 . A toxin comparison o f autoxidation reaction orders and rate constants.
Reaction Orders
ra te  = k[tox]*[0 2 ]yrH+l*
Agents X y z k (M0'**y-2)sec'0
6,7-ADTQ 0.95 ±0.06 0.86 ±0.08 -0.47 ± 0 .02 0.0010 ±  0.0005
6,7-AMDTQ 0.96 ±  0.03 0.54 ±0.06 -0.24 ± 0 .02 0.0485 ±  0.0009
6,8-ADTQ 1.20 ±0.03 0.74 ±  0.03 -0.56 ±  0.05 0.0048 ±  0.0003
6-HDA 1.49 ±  0.07 0 J 4  ±  0.03 -0 J4 ± 0 .0 5 0.031 ±0.003
218
2. Effects of SOD, Catalase, and H2O2
As noted earlier, SOD effectively removes any "free" O 2* and produces singlet 
oxygen, O2*, and H2O2 . Catalase eliminates H2O2 to produce oxygen and water. 
Therefore, by individually including these enzymes in the reaction cell with our 
compounds, we were able to determine autoxidation dependence, if any, on these reduced 
oxygen species.
Spin restrictions dictate that, whether by direct reduction of molecular oxygen or 
by way of a co-reductant, electrons are transferred to oxygen one at a time. Therefore, 
autoxidation must generate «O2*. However, this may not be "ftee" «02* and/or may be 
extremely short lived due to rapid electron transfer kinetics. The mechanism of 
autoxidation of 6-HDA and some related analogs depends on the presence of *02", where 
as other 6-HDA analogs, in particular 6-ADA, proceed by pathways unaffected by the 
removal of *0 2 ", suggesting very rapid electron transfer kinetics.
We found that SOD, at 100 units/mL, actually stimulated autoxidation o f the 
quinoline analogs, while inhibiting that of 6-HDA. This inhibition of 6-HDA 
autoxidation has been reported by many research groups.34,35,65,164,165 i t  has 
recently been shown, however, that small, catalytic amounts of SOD (<10 units/mL) have 
no major effect on 6-HDA autoxidation except in the presence o f strong metal 
chelators.3^'38,175 This suggests that in the absence o f metal chelation, 6-HDA 
produces a toxin«metaI*oxygen complex by which no "free" *0%' is produced. However, 
in the presence of a metal chelator or high concentrations of SOD, which has been 
established to effectively chelate metal ions,38 6-HDA oxidation mechanism changes to 
produce "&ee" *0 2 ", which then participates in the overall oxidation reaction and is shown 
in Figure 7-19.
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6-HDA + 0 2 ----- > *SQ + «02- + H+
6-HDA + O 2- + H +  > *SQ + H2O2
•SQ + O2  > Q + O 2- + H+
•SQ+*02*-----> Q + H2Q2
•SQ + *SQ----- > Q+6-HDA
overall summary 6-HDA + O2  > Q + H2O2
Figure 7 19. Possible autoxidation mechanisms of 6-HDA.
At SOD concentration used in our studies, we observed no inhibition of quinoline analog 
autoxidation and, in fact, we observed a stimulation. This may partially be explained 
from the fact that H2O2 inhibits the quinoline autoxidation rates, and by removing O 2'  
with SOD, little or no H2O2 can be formed. This suggests that the mechanism by which 
our toxins autoxidize is different than that of 6-HDA, Le., O 2 independent. However, 
another plausible explanation for this observance, which does not explain the stimulation, 
is that our toxins may form tighter complexes with metal ions than does 6-HDA, thereby 
not allowing SOD to chelate all of the metal ions, forcing the existence of "free" •Oz'- 
Furthermore, the electron transfer kinetics of our toxins may be such, that both electrons 
are transferred almost instantaneously, thus, not allowing time for SOD to exert its 
effects.
Catalase exerted stimulatory effects on autoxidation of the quinoline analogs and 
inhibited 6-HDA autoxidation. It was found that H2O2, added to the reaction solution, 
actually inhibited autoxidation of 6,7-ADTQ, 6,7-AMDTQ, and 6-HDA to some degree. 
Therefore, the stimulation elicited by catalase is most likely due to the removal of H2O2 
from the reaction medium. This, however, does not explain the effects observed with
6,8-ADTQ in uduch there is a stimulation in rate with both H2Q2 and catalyst
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The inhibition of 6-EIDA by catalase has been reported previously.^5«1^5 
However, recent reports suggest that catalase, itself, does not exert the inhibitory effects, 
but rather the inhibition is due to the trace contamination o f catalase with SOD.^^ We 
find this SOD contamination theory insufficient to ocplain the massive inhibition observed 
with catalyst on 6-HDA. Even assuming 5% contamination in our study, there would 
only be 10 units/mL SOD in the reaction cell. And this concentration o f SOD has been 
shown to produces little 6-HDA inhibition (approx. 7% in h ib i t io n ) .3 8
3. Role of Metal Ions in Autoxidation
It has been proposed that the oxidation of 6 -HDA and related agents is mediated 
by a co-reductant, such as transition metal ions.38,172 Various research groups have 
reported some degree of inhibition of 6 -HDA autoxidation in response to complete metal 
chelation by desferrioxamine^^, 173 and DTPA.36,65,173 Our current results indicate 
that autoxidation of our compounds and 6 -HDA are, at least in part, metal ion mediated 
and/or catalyzed.
Autoxidation rates of our toxins were stimulated by Fe^+ and Cu^+ in a 
concentration dependent manner, and is exemplified in Figure 7-20 for 100 Fe2+ and 
in Figure 7-21 for 10 p.M Cu^+. However, in the presence of DTPA (1 mM), 
autoxidation rates of the quinoline agents were not dramatically effected (see Figure
7-23). And, as mentioned previously, SOD inhibited only 6-HDA autoxidation, while 
actually stimulating autoxidation of the ADTQ analogs. This inhibition of 6-HDA 
autoxidation by SOD has been previously discussed and is believed to dependent on both 
the SOD activi^ and the ability of SOD to chelate metal ions at the concentrations used.
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Figure 7-20. A toxin comparison of the rates of autoxidation in the presence o f 100 
^iM in % controls. Rates presented in this graph are not reflective of direct 
comparisons, but are in percent of their corresponding control group.
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Figure 7-21. A toxin comparison of the rates of autoxidation in the presence of 10 pM 
Cu^+ in % controls. Rates presented in this graph are not reflective of direct 
comparisons, but are in percent of their corresponding control group.
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Figure 7-22. A toxin comparison of the rates o f autoxidation in the presence of 10*^  M 
DTPA in % controls. Rales presented in this graph are not reflective of direct 
comparisons, but are in percent of their corresponding control group.
This observed stimulation of quinoline analog autoxidation by metal ions, and 
lack of inhibition by SOD, suggests a reaction mechanism by which there exists a ternary 
complex between toxin«metal*oxygen similar to that proposed for 6-HDA.25,38 jn  such 
a complex, electrons are sequentially passed to oxygen without the existence of "free" 
O 2'  via innersphere electron transfer. Furthermore, firom the absence of SOD inhibition 
on our quinoline analogs, (1) the electron transfer kinetics must be very fast, and/or (2) 
the quinoline agents may chelate metal ions more strongly than that of agents inhibited by 
SOD, such as 6-HDA This ternary complex idea is shown in the following scheme.
Toxin + M“+ + oxygen rroxin*M=+*oxygen] p-Q + M=+ + H2O2
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This could explain not only the lack of inhibition by SOD, but also the stimulation 
observed with metal ions,
4. Effects o f Fe2+/ED TA
EDTA in the presence of Fe2+ has previously been shown to accelerate 6-ElDA 
autoxidation.38,173 Additionally, EDTA, both in the presence of and absence of FeZ+, 
has also been reported to increase the inhibition of SOD on 6-HDA autoxidation.^^ This 
suggests that EDTA changes the mechanism by which 6-HDA autoxidation occurs, 
making the formation of the ternary 6-HDA*metal«oxygen complex difBcult; thus, more 
dependent on a "free" •O2 '  mechanism(s). The stimulation in autoxidation seen with 
EDTA is believed to be associated with the seventh binding site of Fe^+ in the 
Fe^+ZEDTA complex.38,176 The seventh binding site, while normally being occupied 
by water, can be occupied by O2 and •O2’. This allows for rapid electron transfer to 
occur due to the conformational arrangement of the metal ion and O2,
Our results show an overall stimulation of toxin autoxidation in the presence of 
100 tiM Fe^+ZEDTA. 6-HDA was accelerated to approximately 1000% of controls. 
However, while our quinoline analogs also displayed stimulation o f their autoxidation 
rates, they were similar to the rates observed at equal concentration of Fe2+ alone. This 
lack of substantial rate increase seen with the quinoline analogs suggests that the 
reduction of the metal ion is the rate limiting step in the quinoline analog autoxidation.
B. Production of H2O2 From Autoxidation
The sequential reduction of or^gen by one electron transfer is shown below:
O2 > 0 i  >-0H (+ OH ) >H ;0
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1. Toxin effects
Autoxidation o f 6-HDA has been reported to produce H2O2 in close to 
stoichiometric a m o u n t s .3 3 ,3 4 ,3 7 ,1 6 5  Our results concur with these reports. The percent 
oxygen consumed during our quinoline analog and 6-HDA autoxidations which led to the 
production of H2O2 is presented in Figure 7 - 2 3 .  For 6,7-ADTQ, 6,7-AMDTQ, and 
6-HDA, the majority o f oxygen consumed during autoxidation went to produce H2O2. 
While the conversion of O2 to H2O2  appears to be less than 100% for all of the agents, 
this may be attributed to the H2O2 (1) participating in toxin oxidation, thereby producing 
H2O, ( 2 )  participating in O H  formation through Fenton and Haber-Weiss chemistry, 
resulting firom trace metal ions which exist in the solutions or the reagents, ( 3 )  reaction of 
H2O2 with various components in the reaction cell and the reaction cell itself, and ( 4 )  the 
iimate instabili^ of H2O2 in aqueous systems. Interestingly, 6,8-ADTQ only showed a 
60% conversion of O2 to H2Q2. This could be a result of the above mentioned reactions, 
but doubtful in that this was not observed with the other toxins. An alternative answer 
could be that oxygen is incorporated directly into the molecular structure of 6,8-ADTQ, 
similar to that seen with 5,7-DHT,^5,89 & methidei77 or carbanion85 radical
mechanism.
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Figure 7-23. Oxygen consumed during autoxidation leading to the production of
H 2O 2.
2. DTPA Effects
In order to eliminate trace metal ion interactions with H2O2  produced during 
autoxidation, via Fenton chemistry, DTPA was used to effectively remove any 
participatory ions. In the presence o f DTPA, the H2O2 produced from 6-HDA 
autoxidation accounted for almost 100% of the oxygen consumed. However,
6,7-ADTQ, 6,7-AMDTQ, and 6,8-ADTQ showed relatively no change in the H2O2 
produced from that of their respective controls. Therefore, it does not appear that trace 
metal ion contaminants in the buffer solutions effect, to any substantial degree, the 
resulting H2Q2 via «OH production.
3. M etal Ion Effects
H2O2 and 0 2 ", in the presence of metal ions, can produce O H  through Fenton 
and Haber-Weiss processes. The Fenton reaction is shown below. The Haber-Weiss
2 2 6
reaction is similar to the Fenton reaction with the addition of •O2* recycling of F e ^  to 
Fe2+, and is also shown below.
Fe^^+HgO; >Ffe^+«OH+OH" (Fenton reaction)
+  - % '% .>O H + O H  + o ; (Haber-Weiss reaction)
As we saw earlier, metal ions accelerated the autoxidation of all compounds 
tested. Paralleling this increase in rate was a metal ion concentration dependent decrease 
in the recoverable H2O2 at the completion of autoxidation. These effects were observed 
with FeZ+ and Fe^+ZEDTA, and, to a much lesser extent, Cu^+. At high concentration of 
Cu2+ (l(h5 M) the available H2O2 resulting from the autoxidation of 6,7-ADTQ and
6,8-ADTQ decrease slightly; however, no significant change in H2O2  production was 
observed for 6,7-AMDTQ or 6-HDA. While Cu^+ can participate in free radical 
production, it does so to a much lesser extent than iron.
Iron participates readily in O H  formation through Fenton and Haber-Weiss 
mechanisms. In the presence o f Fe^+, it has been reported that 6-HDA produces O H , 
which is paralleled by a decrease in H2O2 available at the completion of autoxidation.
Our study of 6-HDA with Fie2+ also showed a decrease in available H2O2 following the 
completion of autoxidation, which we presume is due to formation of the O H  through 
Fenton type chemistry. The percent oxygen consumed during autoxidation of the 
quinoline compounds, in the presence of 1(X) pM F^+ , remaining as H2O2 is presented 
in Figure 7-24. We found with both 6,8-ADTQ and 6-HDA that the m ajori^ o f oxygen 
consumed was unaccounted for by the remaining H2O2 in solution. 6,7-ADTQ also 
showed a substantial, but lesser, decrease in recoverable oxygen related to the remaining 
H2O2 following autoxidation. 6,7-AMDTQ showed a significant, yet not substantial.
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decrease in the available H2O2 produced during autoxidation when in the presence of 
Fe^+. These decreases in recoverable oxygen from H2O2 are believed to result from 
H2O2  and Fe^+ participation in O H  formation. Furthermore, preliminary studies 
currently being conducted on these compounds do show «OH production when 
autoxidation is carried out in the presence of Fe^+. However, this does not explain why 
there is more O H  production, through the above described processes, with any one toxin 
vs. the others.
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Figure 7-24. Oxygen consumed during toxin autoxidation, in the presence o f ICH M
Fe^ '*’, leading to the production of H2O2.
Fe^+ZEDTA with H2Q2 is a classic O H  generating system .^’^ ^» Xhere was
dramatic decreases in the remaining H2O2  following toxin autoxidation when in the 
presence of 100 pM Fe^+ZEDTA. This is shown in Figure 7-25. The m ajoci^ of the 
oxygen consumed during autoxidation, o f all of the toxins studied, was unaccounted for 
by the H2O2 remaining following this process. This disappearance or lack o f generation
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of H2O2, from toxin autoxidation in the presence of Fe^+ZEDTA, suggests strongly the 
production of O H  from H2O2 Furthermore, it has been shown with 6-HDA and related 
analogs, that the loss of H2O2 was accounted for by the formation of O H . 1^ 65
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Figure 7-25. Oxygen consumed during autoxidation, in the presence o f 1(H M 
Fe^+ZEDTA, leading to the production of H2O2.
VI. Conclusions
It is apparent from the preceding autoxidation studies that our toxins have the 
capability to rapidly autoxidize when in aqueous solutions at physiological pH. We 
believe this autoxidation to be a prerequisite for our toxin-induced neuronal damage 
and/or degeneration. From the effects observed, it sp e a rs  that metal ions serve as an 
electron transfer catalyst in the autoxidation process. This may be envisioned to involve
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the formation of a ternary toun«metai*oxygen complex, thereby promoting inner sphere 
electron transfer. The complex most likely facilitates electron transfer to molecular 
oxygen by two sequential and coupled one-electron steps, resulting in the formation of 
H2O2 and absence of "Aee" intermediate 0 2 '.  Additionally, as metal ion concentrations 
increase, there is a decrease in available H2O 2 following toxin autoxidation, which is 
suggestive of O H  production via Fenton and/or Haber-Weiss mechanisms.
The absence of inhibition by SOD on the autoxidation o f the quinoline analogs 
suggests a O 2* independent oxidation mechanism. The stimulation in rate observed in 
the presence of catalase and SOD, individually, along with the general decrease in rate 
seen in the presence of H2O2, implies that H2O2 inhibits the preferred mechanism of 
oxidation of the quinoline agents.
Two of the toxins tested, 6,7-ADTQ and 6,8-ADTQ, rapidly underwent some 
form of polymerization following autoxidation. This suggests that they would readily 
react with nucleophiles in the cellular milieu.
All of the agents tested have been shown to elicit considerable neurodestruction in 
the CNS. From our findings in this chapter, it  is not unreasonable to suggest multiple 
possibilities which could result in neuronal damage and/or destruction. These would 
include, but are not limited to: (I) production of damaging reactive oxygen species; (2) 
binding of oxidized toxin to essential proteins and enzymes; (3) neuronal hypoxia via 
toxin redox cycling; and (4) depletion of cellular antioxidant defenses.^^
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Mode of Action IV: Disruption of 
Mitochondrial Oxidative 
Phosphorylation
Chapter 8
I. Introduction
Adenosine triphosphate (ATP) plays a fundamental role in the proper functioning 
of neurons in the brain. ATP is produced almost exclusively in the mitochondria by 
oxidative phosphorylation; thus, the primary role of mitochondria is to furnish the cell 
with energy.178-183 ^  disruption in energy production within a neuron generally results 
in neuronal dysfunction and/or death. There is a large body of evidence suggesting that 
numerous mental disorders arc a result of energy metabolism dysfunctions, including
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Parkinson's and Alzheimer's diseases78,184 Furthermore, it has been shown that a 
substantial number of drug-induced toxicities result from the interference o f energy 
production in the brain.
As discussed in Chapter I, MPT? induced neurotoxicity is believed to be a result 
o f inhibition o f electron transport at the level of complex L^9,72,73 jt has been 
suggested that 5,6-DHT and 5,7-DHT interfere with electron transport.82,86 
Researchers have proposed that 6-HDA produces its neurotoxiciQr, at least in part, by 
uncoupling o f oxidative phosphorylation^^,60,165 and by inhibiting electron 
transport.^8 ,59 Additionally, 6-HDA has been shown to cause a disruption 
mitochondrial Ca^+ homeostasis.^^*^ 1 «^2 Further, when brain tissue homogenates of 
3H-6-HDA, l^C-5,6-DHT and l^C-5,7-DHT treated rats were separated on a 
discontinuous sucrose gradient, most of the radioactivi^ was found to be located in the 
mitochondrial fiaction.26
When considering that all of the above mentioned toxins elicit some degree of 
dysfunction in mitochondrial oxidative phosphorylation, it is not unreasonable to suggest 
that impairment of mitochondrial function may be a common underlying mechanism by 
which many neurotoxins produce their damaging effects. Therefore, it was of interest to 
us to evaluate the effects of our fixed side chain toxins, along with 6-HDA, for possible 
mitochondrial interactions.
n. Background
The viability of mitochondria are fiequently discussed in terms of how tightly or 
loosely mitochondria are coupled, or, how well the flow of electrons through the 
respiratory chain is reflected in the phosphorylation of ADP to ATP. Mitochondrial
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coupling is most generally expressed quantitatively in two ways; the respiratory control 
ratio (RCR) and the P/O ratio. 178,179,183,186 goth of these ratios can be determined 
by monitoring the amount and rate o f oxygen consumption a solution containing 
mitochondria and an electron donating substrate in the absence (state 4) and presence 
(state 3) o f the phosphate acceptor, ADP. Substances added, states observed, and 
quantities measured for the determination of the ratios are exhibited on the typical oxygen 
trace shown in Rgure 8-1 for a mitochondrial preparation.
substrate
ADP
mitochondria
stale 3oxy. consumed
ADP
Hme
Figure 8-1. Typical 0% trace showing stimulated and non-stimulated mitochondrial
respiration.
The mitochondrial respiratory control ratio (RCR) is defined as the respiration rate 
in the presence of ADP divided by the respiration rate in the absence of ADP. In Figure
8-1 we see this corresponds to (state 3 rate)/(state 4 rate). Ifigh RCR values indicate a
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tight coupling or a  good energy-conversion capability. Low RCR values indicate loose 
coupling and a damaged or poorly functioning mitochondria.
The P/O ratio is defined as the number o f ATP molecules produced in oxidative 
phosphorylation per oxygen atom consumed. In a tightly coupled NAD-linked pathway, 
approximately 3 ATP are produced per oxygen atom converted to water, and in a tightly 
coupled succinate-linked system, 2 ATP are produced per oxygen atom converted to 
water. Thus, by making ADP the limiting reactant and measuring the oxygen consumed, 
the P/O ratio can easily be calculated. This is mathematically expressed as P/O = (mol 
ADP added)/(mol oxygen atoms consumed).
Another important parameter in mitochondrial oxidative phosphorylation is the 
state 4 respiration rate. In a highly coupled system, oxygen consumption is very low in 
the absence of a phosphate acceptor. While a small amount of oxygen consumption will 
exist in the absence of ADP due to endogenous phosphorylatable substrates and residual 
energy leakage, a large state 4 rate indicates massive energy leakage from the electron 
chain and, hence, a non-viable mitochondrial preparation.
Toxins may elicit their neurodestructive action by interfering with the proper 
functioning of mitochondrial oxidative phosphorylation. The two most prominent ways 
in which an agent could produce an energy deficit are (1) inhibition o f the electron 
transport chain, and (2) uncoupling of oxidative phosphorylation.
Inhibitors prevent production of ATP by blocking the flow of electrons through 
the respiratory chain. Lihibitors, thus, cause the rate o f oxygen consumption to return to 
that of state 4. This is exemplified in Figure 8-2. Inhibitors are generally lipophilic 
molecules; however, there are no obvious functional or structural properties which they 
all possess to describe or characterize them as a  group. Classic inhibitors of oxidative 
phosphorylation are antimycin and t^anide.^^
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Figure 8-2. Typical effects of an inhibitor (solid line) on ADP stimulated respiration
(broken line).
Uncouplers also prevent production of ATP, but by a completely different 
mechanism than that of inhibitors. Uncouplers are believed to elicit their action by 
breaking down the transmembrane proton gradient They are generally lipid soluble weak 
acids. The weak acid characteristic allows an uncoupler to be protonated outside of the 
mitochondrial intermembrane, shuttle inside as the protonated form, become 
deprotonated, and then shuttle back out again in the deprotonated form. The 
mitochondrial proton gradient is built up by the passage of electrons down the respiratory 
chain and is essential for the production of ATP. In the absence of ADP, the proton 
gradient inhibits the further flow of electrons through the chain, therefore stopping the 
consumption of oxygen. When this proton gradient is dissipated, electrons flow through 
the respiratory chain and oxygen is consumed with little or no regulation. Thus, 
uncouplers not only eliminate production of ATP, but also produce a hypoxic state within 
the mitochondria and the cell
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Uncouplers display the ability to release state 4 respiration in the absence of a 
phosphate acceptor, resulting in a rate which approaches that of state 3. This release 
continues until all available oxygen is depleted. The effect of an uncoupler is depicted in 
Rgure 8-3. 2,6- and 2,4-Dinitrophenol (2,4-DNP) are classic oxidative phosphorylation 
uncouplersl^ which are still commonly employed.
substrate
uncoupler
miiocbondria
Time
R gure 8*3. The effects of an uncoupler on non-ADP stimulated respiration.
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m . Methods and Materials
A. Chemicals and Solutions
1. Chemicals
All aqueous solutions employed 18 MA distilled/deionized water which was 
prepared by passing distilled water through a Milli-Q Reagent Water System (Millipore, 
Continental Water Systems, El Paso, TX).
Chenticals listed below were purchased through Sigma Chemical Company (Sl 
Louis, Mo.) in high puriQr and used without further purification. A ll other chemicals 
were obtained and used as described in previous chapters.
ethyleneglycol-bis-(B-aminoethylether)-N,N,N'J^-tetraacetic acid (EGTA), 98% 
3-(N-morpholino)-propanesulfonic acid, sodium salt (MOPS) 
bovine serum albumin (BSA), fatty acid free, 99%
L-glutamic acid monosodium, 99%
L-malic acid monosodium, 98% 
adenosine-5'-diphosphate (ADP), sodium salt, 96%
2. Homogenization Buffer
The homogenization solution was 030  M sucrose. This buffer was stored at 2*C 
and discarded after seven days. Component additions and solution adjustments were 
performed sequentially as shown in Table 8-1.
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Table 8-1. Homogenization buffer preparation.
Compound Amount Hnal concentration
sucrose 51.35 g 0.30 M
EGTA 190.2 mg 1.0 mM
MOPS 523.3 mg 5.0 mM
KiHPOa 340.3 mg 5.0 mM
BSA 50.0 mg 0.10%
add 475 mL water and adjust to pH 7.4 with cone. KOH
dilute to a final volume o f500 mL
3. M itochondrial Incubation Buffer
The incubation buffer was the same as homogenization buffer except EGTA and 
BSA were excluded. This buffer was also stored at 2°C and discarded after 7 days.
4. M itochondrial S ubstrate Solution
The mitochondria substrate solution was a malate/glutamate mixture. This 
solution was stored at 2"C until use and was discarded after 7 days. Component 
additions and solutitm adjustments were performed sequentially as shown in Table 8-2.
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Table 8-2. Mitochondrial substrate solution preparation.
Malate/Glutamaie S o lu tio n n a i
Compound Amount Final concentration
L-malic acid. Na+ 134.1 mg 0.10 M
L-glutamic acid. Na+ 294.2 mg 0.20 M
add 3 mL water
add 50 pL conc. HCl (aids in dissolving substrate)
adjust to pH 7.4 with KOH
dilute to 10 mL with homogenization buffer
5. ADP Stock Solution
The ADP stock solution was prepared by dissolving 123 mg ADP (96%) in S mL 
homogenization buffer to give a concentration of 55.3 mM. This was divided into 0.5 
mL aliquots and stored at -2Q°C until use. Samples were thawed only once then 
discarded.
6. Toxin Stock Solution
A stock toxin solution was made by dissolving a desired amount of toxin in an 
appropriate volume of degassed homogenization solution, ^ ic a lly  500-7(X) ^L, to yield 
a concentration of 10 mM. This solution was stored on ice. For the experiment, 10,40, 
or 80 itL of the stock solution was injected into the 2.036 mL incubation cell to yield a 
final incubation concentration o f 50, 200, or 400 ^M, respectively. The stock toxin 
solution was stable in excess o f 8 h. When needed, the toxin was converted to its 
oxidized form just prior to injection into the incubation mixture by bubbling with oxygen 
for 3-5 miiL
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B. Experimental
1. Anim als
Animals used in mitochondrial studies were male Sprague-Dawley rats (Harlan 
Sprague Dawley, Indianapolis, IN). The typical rat weighed 350 to 420 g, and a typical 
liver weight was 15 to 25 g.
2. L iver Homogenate
Since mitochondrial preparations are only viable for 3 to 4 hours, time is critical in 
the homogenization, isolation, and utilization of such preparations.
The rat was deprived of food for 15-20 h prior to the experiment to decrease the 
fatty acid and glycogen content o f the liver. The animal was then sacrificed by 
decapitation without anesthesia. The liver was r^ id ly  excised, and all fat and connective 
tissue were removed. The liver was weighed and placed into 30 mL o f ice-cold 
homogenization buffer. All subsequent steps were completed at 0°C in order to enhance 
survival of the mitochondria. All solutions, glassware, homogenizing equipment, and 
centrifuges were maintained at O t  throughout the experimental procedures.
While in the buffer solution, the liver tissue was chopped into approximately 1 
mm cubes with scissors. The chopped tissue was rinsed three times with clean buffer 
during the chopping procedure to remove blood. Tissue chopping was completed within 
3 min. The tissue mixture was drained and resuspended in homogenizing buffer, using 2 
mL of fresh buffer per gram of original tissue. The mixture was then divided into four 
approximately equal parts which were transferred, one at a time, to the homogenization 
mortar. With the homogenization mortar in ice, the tissue was homogenized at a pestle 
rotation of 1(X) to 120 rpm using 5 complete up and down strokes. Caution was taken 
not to apply excessive pressure or to pull a vacuum, which caused damage to the integrity 
of the mitochondria. The four individual homogenates were subsequently combined.
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mixed, and then equally divided between two SO mL polycarbonate centrifuge tubes. The 
final homogenate was a reddish-brown color. The homogenization process was 
completed within 10 to 15 min after sacrifice.
3. Isolation of M i t o c h o n d r i a l 79,183,188
All centrifuge steps were carried out at 0°C. The homogenate was centrifuged 
using a model RC-5B Sorvall (DuPont Instruments, Newtown, CT) superspeed 
centrifuge with a model SM-24 rotor at 3,(XX) rpm (l,CMX)g) for 5 min. This step 
separated cellular debris from the suspended mitochondria. Three layers resulted from 
this initial centrifugation: a top, milky white layer which consisted of fats; a middle layer, 
which was the desired layer; and a bottom layer, which was a pellet of cellular debris and 
blood. The middle layers of each tube were collected using a Pasteur pipette, combined, 
and put on ice. Throughout this collection, caution was used to avoid gathering any of 
the white milky material at the top or the sediment at the bottom, since these materials 
would contaminate the preparation. After discarding the remaining upper layer, the 
resultant pellets were combined, resuspended in 20 mL of homogenization buffer, and 
centrifuged again at 3,000 rpm (l,000g) for 5 min. The middle layer was again isolated 
and combined with the previously collected material. The remaining top and bottom 
layers were discarded. The combined middle layers were centrifuged at 12,(XX) rpm 
(15,0(X)g) for 10 min. The resultant supernatant was discarded. Any white material 
present on the tube walls was wiped away. The pellet was resuspended in 20 mL 
homogenization buffer and centrifuged again at 12,000 rpm (15,0(X)g) for 5 min. 
Following the final centrifugation, the supernatant was discarded and the remaining pellet 
saved. The pellet was light brown in color and was composed of the desired 
mitochondria. This pellet was resuspended in 1.0 mL of homogenization buffer and 
stored on ice. To ensure homogenei^ of the final mitochondrial mixture, two complete 
manual revolutions of the pestle were employed. The entire isolation procedure required
2 4 1
approximately one hour to complete. A typical rat liver preparation yielded 2 mL of final 
mitochondrial suspension.
4. RCR Ratio, P/O Ratio & State 4 Rate
Viability o f the preparation and coupling o f the mitochondria in a typical 
preparation was assessed by measuring the RCR and P/O ratios and the state 4 oxygen 
consumption rate.
A model 58 YSI dissolved oxygen meter outfitted with a model 5739 YSI 
dissolved oxygen probe (Yellow Springs Instrument Co., Yellow Springs, OH) was 
equipped with fiesh internal KCl solution, a new 0.001" standard electrode membrane, 
and calibrated prior to each complete experiment. The reaction cell used for all 
experiments was a 2.036 mL temperature regulated, water jacketed cell that fit tightly over 
the end of the O2 probe. The temperature was held at 37°C for all experiments. The 
oxygen trace was recorded on a model 156 Cole/Parmer chart recorder. Stirring of the 
solution inside the cell was held constant at a setting of 4 on a model 120M Fisher 
magnetic stirrer. Stock incubation buffer was kept at 37°C during the experiment The 
cell was filled with the incubation buffer using a 5 mL plastic syringe, being careful to 
eliminate any oxygen bubbles inside the reaction cell. The temperature was then allowed 
to equilibrate 1 min. A MX) itL aliquot of the mitochondria suspension was injected into 
the cell and, then, 100 pL of the malate/glutamate solution was injected. This was 
allowed to equilibrate until a steady oxygen trace was achieved. A lO^iL aliquot of 55.3 
mM ADP was then injected into the cell with a resultant oxygen consumption rate 
increase. Upon mitochondrial utilization of all available ADP, the oxygen consumption 
rate slowed and gave a  steady, non-phosphorylation respiratory state. This state was then 
observed for approximately 1 min, followed by another 10 iiL injection of ADP. Using 
this approach, mitochondria integri^ was evaluated and experimental control values 
obtained.
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When investigating the interaction of the toxin with mitochondria, the same 
experimental approach as described immediately above was conducted with the addition 
of one step. An appropriate amount o f 10 mM toxin in either the reduced or the oxidized 
form (10, 40, 80 pL) was added to the reaction cell following the addition of the 
mitochondria. For the majority of the studies, the oxidized form of the toxin was 
employed unless otherwise noted. This was done in order to eliminate any mitochondrial 
damage resulting from possible short-lived reactive by-products of toxin autoxidation, 
and to eliminate changes in oxygen concentrations resulting from toxin autoxidation. 
Additionally, since these toxins are most likely in their oxidized form in the brain, it 
seems only logical that the oxidized form be used in these investigations. For 
investigation of the effect of toxin autoxidation process on mitochondrial function, the 
reduced toxin was injected immediately following mitochondria. In these studies, the 
dissolved oxygen content in the cell was increased prior to the experiment to compensate 
for the initial, large oxygen consumption via toxin oxidation. The mitochondria-toxin 
autoxidation studies are denoted in tables and figures by a superscript
Typically, each toxin condition had an N value of 3 to 4, and control values had N 
of 5 to 6. All values presented in tables and figure are reported as the mean ±  SEM. 
Typical RCR and P/O ratio values were found to be 3.5 to 6.0 and 2.7 to 3.1, 
respectively.
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IV. Results and Discussion
A. 6,7-ADTQ
. w
H
The mitochondrial interactions observed with 6,7-ADTQ are presented in Table 
8-3 and Figures 8-4 through 8-6. At 50 pM preoxidized 6,7-ADTQ (ox-6,7-ADTQ) the 
RCR showed a marked decrease (31% inhibition). Along with this decrease, state 4 
respiration. Le., release, was stimulated to 165% of control
Table 8-3. 6,7-ADTQ effects on mitochondrial function.
Respiration values in % control ±  SEM
Conc. (uM) RCR P/O State 4 rate
controls^ 100±1 100±2 100±2
50 69 ±2*** 9 6 ± I 165 ±11***
200 64 ±1*** 86 ±2** 185 ±8***
400 56 ±1*** 80 ±0.6*** 227 ±9***
200 61 ±1*** 88 ±3** 190 ±3***
Significant differences compared to control values (r test): *P < 0.05; **P < 0.01, 
♦♦♦/»< 0.001.
^ Control values (mean ±  SEM): RCR, 3.45 ±  0.03; P/O, 2.87 ±  0.06.
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At 200 ^M, ox-6,7-ADTQ caused decreases in the RCR and P/O values to 64% and 86% 
of controls, respectively. Additionally, state 4 respiration was stimulated to 185% of 
controls. At 400 |iM , ox-6,7-ADTQ further decreased RCR and P/O values and state 4 
respiration was simulated to 227% of control values. In fact, the state 4 release effects 
almost quantitatively accounted for the corresponding RCR effects. Likewise, the P/O 
effects are at least partially attributed to the state 4 effects.
To ensure that the observed concentration dependent effects were a result of 
stimulated mitochondrial oxygen consumption, i.e., state 4 release, and not any residual 
autoxidation of the toxin, similarly prepared, pre oxidized toxin was introduced into the 
reaction cell containing only the incubation buffer. No oxygen consumption was 
observed in these experiments, and in fact, there was a slight increase observed in the 
oxygen level of the reaction ceU, which resulted from the slightly higher oxygen content 
of the oxidized toxin solution.
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Figure 8-4. 6,7-ADTQ effects on RCR. ^  indicates toxin not pre-oxidized.
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Figure 8-5. 6,7-ADTQ effects on P/O ratio. indicates toxin not pre-oxidized.
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Figure 8 -6 . 6,7-ADTQ effects on state 4  rate. indicates toxin not pre-oxidized.
246
We then investigated the effects o f the 6,7-ADTQ autoxidation process on 
mitochondrial function. 6,7-ADTQ, in its reduced form, was introduced to the reaction 
cell containing mitochondria and subsequently underwent autoxidation. Once steady state 
oxygen consumption was observed, the mitochondria were tested for their resultant 
possible functional impairment. The determined RCR and P /0  values were significantly 
lower than controls, but were no different than those observed in the corresponding 200 
pM ox-6,7-ADTQ group. The same was seen for state 4 respiration stimulation. These 
results indicate that autoxidation of 6,7-ADTQ does not substantially impair mitochondrial 
function.
In these studies, we found significant mitochondrial interaction over a  broad toxin 
concentration range. ox-6,7-ADTQ demonstrates a potent uncoupling effect, as seen by 
its abiliQr to release state 4  respiration. If there exists any respiratory inhibition effects, 
they are minimal as both the RCR and P/O inhibition can be attributed to the release in 
state 4 respiratiorL
B. 6,7-AMDTQ
XXX"HO
H
The effects exerted by 6,7-AMDTQ on mitochondrial function are presented in 
Table 8-4 and Figures 8-7 to 8-9. At the lowest concentration of 6,7-AMDTQ tested, SO 
pM, there was a  20% decrease in the RCR. This was also seen in the P/O value. These 
decreases were paralleled by, and may be easily attributed to, a 22% stimulation in the 
state 4  respiration, suggesting uncoupling.
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Table 8-4. 6,7-AMDTQ effects on mitochondrial function.
Respiration values in % control ±  SEM
Cone. (uM) RCR P/O State 4  rate
controls» 100±2 100±3 100± 5
50 80 ±0.1*** 83 ±2** 122 ±1**
200 7 3 ± 1*** 74 ±2*** 123 ± 6*
400 67 ±4*** 75 ±2*** 128 ±  12
200»^ 60 ±1*** 80 ±2** 142 ±1***
Significant difieiences compared to control values (t test): *P < 0.05; **P < 0.01, 
***P< 0.001.
a Control values (mean ±  SEM): RCR, 4.49 ±  0.08; P/O, 2.74 ±  0.09.
At 200 nM oxidized toxin, further lowering of RCR and P/O values were 
observed. However, the release of state 4  respiration, while being 123% of controls, 
was approximately the same as that observed at SO pM ox-6,7-AMDTQ. At 4(X) ^M , 
ox-6,7-AMDTQ produced RCR and P/O values similar to those at 200 pM. Additionally, 
state 4  release was observed, but the release was not significantly different from that 
observed at 50 and 200 ^iM. At the two higher toxin concentrations, state 4  
respiration release did not completely account for the decreases seen in RCR and P/O 
values. These results suggest that at low concentrations, ox-6,7-AMDTQ acts primarily 
as an uncoupler, while at higher concentrations it may act as both an uncoupler and weak 
inhibitor.
The effects of 6,7-AMDTQ autoxidation on mitochondrial function showed 
interactions greater than those seen with ox-6,7-AMDTQ. RCR values decreased a 
further 13% below that observed for the corresponding 200 jiM preoxidized group.
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Moreover, stale 4 respiration was stimulated to 142% of control, which was 19% above 
that found in the preoxidized group. These potentiated mitochondrial effects suggest that 
reactive oxidation intermediates and/or by-products interfere with and/or damage 
mitochondrial function above and beyond that of the oxidized form of the toxin.
6,7-AMDTQ (uM)
Figure 8-7. 6,7-AMDTQ effects on RCR. indicates toxin not pre-oxidized.
249
& 2.0
controls 50 200 400 20(f"^
6,7-AMDTQ (jiM)
Figure 8-8. 6,7-AMDTQ effects on P/O ratio. indicates toxin not pre-oxidized.
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Figure 8-9. 6,7-AMDTQ effects on state 4 rate. ^  indicates toxin not pie-oxidized.
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Stimulation of state 4  respiration directly indicates uncoupling produced by 
OX-6.7-AMDTQ. However, at high concentrations of ox-6,7-AMDTQ, stimulation of 
state 4 respiration does not appear to account for the total decrease in RCR or P/O values. 
Thus, 6,7-AMDTQ may also be partially acting as a weak inhibitor o f oxidative 
phosphorylation. Further studies have not been conducted to investigate the exact nature 
of this possible action. Toxin autoxidation in the presence o f mitochondria displayed 
potentiated effects compared to preoxidized toxin. This is believed to result from reactive 
oxidation intermediates or, more likely, reactive m^gen species damaging mitochondrial 
membranes and/or enzyme integri^.
C. 6,8-ADTQ
w
HO *
The mitochondrial interactions displayed by 6,8-ADTQ are presented in Table 8-5 
and Figures 8-10 to 8-12. The interactions produced at 50 |iM  were minimal, yet 
significant. The RCR was lowered by approximately 13% and the P/O by 8%. 
Furthermore, state 4 respiration was stimulated to 115% o f controls. Thus, the 
reductions in RCR and P/O values were primarily attributed to uncoupling.
Oxidized 6,8-ADTQ (ox-6,8-ADTQ) at 200 itM produced a further decrease in the 
RCR to 81% of control, while P/O values exhibited relatively no change from those 
produced at 50 pM. Additionally, state 4  respiration showed a concentration dependent 
effect with an increase in oxygen consumption to 129% of controL
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Table 8-5. 6 ,8 -ADTQ effects on mitochondrial function.
Respiration values in % control ±  SEM
Cone. (uM) RCR P/O State 4 rate
controls^ 100±1 100±1 100±3
50 87 ±2*** 92 ±2** 115 ±3*
200 81± 92 ±  1** 129 ±3***
400 77 ±  0.3*** 90 ±1*** 136 ±7**
200 ant 69 ±2*** 96 ±2* 125 ±6*
Significant differences compared to control values (r test): *P < 0.05; **P < 0.01, 
0.001.
a Control values (mean ±  SEM): R(]R, 4.99 ±  0.04 ; P/O, 2.91 ±  0.04.
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Figure 8-10. 6 ,8 -ADTQ effects on RCR. indicates toxin not pre-oxidized.
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Figure 8-11. 6,8-ADTQ effects on P/O ratio. ^  indicates toxin not pre-oxidized.
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fig u re  8-12. 6 ,8 -ADTQ effects on state 4  rate. indicates toxin not pre-oxidized.
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Oxidized 6,8-ADTQ at 400 pM resulted in a state 4 release to 36% above 
controls. This was reflected in the RCR, which was lowered to 77%. Riterestingly, at all 
concentrations tested, the P/O values remained approximately unchanged at 90% of 
controL It is possible, however, that this may be a result of experimental error in the 
measurement of absolute oxygen consumption. Since state 4  release was reflected in and 
primarily accounted for by the decrease in RCR values, the results suggest this compound 
acts predominantly as an uncoupler.
Additionally, we investigated the effects of 6,8-ADTQ autoxidation on 
mitochondrial fonction. At 200 pM we observed a decrease in the RCR below that seen 
in the preoxidized 200 pM group. However, P/O values remained statistically unchanged 
from the corresponding preoxidized group, as did state 4  respiration rates. Thus, it 
appears there is little to no substantial effect produced by 6,8-ADTQ autoxidation itself 
beyond that elicited by the oxidized form of the toxm.
The RCR inhibition and stale 4 stimulation occurred in a concentration dependent 
manner. And for the most part, the decrease observed in RCR was accounted for by the 
state 4 release. No substantial effects are produced by the toxin autoxidation process 
beyond those found with ox-6,8-ADTQ. Thus, we have concluded that 6,8-ADTQ acts 
primarily as an uncoupler of oxidative phosphorylation.
D. 6-HDA
..xc
The results of 6-HDA interactions with mitochondria are presented in Table 8-6 
and Figures 8-13 to 8-15. fo studies using 50 pM oxidized 6-HDA (ox-6-HDA), we
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observed a general lowering of RCR and P/O values and an increase in state 4 respiration, 
but none to a significant extent In the presence of higher concentrations of ox-6-HDA, 
however, significant mitochondrial interference was observed.
Table 8-6. 6-HDA effects on mitochondrial function.
Respiration values in % control ±  SEM
Cone. (uM) RCR P/O State 4 rate
controls^ 100±3 100±3 lo o t  3
50 94± 1 9 6 ± 6 111±9
200 79 ±1** 87 ±2** 116 ±2*
400 69 ±1*** 70 ±5** 137 ±3**
200 62 ±2*** 89 ±2* 162 ±7***
Significant differences compared to control values (r test): *P < 0.05; **P < 0.01, 
* * * ? <  0.001.
a Control values (mean ±  SEM): RCR, 3.26 ±0.11; P/O, 2.59 ±  0.08.
Using 2 0 0  iiM ox-6-HDA, the R(]R inhibition was approximately 2 1 % .  At this 
concentration, the P/O value was found to be 87% of controls. Furthermore, state 4 
respiration was stimulated to 1 1 6 %  of control. The stimulation o f state 4 respiration 
indicates uncoupling and can accotmt for the m ajori^ of the decrease in RCR and P/O 
values. However, some slight respiratory chain inhibition effects may be indicated. Both 
uncoupling and inhibition by 6-HDA has been reported in the I i te r a tu r e .^ 7 - 6 0 ,1 6 5
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Figure 8*13. 6-HDA effects on RCR. indicates toxin not pre-oxidized.
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Figure 8-14. 6 -HDA effects on P/O ratio. 4"* indicates toxin not pre-oxidized.
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Figure 8-15. 6-HDA effects on state 4 rate. indicates toxin not pre-oxidized.
At 400 pM 0X-6 -HDA, we observed a concentration dependent increase in 
mitochondrial interaction. Both RCR and P/O values were inhibited by approximately 
30%. State 4 respiration was stimulated to 137% of controls, which, for the most part, 
accounted for the lowering of the RCR and P/O values. However, again it appears that 
there may exist a very small degree of respiratory chain inhibition.
Investigating the effects of 6-HDA autoxidation on mitochondrial function yielded 
significantly different results than were found with the 200 pM preoxidized group. RCR 
values were 17% of control lower than observed with the preoxidized group. 
Furthermore, autoxidation resulted in an apparent increase in state 4 respiration to 162% 
of control, 46% of control higher than the preoxidized group. The potentiation in 
m itochondrial dysfunction resulting from toxin autoxidation suggests reactive 
intermediates and/or by-products that possibly disrupt mitochondrial membrane integrity, 
allowing respiration to occur at a higher, more uninhibited rate.
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The decreases found in RCR and P/O values suggest either oxidative 
phosphorylation uncoupling or inhibition. However, stimulation o f state 4 respiration is 
strongly indicative of uncoupling. The release of state 4 respiration by 6 -HDA appears to 
account for the m ajori^ o f the decreases observed in RCR and P/O values. The results 
found in our studies are in good agreement with those reported e l s e w h e r e . ^ 7 ,60,165 
Thus, it is our conclusion that 6 -HDA, while possibly eliciting slight inhibition of the 
respiratory chain, acts primarily as a mitochondrial oxidative phosphorylation uncoupler.
E. Toxin Effects on Mitochondria, A Toxin Comparison
1. Respiratory Control Ratios (RCR)
Our studies indicate that there exists strong mitochondrial interactions with all of 
the quinoline toxins as well as 6-HDA The RCR results are summarized in Table 8-7.
Table 8-7. RCR values of various toxins.
RCR values in % control ±  SEM
Compound Controls 50 uM 200  uM 400 uM 2 0 0 uMa“t
6,7-ADTQ 1 0 0 ± 1 69 ±2*** 64 ±1*** 56 ±1*** 61 ± 1***
6,7-AMDTQ 1 0 0 ± 2 80 ± 0 .1*** 73 ± 1*** 67 ±4*** 60 ± 1***
6 ,8-ADTQ 1 0 0 ± I 87 ±2*** 8 1 ± 1*** 7 7 ± 0 J* * * 69 ±2***
6-HDA iOO±3 94± 1 79 ±1** 69 ±1*** 62 ± 2 ***
Significant differences compared to control values (r test): *P < 0.05; **P < 0.01, 
0.001.
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As we see in Table 8-7, these toxins elicit substantial decreases in the RCR 
values, of intact mitochondria, which correlates to serious oxidative phosphorylation 
interference. Moreover, the RCR values were found to consistently decrease in a toxin 
concentration-dependent manner. 6-HDA was included in these studœs for comparative 
purposes, and the results obtained for this toxin agreed well with those reported in the 
literature.^^
At all concentrations tested, 6,7-ADTQ produced the greatest decreases in RCR 
values, ranging from 31% inhibition in RCR at SO pM to 46% at 400 pM. 6,7-AMDTQ 
showed the same trend as 6,7-ADTQ, but gave RCR values that were consistently 
approximately 10% higher than those of 6,7-ADTQ. 6,8-ADTQ also displayed the same 
trend, yet was even less potent in its ability to lower RCR values. 6-HDA did not tightly 
parallel the trend observed with the other compounds in that it produced very little RCR 
effects at 50 pM and only a 31% decrease in RCR values at 400 pM.
While we were primarily interested in the effects o f the oxidized toxins on 
mitochondrial respiration, we were also curious to see if the process of toxin autoxidation 
had any additional effects on mitochondrial function. Not expecting to see any major 
differences between the pre-oxidized and the autoxidized 200 pM groups, we were quite 
surprised when differences appeared. 6,7-ADTQ^"^ was the only toxin that did not 
display a substantial and significant decrease in the RCR value from that o f its pre- 
oxidized group (64% vs. 61%®“  ^of controls). 6,7-AM DT(^^ showed a significant 13% 
drop in its RCR below that of the pre-oxidized group, to 60% of control. 6 ,8-A D T (yt 
also showed significantly lower RCR values than the pre-oxidized group. 6-HDA®®  ^
produced the most dramatic drop in RCR values, from the pre-oxidized group value of 
79% to 62% of control values.
The pre-oxidized toxins showed a significant and substantial inhibition of the 
RCR, which was concentration dependent This overall inhibition, occurring with the 
oxidized forms of the toxins, indicates either moderate inhibition or uncoupling of
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oxidative phosphorylation. The further lowering o f RCR values resulting from toxin 
autoxidation process suggests that there are reactive oxidation intennediates which interact 
with and/or damage the mitochondria, independent from the effects of the oxidized form 
of the toxin. This observed potentiation may also be a result of reactive oxygen species 
produced during toxin autoxidation.
2. P/O Ratios
For comparative purposes, P/O values are summarized in Table 8-8. 6,7-ADTQ 
and 6-HDA displayed a similar concentration-dependent reduction in P/O values, much 
like the trend seen with their RCR values. A t 200 they both lower P/O values by 
approximately 14%, while at 400 pM P/O values were decreased by 20% and 30%, 
respectively. It appears that 6,7-AMDTQ exerted its maximal P/O effects of 
approximately 25% inhibition, over the entire concentration range tested. 6,8-ADTQ 
shows the least potency in lowering the P/O ratio, which parallels its effects on RCR 
values. 6,8-ADTQ, while not eliciting large decreases in P/O ratios, resulted in a 
consistent 10% RCR decrease from the lowest to the highest toxin concentration tested.
Table 8-8. P/O values of various toxins.
P/O values in % controls ±  SEM
Compotmd Control 50 uM 200 uM 400uM 200uMa»t
6,7-ADTQ 100±2 9 6 ± 1 86 ±2** 80 ±0.6*** 88 ±3**
6,7-AMDTQ 100±3 83 ±2** 74 ±2*** 75 ±2*** 80 ±2**
6,8-ADTQ 100±1 92 ±2** 92 ±1** 90 ±1*** 96 ±2*
6-HDA 100±3 9 6 ± 6 87 ±2** 70 ±5** 89 ±2*
Significant differences compared to control values (r test): *P < 0.05; **P < 0.01, 
♦♦*P< 0.001.
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When looking at the effects of the toxin autoxidation process on P/O ratios, we 
expected to observe similar trends as with the overall lowering in the RCR values, or at 
least equivalent P/O values to those foimd with the 200 )iM pre-oxidized toxin group. 
Surprisingly, however, the P/O values observed with toxin autoxidation did not parallel 
the increased R C R ^  inhibition effects. And in fact, P/O^nt values were slightly larger 
than those of their corresponding 200 iiM pre-oxidized toxin group. However, these 
results were not substantial nor significant in comparison to that of the pre-oxidized test 
group, except in the case of 6,8-ADTQ.
Lowering of the P/O value, while possibly occurring in multiple mitochondrial 
dysfunctions, is most suggestive of oxidative phosphorylation uncoupling. 6-HDA has 
previously been reported by many researchers to act primarily as an u n c o u p l e r .5 7 ,60,165 
Additionally, 6-HDA has been suggested to possess possible respiratory chain inhibitor 
activities.^8,59 q u t  toxic agents demonstrated equal or greater mitochondrial interactions 
than was observed with 6-HDA. All toxins tested displayed substantial enough decreases 
in P/O values that one could suggest their neurotoxic effects could be attributed, at least in 
part, to the associated mitochondrial interactions.
3. State 4 Respiration Rates
State 4 oxygen consumption rates were investigated to determine the ability of 
these toxins to release state 4  respiration. For comparative purposes, the results are 
summarized in Table 8-9.
6-HDA was found to release state 4  respiration to 116% of control at 200 pM  and 
137% a t400 iiM, presumably by uncoupling oxidative phosphorylatioiL This correlates 
well with its ability to decrease RCR and P/O values and is further substantiated by 
reports of uncoupling in the literature.^7,60,165 The increase in state 4 rate produced by
6,8-ADTQ was very similar to 6-HDA. 6,7-AMDTQ was also much like 6-HDA and
261
6,8-ADTQ in that it increased state 4 respiration, at 200 piM, to 23% above controls. 
Interestingly, yet somewhat expected from its RCR values, 6,7-ADTQ resulted in a 
substantial state 4 release, to 185% of controls at 200 pM and 227% at 400 pM,
Table 8-9. State 4 respiration rates of various toxins.
State 4  rate» in % controls ±  SEM
Compotmd Controls 50 uM 200 uM 400 uM 200uM»“t
6,7-ADTQ 100±2 165 ±11** 185 ±8*** 227 ±9*** 190 ±3***
6,7-AMDTQ 100±5 122 ±1** 123 ±6* 128 ±  12 142 ±1***
6,8-ADTQ 100±3 115 ±3* 129 ±3*** 136 ±7** 125 ± 6*
6-HDA 100±3 111±9 116 ±2* 137 ±3** 162 ±7***
Significant differences compared to control values (f test): *P < 0.05; < 0.01,
< 0.001.
^ Typical control state 4 oxygen consumption rates were 31 ±  1 (pmol 0% / Lnnin).
The effects of toxin autoxidation on state 4 respiration were also investigated. For
6,7-ADTQ and 6,8-ADTQ, state 4  rates were similar to those of their pre-oxidized toxin 
values. 6,7-AMDTQ autoxidation resulted in an increase o f 19% in state 4 respiration 
over the corresponding pre-oxidized group, but this was not significant Autoxidation of 
6-HDA showed a greater ability to release state 4 than was shown by its pre-oxidized 
counterpart resulting in a  stimulation to approximately 162% of controL Thus, 6-HDA 
appears to produce some oxidation intermediate and/or reactive by-product by which 
more complete mitochondrial uncoupling, damage, and/or inhibition is produced than by 
its oxidized form alone.
The abili^ of a compound to release state 4 respiration positively identifies it as an 
uncoupler. Therefore, our results show all of these toxic agents to be uncouplers to at
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least some degree. While all toxins tested displayed uncoupling substantial enough to 
elicit mitochondrial dysfunction, 6,7-ADTQ was fotmd to be the most potent in its 
uncoupling efifects. 6,7-ADTQ, at 200 to 400 pM, displayed state 4 rates approaching 
those seen for state 3 respiration.
V. Conclusions
There must exist an adequate electron flow through the respiratory chain, 
sufficient oxygen delivery, and efficient coupling between the electron transport and 
oxidative phosphorylation in order to maintain the balance between ATP production and 
utilization in mitochondria. Our toxins have demonstrated the ability to interfere with 
production of ATP through what appears to be predominantly an uncoupling mechanism. 
The release in state 4 respiration produced by our toxins most likely results from the 
collapse of the mitochondrial proton gradient, thus allowing electrons to move through 
the respiratory chain with only limited regulation until all available oxygen is depleted. 
This hyperactive respiration could lead to the production of reactive oxygen species, 
hypoxia, reduced cytochrome activities, and a decrease in ATP levels. Many neuronal 
functions depend heavily on ATP and, when exposed to such disruptions, would be 
expected to be severely stressed. For example, one of the early results of ATP depletion 
is the impairment of the neuronal membrane ATP-linked Na+/K+ pump. Increases in 
extracellular K t depolarize voltage sensitive Ca^+ channels allowing Ca^+ to enter the 
cell, which in turn results in cell deatb.^3,64
All toxins tested displayed a substantial lowering of RCR and P/O values and a 
release of state 4 respiratiorL Of these toxins, 6,7-ADTQ showed the highest potency for 
tmcoupling oxidative phosphorylation, followed by 6,7-AMDTQ and 6-HDA, then
6,8-ADTQ. And, as shown in chapter four, 6,7-ADTQ was the most potent depleting
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agent of the dihydioj^tetrahydroquinoline derivatives. Thus, the mitochondrial effects at 
least correspond qualitatively to the observed netnodegenerative effects.
The pKa values determined for the oxidized forms of these compounds were 
discussed in chapter six and are presented in Table 8-10. 2,6- and 2,4-DNP, classic 
mitochondrial oxidative phosphorylation uncouplers, are additionally included in Table 
8-10 for comparative purposes. The pKa values o f the oxidized toxins are well within a 
reasonable range to act as uncouplers. While simple charged atoms and molecules cannot 
cross the mitochondrial inner membrane without specific carrier systems, charged 
molecules with an extended lipophilic structure and/or the ability to substantially 
delocalize charge are capable of passive transporL^Z Our toxins may, thus, produce 
uncoupling by this acid/base/transport phenomenon.
Table 8-10. pKa values of oxidized toxins and standard uncoupling agents.
Agent pKa
ox-6,7-ADTQ 6.61 ± 0.17
ox-6,7-AMDTQ 7.57 ± 0.03
ox-6,8-ADTQ 4.32 ± 0.09
0X-6-HDA 3.87 ± 0.04
2,4-DNP179 3.96
2,6-DNPl79 5.63
While the toxin concentrations used in the current investigations may seem quite 
high, they are actually much lower than expected intraneuronally upon CNS injection. 
Studies have shown for 6-HDA that the intraneuronal threshold concentration, i.e., the
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concentration which must be reached in order to initiate neurodestruction, is 30-100 
mM.^7 Thus, the mitochondrial effects described above would be increased substantially 
in a neuron experiencing a neurotoxin insult
W hether the impairment of mitochondrial function is a major factor in the 
neurotoxic mode of action of our toxins remains to be showtL However, the fact that our 
toxins all produce alterations in mitochondrial oxidative phosphorylation suggests that 
impairment o f mitochondrial function is certainly a common, underlying property of 
6-HDA and related neurotoxins.
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